Annual report 2020  
Allergy  
solutions  
for life  
 
Management’s review • Annual report 2020 • ALK  
2
Table of contents  
p8  
Letter from the  
Chairman and CEO  
Management’s review  
Financial statements  
"2020 represented the final year  
of ALK's strategic transformation,  
and our focus remained on the  
relentless execution of our goals."  
Introduction  
Statements  
4
5
8
2020 highlights  
48 Statement by Management on the annual report  
49 Independent auditor’s reports  
ALK at a glance  
Letter from the Chairman and CEO  
Consolidated financial statements  
10 2021 outlook  
54 Income statement  
p10  
Performance  
54 Statement of comprehensive income  
55 Cash flow statement  
56 Balance sheet  
2021 outlook  
ALK expects growth across all  
sales regions in 2021.  
13 Financial highlights and key ratios  
14 Sales and market trends  
16 COVID-19: The defining challenge of 2020  
17 Financial review of 2020  
19 Q4 review  
57 Statement of changes in equity  
58 Notes  
Parent company financial statements  
Strategic transformation  
88 Income statement  
89 Balance sheet  
22 Strategy update  
p14  
26 Succeed in North America  
90 Statement of changes in equity  
91 Notes  
Tablet sales up strongly  
Tablet sales grew by 42% in  
2020 with ITULAZAX® leading  
the way.  
27 Complete and commercialise the tablet  
portfolio for all relevant ages  
29 Consumer engagement and new horizons  
30 Optimise for excellence  
97 Financial highlights by quarter  
31 Lead the way – people and planet  
32 Medium-term financial ambitions  
Corporate matters  
34 Sustainability  
p22  
37 Governance and ownership  
40 Risk management  
43 Remuneration  
Delivering sustainable  
growth and profitability  
With the transformation  
complete, ALK is now entering  
the next phase of its strategic  
development.  
Cover picture: Collection of catkins from ALK's birch tree  
orchard in Post Falls, Idaho. Allergenic source materials are the  
main ingredients of ALK's allergy immunotherapy products  
44 Board of Directors  
46 Board of Management  
 
Management’s review • Annual report 2020 • ALK  
3
After collection, the catkins are dried in  
special areas with carefully controlled  
environments  
Introduction  
4
5
8
2020 highlights  
ALK at a glance  
Letter from the Chairman and CEO  
10 2021 outlook  
 
 
Management’s review • Annual report 2020 • ALK  
4
2020 highlights  
Succeed in North America  
Complete and commercialise the tablet portfolio for all relevant ages  
Consumer engagement and new horizons  
Optimise for excellence  
Other  
ALK launches ITULATEK™  
tablet for tree pollen  
allergy in Canada  
Annual general meeting  
elects Anders Hedegaard as  
new Chairman of ALK’s Board  
RAGWIZAX® for  
ragweed allergy  
is approved for  
children in Europe  
ALK launches klarify digital  
platform in Denmark  
ALK launches klarify  
digital platform in  
Ireland  
COVID begins to  
impact business  
operations and  
clinical activities  
New clinical Phase III trial  
for ALK’s house dust mite  
tablet initiated in China  
ALK secures rights to  
market OTIPRIO™ in  
the USA  
Jan  
Feb  
Mar  
Apr  
May  
Jun  
Jul  
Aug  
Sep  
Oct  
Nov  
Dec  
ALK announces drug  
ALK launches klarify  
digital platform in Slovakia  
Q2 report: Revenue  
unchanged with tablet  
sales up 25% and  
EBITDA up 213%  
RAGWITEK® for ragweed  
allergy is approved for  
children in Canada  
discovery partnership  
with American biotech  
company X-Chem  
Q1 report: Revenue up  
10% with tablet sales up  
38% and EBITDA up 49%  
Full-year 2020 financial  
results: Revenue up 8%  
with tablet sales up 42%  
and EBITDA up 64%  
ALK launches klarify  
ALK updates its full-year financial  
digital platform in  
the USA  
outlook to reflect improved earnings  
and cash flow as well as growth at the  
lower end of the guidance range  
Q3 report: Revenue up 7% with tablet  
sales up 52% and EBITDA up 61%  
 
 
Management’s review • Annual report 2020 • ALK  
5
ALK at a glance  
ALK key figures  
Global presence  
ALK is a global allergy solutions company
with a wide range of treatments, products
and services to meet the unique needs of
allergy sufferers, their families and doctors.
Headquartered in Hørsholm, Denmark, the
company is listed on Nasdaq Copenhagen  
(ALKB:DC/OMX: ALK B)  
International  
markets  
North America  
Revenue  
Revenue  
11%  
16%  
Europe  
Revenue  
Established:  
Employees:  
1923  
~2,500  
73%  
Development in revenue  
SLIT-tablets (% growth in local currencies)**  
DKK bn  
Patients in treatment  
with ALK products*:  
Markets:  
Production sites  
ALK’s unique manufacturing  
SCIT/SLIT-drops  
Other  
41  
~2m  
processes ensure its products  
meet required quality standards  
and represent a significant  
barrier to potential competitors,  
making them an important  
factor in maintaining ALK’s  
market position  
3.5  
3.3  
3.0  
2.9  
2.9  
2.6  
2.4  
+45%  
+42%  
2.3  
2.3  
2.2  
+8%  
+28%  
The number of the most common  
global respiratory allergies  
covered by ALK's tablet portfolio:  
Participated in clinical  
trials for the tablets:  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
5
>23,000  
** Includes certain milestone payments from partnerships in the period 2011 to 2016  
* Covering AIT and anaphylaxis  
 
 
Management’s review • Annual report 2020 • ALK  
6
ALK's business model  
As a global allergy solutions company with a century of knowledge and expertise, ALK  
helps people to take control of their allergies and their lives.  
Value created  
Patients: ALK’s tablet portfolio is helping to  
democratise AIT by covering the most common  
respiratory allergies, and bringing new treatment  
options to people without easy access to allergy  
specialists.  
Raw materials  
Active Pharmaceutical Ingredient (API ) production  
Allergens undergo thorough analysis, standardisation  
and quality control, so that naturally occuring  
variations are minimised, ensuring quality and  
consistency in the finished products.  
Allergenic source materials, such as grass  
pollen and house dust mites, are the main  
ingredients of our products. Every year  
the company grows, collects or harvests  
several tonnes of allergens.  
Doctors: ALK helps allergists to drive better access and  
outcomes for all AIT-eligible patients, reaching out with  
support, disease information and treatment options.  
Our people: ALK is committed to a sustainable working  
life and keeps a constant focus on being a safe place to  
work for motivated and satisfied employees.  
Key resources  
Society: ALK addresses profound societal challenges  
by producing medicines for the leading cause of  
lost productivity and lost work days. The company  
partners with payers and health authorities to  
advance registered, documented AIT products and is a  
signatory of the United Nations Global compact.  
Our people and culture: Around 2,500 highly-skilled  
employees live our cultural beliefs every day in their  
work to help more people with allergy.  
Finished production  
Production/natural allergens: ALK’s biological  
medicines are derived from natural resources, such  
as pollen, which it harvests, standardises and quality  
controls at its own facilities.  
APIs are purified, then formulated for  
subcutaneous injections, sublingual drops or  
sublingual tablets.  
Our investors: ALK works to create long-term value for  
its shareholders.  
Scientific knowledge: ALK continuously applies its  
scientific knowledge to help people take control of their  
allergies and their lives.  
Allergy solutions for life  
Sales and partnerships: In addition to its own sales  
organisation, ALK partners for growth with leading  
specialty pharma companies worldwide. ALK is present  
in 41 markets, either directly or via partnerships.  
R&D: The completion of the tablet portfolio remains  
the primary focus of ALK’s R&D efforts. In addition,  
the company is conducting research into innovative  
solutions for high-impact allergic conditions – such as  
food allergies.  
Packaging and distribution  
Following careful quality control,  
the finished products are labelled,  
packaged and distributed.  
Through information resources, services  
People with allergies  
often endure a decade  
or more of symptoms  
before turning to AIT.  
and products, ALK is working to support  
people with allergy early in their disease  
journey, smoothing the path to treatment.  
 
Management’s review • Annual report 2020 • ALK  
7
Megatrends shaping allergy  
Most common chronic  
Shift towards  
Food allergy  
If you are allergic to a specific food, exposure  
disease in the world  
evidence-based medicine  
may trigger an acute allergic reaction -  
In Europe, authorities, prescribers and  
payers are increasingly turning to registered  
and documented products to treat allergies.  
anaphylaxis - for which adrenaline auto-injectors  
are an effective rescue medication. In addition,  
recent advances in food AIT hold promise of a  
better life for people with food allergy.  
~500m  
people around the world are affected and  
consume products and services worth more  
than DKK 100 billion annually.  
ALK’s allergy solutions  
Allergy can  
lead to asthma  
Asthma is one of the world’s most common  
chronic childhood diseases. Preventing the  
progression of allergy into asthma would  
represent a major health breakthrough for  
millions of children.  
Internet  
The internet is the principal source of  
disease information for people with allergy:  
allergy is googled >100 million times a year.  
1 in 10 AIT candidates  
receives treatment  
SLIT-tablets are  
the best documented  
AIT treatments  
~50m  
Since 2001, 23,000 people have taken part  
in ALK’s clinical programmes. Its tablets are  
now the best documented AIT products in  
the world and are approved to the highest  
regulatory standards  
people with allergy are so seriously affected  
that they are potential candidates  
The COVID effect  
for treatment with AIT, but fewer than 5m  
people receive treatment today.  
In 2020, the coronavirus pandemic and  
associated containment measures restricted the  
ability of people with allergy to visit clinics in many  
countries, increasing interest in telemedicine and  
home-based treatment options.  
Symptoms of  
respiratory allergies  
Respiratory allergies can affect  
both the upper and lower  
respiratory tract.  
(FDA, EMA, PMDA etc).  
Climate change may  
increase number of people  
with severe allergy  
Climate change means longer pollen  
seasons and more people suffering from  
severe allergies. Warmer weather is also  
causing ragweed to spread to new regions.  
Biological products  
ALK's SLIT-tablets have been developed  
from natural ingredients and are  
strongly protected thanks to unique  
biological manufacturing processes and  
standardisation procedures.  
Digital engagement  
Through ALK’s klarify digital platform, people with  
allergy are able to get information about their  
condition and seek treatment in greater numbers.  
Upper respiratory  
tract – allergic  
rhinitis  
Eyes  
Nose  
Runny or blocked  
nose, itchy eyes,  
sneezing.  
Mouth  
Throat  
Included in  
asthma guidelines  
The Global Initiative for Asthma,  
GINA, recommends sublingual  
AIT as a treatment option in  
patients with house dust mite-  
induced allergic asthma.  
Complete tablet portfolio  
Lower respiratory  
tract – allergic  
asthma  
Trachea  
Bronchus  
Lungs  
>80%  
Urbanisation  
Shortness of  
of adults with respiratory allergic disease  
requiring AIT are now covered by ALK's  
portfolio of five SLIT-tablets which can be  
taken at home.  
Increasing migration to cities - especially  
in Asia - will further drive the prevalence of  
allergies such that ALK expects it to reach  
similar levels to Europe and the USA.  
breath, narrowed  
airways, coughing,  
wheezing.  
 
Management’s review • Annual report 2020 • ALK  
8
Letter from  
the Chairman and CEO  
2020 represented the final year of ALK’s strategic transformation, and our focus remained on the  
relentless execution of our goals. When we first announced this transformation, we said that we  
wanted to ‘fix and grow’ ALK by cleaning up past issues and establishing strong foundations to  
support growth. What 2020 clearly demonstrated is that we have been able to deliver on both of  
those promises, as a refocused ALK delivered 8% revenue growth while also proving resilient  
to an unprecedented global challenge, without which, growth would have been even stronger.  
Revenue growth was fuelled in the large part by a further spectacular increase in sales from our  
tablet portfolio of 42%, with the newly launched ITULAZAX® leading the way.  
Everyone at ALK  
can feel justifiably  
proud of the cultural and  
organisational transformation  
Throughout the transformation period, we have consistently  
overperformed relative to our promises, exceeding the  
cumulative sales forecast for 2018-20 by more than DKK  
700 million, delivering EBITDA that was ahead of target, and  
registering significantly improved cash flow that was more  
than DKK 700 million ahead of plan. The positive results are  
also there to see across our four areas of strategic focus:  
ODACTRA®, although long-standing financial disincentives  
for prescribers, and the impact of COVID, have challenged  
commercial progress there. We have invested significantly to  
improve our patient engagement capabilities by developing  
our klarify digital ecosystem, which offers help and resources  
to the millions of people living with allergy so they can better  
understand and manage their condition. Importantly, klarify  
also enables us to mobilise patients to seek diagnosis  
and treatment in greater numbers. In addition to all of the  
above, we have advanced our site specialisation strategy  
and significantly pruned our portfolio, while also enhancing  
manufacturing efficiency, quality, and robustness. Together,  
these initiatives will secure long-term margin improvements.  
that they have contributed to  
over the past three years.  
Anders Hedegaard,  
Chairman of the Board  
Tablets are now the undisputed growth engine of ALK,  
delivering an average growth of 37% over three years  
(CAGR). Meanwhile, the addition of ITULAZAX® to our range  
completed our mission to cover the five major most important  
respiratory allergies. In North America, we have established  
a new sales infrastructure and launched ACARIZAX®/  
Continues  
 
 
Management’s review • Annual report 2020 • ALK  
9
Sustainable growth and profitability  
opportunities over the next five-to-10 years – such as an  
expanded offering in anaphylaxis, an entry into food allergy  
treatment, and research into innovative new treatments  
for high-impact allergic conditions. If we repeat our recent  
success in each of these areas over the coming years, we  
will establish a much larger ALK capable of continuously  
generating attractive shareholder returns.  
Having made the necessary, significant investments to  
transform ALK, we are now entering the next phase of the  
company’s development, where we must carefully work  
to sustain long-term growth, while also returning ALK to  
profitability.  
Our overall trajectory remains unchanged, because we are  
still convinced that the four priorities we established three  
years ago are the most critical to delivering future growth.  
Moreover, maintaining this continuity of focus will allow us to  
build on the foundations that we have now established, using  
our progress in each of these areas as a springboard from  
which to drive further growth.  
The commitment of our employees has been instrumental  
to delivering on the very ambitious targets we set when  
the strategy was first announced, and everyone at ALK  
can feel justifiably proud of the cultural and organisational  
transformation that they have contributed to over the past  
three years. Moreover, the work we have done together to  
strengthen ALK’s foundations has been critical to our ability  
to withstand the challenge of COVID, in response to which, not  
only did our employees swiftly implement our contingency  
plans and keep each other safe, but they also enabled ALK to  
maintain an uninterrupted supply of medicines for those who  
rely upon them.  
Tablets will remain our primary growth driver for the  
foreseeable future, and effective life-cycle management  
will be important to supporting their continued strong  
performance. This means expanding into new countries  
– such as China, and extending coverage to new patient  
groups – including children. Clearly, the US market still has  
largely untapped potential for ALK and will require much  
creativity and persistence before it fulfils our expectations  
but, as in other parts of the world, if we support our efforts  
with an effective commercial strategy by expanding the reach  
of klarify and establishing a broader, scalable sales model,  
and we back that up with excellence and robustness within  
our organisation, there is much more that we can achieve with  
the assets already at our disposal.  
Having made the  
necessary, significant  
investments to transform  
ALK, we are now entering the  
We continue to value the trust placed in us by patients,  
prescribers, and investors, and we will maintain our efforts  
to sustain and strengthen that trust wherever possible. By  
successfully executing the next phase of our development,  
which is designed to deliver sustainable growth and  
profitability, we can continue our progress towards becoming  
the 'go-to' allergy company.  
next phase of the company’s  
development, where we must  
carefully work to sustain  
long-term growth, while also  
returning ALK to profitability.  
Carsten Hellmann,  
President & CEO  
Nevertheless, we have also taken care to incorporate  
initiatives that have the ability to accelerate our long-term  
development. Projects that may not make a significant  
contribution immediately, but which offer even further growth  
Anders Hedegaard  
Chairman of the Board  
Carsten Hellmann  
President & CEO  
 
Management’s review • Annual report 2020 • ALK 10  
2021 outlook  
ALK expects growth across all sales regions  
in 2021, and revenue is projected to increase  
by 8-12% organically in local currencies, with  
the tablet portfolio expected to remain the key  
growth driver.  
growth negatively by approximately 1  
percentage point.  
2021 expectations  
ALK expects broad-based growth across  
all sales regions. The mid-point of the  
projected revenue range assumes that  
sales in Europe will increase by around  
10%. Sales in North America are expected  
to recover from the impact of COVID during  
2021, growing in double digits, while  
sales growth in International markets is  
projected to temporarily slow to high single  
digits. This is mainly due to growth in Japan  
becoming more incremental following the  
extraordinarily high rates seen when Torii  
converted patients from an outgoing legacy  
product to the CEDARCURE™ tablet, and  
built up its inventories of CEDARCURE™ and  
MITICURE™.  
Revenue  
8-12% organic growth  
– in local currencies  
Growth across all sales regions  
As a consequence of significant R&D cost  
delays from 2020 to 2021 due to the impact  
of COVID, and a gradual normalisation of  
capacity costs, operating profit (EBITDA) is  
expected to be close to that seen in 2020,  
despite revenue growth and an improved  
gross margin, attributable to tablet sales  
growth, and efficiencies.  
EBITDA  
ALK’s working assumption is that the first half  
of 2021, and especially Q1, will continue to  
be impacted by COVID, especially in relation  
to allergy patients’ ability and willingness to  
visit healthcare professionals. This is likely  
to continue to impact the sales of treatments  
that rely on more frequent clinic visits, while  
sales of tablets are expected to remain  
resilient.  
DKK 325-425 million  
Operating profit (EBITDA) – close to that seen in 2020, mainly due to  
COVID-related delays in R&D activities  
Substantial, DKK ~150 million increase in R&D costs  
Tablets, ALK’s single largest product  
category, will remain key to growth in 2021.  
ALK plans for strong, double-digit tablet sales  
growth in Europe and North America, while  
growth in Japan will be slower for the reasons  
stated above. Taking these factors together,  
ALK estimates that global tablet sales growth  
will exceed 20% in 2021, continuing their  
strong positive trajectory.  
Free cash flow  
Consequently, and as a result of the quarterly  
variations in 2020, fluctuations in revenue  
growth and earnings are likely from quarter to  
quarter during 2021.  
DKK minus 200-300 million  
vs. DKK +56 million in 2020  
Impacted by payments postponed from 2020  
Revenue  
In addition, ALK expects low single-digit  
sales growth from the remaining, non-tablet  
product portfolio, mainly driven by SCIT  
products, and double-digit sales growth from  
the Jext® adrenaline auto-injector.  
Organic growth is projected at 8-12% in  
local currencies. Discontinuations of legacy  
products are estimated to impact projected  
Continues  
 
 
Management’s review • Annual report 2020 • ALK 11  
The higher end of the projected revenue  
range assumes accelerated sales growth  
across all regions with tablets leading  
the way and faster market share gains,  
supported by a continuing regulatory  
transition towards evidence-based AIT  
products in key markets. The lower end of the  
revenue range incorporates pricing pressure,  
particularly in southern Europe, and/or more  
pronounced, ongoing negative effects from  
COVID.  
Operating profit  
Free cash flow  
Forward-looking statements  
Capacity costs will be influenced by a  
significant increase in R&D expenses in  
order to complete the clinical development  
of the tablet portfolio and gather further  
evidence for the tablets’ use in children,  
adolescents and to secure registrations  
in new geographies. R&D costs for 2021  
are estimated at around DKK 650 million,  
a significant increase over 2020, of which,  
approximately DKK 100 million relates to  
activities that were originally scheduled for  
2020 but were postponed due to the impact of  
COVID on patient recruitment for clinical trials.  
Free cash flow is expected to be negative, in  
the region of DKK 200-300 million. Free cash  
flow will be impacted by changes in working  
capital, including a one-off repayment of up  
to DKK 175 million in accrued rebates, which  
was originally scheduled for 2020, as well  
as a deadline extension for the settlement  
of around DKK 50 million related to 2020 tax  
payments for employees in Denmark. CAPEX  
is projected at approximately DKK 300 million  
with investments focused on streamlining  
the manufacturing footprint and further  
specialisation at ALK’s production facilities.  
This report contains forward-looking  
statements, including forecasts of future  
revenue, operating profit and cash  
flow, as well as expected business-  
related events. Such statements are,  
by their very nature, subject to risks  
and uncertainties, as various factors,  
some of which are beyond the control  
of ALK, may cause actual results and  
performance to differ materially from the  
forecasts made in this report. Without  
being exhaustive, such factors include,  
e.g., consequences of the global COVID  
pandemic, general economic and  
business-related conditions, including:  
legal issues, uncertainty relating to  
demand, pricing, reimbursement  
rules, partners’ plans and forecasts,  
fluctuations in exchange rates,  
competitive factors and reliance on  
suppliers. Additional factors include  
the risks associated with the sourcing  
and manufacturing of ALK’s products  
as well as the potential for side effects  
from the use of ALK’s existing and future  
products, as allergy immunotherapy  
may be associated with allergic  
Margins  
The gross margin is expected to increase by  
1-2 percentage points versus 2020, driven  
by efficiencies and higher sales – especially  
from tablets, with higher volumes absorbed  
by existing capacity. ALK will continue  
to allocate significant resources to the  
execution of its portfolio and site strategy,  
which designates each production facility  
as a centre of manufacturing excellence  
and is consolidating the number of active  
pharmaceutical ingredients used across the  
portfolio. These activities – in combination  
with increased sales and efficiencies that  
come from utilising higher-volume production  
lines – are expected to lead to substantial,  
long-term margin improvements.  
Sales and marketing activities are expected  
to gradually return to normal as the impact of  
COVID eases, particularly in the second half of  
the year. For the full year, costs are expected  
to rise in line with support for growth  
initiatives, although ALK will continue to seek  
to leverage its existing sales and marketing  
platforms to drive margin improvement.  
Other assumptions  
The outlook does not include any revenue  
from acquisitions, new partnerships or the in-  
licensing of adjacent products and services,  
nor does it include any sizeable payments  
related to M&As or in-licensing activities. The  
outlook is based on current exchange rates,  
resulting in a negative effect of approximately  
1 percentage point on reported revenue  
growth and an immaterial effect on reported  
EBITDA.  
On this basis, ALK expects the operating profit  
(EBITDA) to be in the range of DKK 325-425  
million, which is largely level with 2020's  
EBITDA of DKK 395 million.  
reactions of differing extents, durations  
and severities.  
 
Management’s review • Annual report 2020 • ALK 12  
Performance  
13 Financial highlights and key ratios  
14 Sales and market trends  
16 COVID-19: The defining challenge of 2020  
17 Financial review of 2020  
19 Q4 review  
 
 
Management’s review • Annual report 2020 • ALK 13  
Financial highlights and key ratios for the ALK Group*  
DKK  
2020  
DKK  
2019  
DKK  
2018  
DKK  
2017  
DKK  
2016  
EUR  
2020  
EUR  
2019  
DKK  
2020  
DKK  
2019  
DKK  
2018  
DKK  
2017  
DKK  
2016  
EUR  
2020  
EUR  
2019  
Amounts in DKKm/EURm**  
Amounts in DKKm/EURm**  
Income statement  
Revenue  
Information on shares  
Proposed dividend  
3,491  
395  
3,274  
241  
2,915  
136  
2,910  
253  
3,005  
642  
479  
8
469  
53  
438  
32  
-
-
-
-
51  
101  
-
14.9  
-
14.9  
EBITDA  
Share capital  
111  
111  
111  
111  
Operating profit/(loss) (EBIT)  
Net financial items  
150  
(14)  
(17)  
(31)  
(50)  
2,385  
(96)  
(80)  
20  
(2)  
Shares in thousands of DKK 10 each  
Share price, at year end  
Net asset value per share  
11,141 11,141 11,141 11,141  
10,128  
920  
11,141  
336.1  
38.0  
11,141  
218.9  
38.2  
(49)  
101  
(7)  
(42)  
(7)  
(2)  
(4)  
(7)  
2,500  
283  
1,635  
285  
960  
285  
740  
295  
Profit/(loss) before tax (EBT)  
Net profit/(loss)  
(103)  
(170)  
2,341  
(122)  
(158)  
2,213  
487  
270  
2,010  
14  
3
284  
25  
Average number of employees (FTE)  
2,419  
2,419  
2,385  
Key figures  
Gross margin – %  
58.1  
11.3  
0.8  
57.8  
7.4  
56.0  
4.7  
56.4  
8.7  
66.9  
21.4  
9.7  
58.1  
11.3  
0.8  
57.8  
7.4  
EBITDA margin – %  
Balance sheet  
Total assets  
Return on equity (ROE) – %  
ROIC incl. goodwill – %  
Pay-out ratio – %  
(1.6)  
(0.5)  
-
(5.3)  
(3.3)  
-
(5.1)  
(3.1)  
-
(1.6)  
(0.5)  
-
5,563  
2,664  
3,153  
5,495  
2,759  
3,176  
4,865  
2,968  
3,179  
4,958  
2,864  
3,290  
4,799  
2,353  
2,875  
748  
358  
424  
736  
369  
425  
5.5  
20.0  
18.9  
27.5  
27.2  
41.3  
33  
5.5  
Invested capital  
Equity  
-
-
Earnings/(loss) per share (EPS)  
Earnings/(loss) per share (DEPS), diluted  
Cash flow per share (CFPS)  
Price earnings ratio (PE)  
Share price/Net asset value  
2.3  
(4.6)  
(4.6)  
12.1  
(356)  
5.7  
(15.6)  
(15.6)  
(8.7)  
(61)  
3.4  
(15.9)  
(15.9)  
(39.0)  
(46)  
2.5  
0.3  
(0.6)  
(0.6)  
1.6  
2.3  
0.3  
Cash flow and investments  
Depreciation, amortisation  
and impairment  
27.6  
1,092  
8.8  
3.7  
1,092  
8.8  
(356)  
5.7  
245  
301  
255  
132  
232  
(95)  
333  
163  
405  
33  
40  
34  
18  
3.2  
Cash flow from operating activities  
Cash flow from investing activities  
(387)  
(358)  
(245)  
(157)  
(199)  
(204)  
(33)  
(21)  
Revenue growth – %  
Organic growth  
– of which investment in intangible assets  
– of which investment in tangible assetss  
(26)  
(196)  
(20)  
(147)  
(52)  
(126)  
(27)  
(240)  
(46)  
(179)  
(3)  
(26)  
(3)  
(20)  
8
11  
1
1
(1)  
-
(6)  
(1)  
4
19  
8
11  
1
Exchange rate differences  
Acquisitions/divestments  
Total growth revenue  
(1)  
(2)  
(1)  
– of which acquisitions of  
companies and operations  
-
(20)  
(25)  
(21)  
(94)  
-
-
(3)  
(3)  
-
-
-
-
-
Free cash flow  
56  
(294)  
(745)  
201  
8
7
12  
-
(3)  
17  
7
12  
*
Management’s review comprises pages 1-46 as well as ‘Financial highlights and key ratios by quarter for the ALK Group’ on page 97  
**Financial highlights and key ratios stated in EUR constitute supplementary information to the Management’s review. The exchange  
rate used in translating from DKK to EUR is the exchange rate prevailing on 31 December 2020 (EUR 100 = DKK 744) (31 December  
2019: EUR 100 = DKK 747)  
Read the ESG key figures overview here  
To come back to this page just click the button  
For definitions and reconciliation of alternative performance measures, see page 86  
 
 
Management’s review • Annual report 2020 • ALK 14  
Sales and market trends  
Overall revenue was DKK 3,491 million  
continuing constraints caused by COVID.  
Planned product discontinuations reduced  
growth by 4 percentage points, as numerous  
older SCIT and SLIT-drops products  
continued to be phased out in favour of  
documented, registered products.  
SCIT treatments rely on more frequent clinic  
visits, and were disproportionately affected  
by COVID since patients were either unable  
or unwilling to visit clinics and, in any case,  
capacity at many clinics – particularly in  
southern Europe – was significantly reduced.  
Revenue grew 8% organically in  
local currencies, and was in line  
with the most recent outlook,  
issued in November 2020. Planned  
portfolio rationalisations reduced  
growth by around 3 percentage  
points in 2020. ALK also saw an  
impact on sales from COVID,  
particularly in the USA, where  
ALK estimates the total value of  
missed sales exceeded DKK 100  
million.  
(3,274), which equates to organic growth of  
8% in local currencies. Growth was driven by  
tablets, which is ALK’s largest single product  
category, and which proved resilient to the  
effects of COVID – in part due to its suitability  
as an alternative option for patients who  
were unable to continue with their usual  
treatments. Tablet sales grew by 42% with  
ITULAZAX® leading the way, while SCIT  
products were negatively affected by the  
impact of COVID as they are administered  
during visits to allergy clinics. The COVID-  
effect impacted sales in the USA in particular,  
where conditions were challenging, with  
significantly fewer patients visiting allergy  
specialists.  
Revenue growth was largely fuelled by sales  
of SLIT-tablets, which were up 40% at DKK  
1,019 million (735). Sales benefited from the  
confluence of several factors: resilience to the  
impact of COVID versus alternative treatment  
options, the ongoing market shift in favour of  
evidence-based medicines, the benefits of  
an ALK sales excellence programme, and the  
ongoing roll-out of ITULAZAX®.  
Sales of other products were up 18% at DKK  
211 million (179), driven by strong demand  
for the adrenaline auto-injector Jext®, which  
registered 42% sales growth and market  
share gains in key markets.  
Overall revenue increased in most markets,  
especially Germany, which delivered double-  
digit growth following a significant increase  
in tablet sales with a promising performance  
by ITULAZAX®. Furthermore, ALK became the  
first company in Germany to offer a complete  
product range for major allergens comprised  
solely of registered AIT treatments, reflecting  
(Comparative figures for 2019 are shown  
in brackets. Revenue growth rates are  
organic and stated in local currencies, unless  
otherwise indicated)  
Combined SCIT and SLIT-drops sales were  
down 9% at DKK 1,320 million (1,454). Of  
this, 6 percentage points related to product  
discontinuations, as well as the fact that  
Europe  
European revenue increased by 8% to  
DKK 2,550 million (2,368) despite some  
Continues  
Revenue by geography  
Growth  
Revenue by geography  
Revenue by product line  
Growth  
Revenue by product line  
Europe  
International markets  
North America  
SCIT/SLIT-drops  
Other  
SLIT-tablets  
DKKm  
2020  
(l.c.)  
2019  
DKKm  
2020  
(l.c.)  
2019  
11% (7%)  
13% (15%)  
Europe  
2,550  
573  
8%  
-10%  
58%  
8%  
2,368  
669  
SCIT/SLIT-drops  
SLIT-tablets  
1,673  
1,370  
448  
-7%  
42%  
-4%  
8%  
1,818  
973  
North America  
Int'l markets  
Overall revenue  
73% (73%)  
48% (55%)  
16% (20%)  
368  
237  
Other products  
Overall revenue  
483  
3,491  
3,274  
3,491  
3,274  
2020  
(2019)  
2020  
(2019)  
39% (30%)  
 
 
Management’s review • Annual report 2020 • ALK 15  
an ongoing market shift in favour of  
North America  
Full-year sales of tablets in the region grew  
by 4% to DKK 85 million (85), driven by  
Canada as US sales stagnated. In volume  
terms, tablet uptake in North America  
increased by 28%, but market-building  
tactics such as rebates and coupons –  
essential to establishing any new medicine in  
this region – reduced effective sales prices.  
Sales of bulk allergen extracts were down  
5% at DKK 275 million (306), while sales of  
diagnostics and other products decreased  
19% to DKK 213 million (278) – mainly due  
to COVID reducing sales of non-allergy  
related life science products and the use of  
PRE-PEN® in hospitals.  
ALK became the first  
company in Germany  
registered, evidence-based products, which  
was further facilitated by a change to the fee  
model, mitigating unintended disincentives  
for doctors to prescribe tablets. In France,  
overall sales were unchanged as growth in  
tablet sales was offset by lower SLIT-drops  
sales. However, ALK remains the market  
leader in terms of the number of patients  
receiving treatment. Meanwhile, sales in  
Spain were also impacted by COVID, while the  
challenging conditions in Italy were further  
exacerbated.  
The fallout from the COVID pandemic  
made market conditions in North America  
challenging, especially in the USA, and  
suppressed sales across the portfolio. A  
major influence on this was patients’ ability  
and willingness to visit allergy clinics, while  
a further challenge came from the fact that  
many clinics were running at a reduced  
capacity. At one point, during Q2, ALK  
estimated that up to half of US allergy clinics  
were fully or partially closed, while those that  
were open were seeing significantly fewer  
patients.  
to offer a complete product  
range for major allergens  
comprised solely of  
registered AIT treatments.  
Overall, market conditions were largely  
stable, and there were no notable changes  
affecting the pricing and reimbursement of  
AIT products, although the risk of pressure in  
southern Europe remains.  
In consequence, revenue in North America  
was down 10% organically in local currencies  
to DKK 573 million (669). This was despite  
some improvements in H2, particularly in  
sales of tablets and bulk SCIT products.  
International markets  
Revenue from International markets was up  
58% in local currencies at DKK 368 million  
(237) as ALK’s largest markets in the region,  
Japan and China, resisted and rebounded  
from COVID, respectively.  
Revenue in Japan from product supply and  
sales royalties grew by 80%. ALK’s partner  
Torii continued to successfully build the  
5-year total revenue by geography  
5-year total revenue by product line  
Europe  
North America  
SCIT/SLIT-drops  
Other  
SLIT-tablets  
market for tablets and MITICURE™ sales were  
up strongly, while sales of CEDARCURE™  
were boosted by the conversion of patients  
from an outgoing legacy product. Revenue  
in Japan also benefited from the effects of  
stock-building by Torii, which provided an  
extraordinary boost to revenue in Q3 and Q4.  
ALK sales in China grew by 28%, while growth  
was also recorded in south-east Asia, Turkey,  
and Israel.  
International markets  
DKKm  
DKKm  
3,500  
3,000  
2,500  
2,000  
1,500  
1,000  
500  
3,500  
3,000  
2,500  
2,000  
1,500  
1,000  
500  
0
0
2016  
2017  
2018  
2019  
2020  
2016  
2017  
2018  
2019  
2020  
 
Management’s review • Annual report 2020 • ALK 16  
COVID-19:  
e defining challenge of 2020  
by patients at home – proved extremely  
resilient. Meanwhile ALK made good use of  
its digital engagement platforms to support  
healthcare professionals and patients.  
e emergence of COVID, its  
global spread, and subsequent  
measures to contain it, all had  
a significant effect on ALK’s  
business in 2020.  
Regions where COVID first took hold, such  
as China and later, Europe, were the first  
to stage a market recovery, meaning that  
Once the seriousness of the pandemic  
became clear, in Q1, ALK took immediate  
action to protect staff, and invoked  
contingency measures to safeguard business  
continuity and maintain the supply of ALK  
products for doctors and their patients. As a  
result of these measures, ALK’s inventories  
of both supplies and finished products  
remained robust throughout the year.  
patients once again became able to visit  
healthcare professionals without significant  
limitations, although, in some countries  
– notably in southern Europe – capacity  
was still constrained to some extent. ALK’s  
working assumption is that the first half of  
2021, and especially Q1, will continue to be  
somewhat impacted by COVID, especially  
in relation to allergy patients’ ability and  
willingness to visit healthcare professionals.  
This is likely to continue to impact treatments  
that rely on more frequent clinic visits, while  
tablets are expected to remain resilient.  
ALK’s COVID task force  
In February 2020, just a few weeks after reports began appearing of a new coronavirus  
emerging in China, ALK convened the first meeting of its COVID task force. Its purpose  
was to anticipate and mitigate the potential consequences of the virus, should it spread  
further, and to promote global guidelines for the ALK organisation on managing the  
situation, including initiatives to maintain a sense of togetherness among employees  
working from home during lockdowns.  
The impact on sales was greatest for those  
products that are typically delivered in an  
allergy clinical or hospital, such as SCIT  
products, and in specific markets, such as the  
USA, where it is estimated that the total value  
of missed sales exceeded DKK 100 million.  
Outside of the USA, sales of ALK’s SLIT-  
tablets – which can be self-administered  
COVID also had a significant effect on ALK’s  
clinical development activities, particularly  
on patient recruitment which, at one point,  
was placed on hold for all trials.  
The task force’s approach was both proactive in that it developed a wide-ranging  
contingency plan to safeguard both employees and the ongoing supply of medicines,  
and conservative in that it applied a ‘safety first’ principle to all the scenarios it  
considered. One example of this was the construction of a separate, temporary staff  
restaurant in Denmark solely for the use of manufacturing staff.  
The task force served a dual role in overseeing business continuity in Denmark, and  
offering guidance to those coordinating contingency measures in other countries, which  
were tailored to ensure compliance with the differing local situations and regulations.  
Two critical successes of ALK’s actions were that, despite many of its employees  
being quarantined at various times, throughout 2020, there was no uncontrolled  
chain of infections within the company and that the supply of ALK's products remained  
uninterrupted throughout the year. The task force will continue to meet in 2021 until the  
threat of COVID subsides.  
Continues  
 
 
Management’s review • Annual report 2020 • ALK 17  
Financial review of 2020  
(Comparative figures for 2019 are shown  
in brackets. Revenue growth rates are  
organic and stated in local currencies, unless  
otherwise indicated)  
58% (58%), and reflected changes in the  
2020 guidance history  
product mix, increased sales – especially  
from tablets – but also lower sales of legacy  
products in Europe and significant costs  
associated with compliance efforts to secure  
robustness in product supply, as well as  
the implementation of the product and site  
strategy. Increased shipments of tablets at  
a lower gross margin to ALK’s partner for  
Japan lowered reported gross margin by  
approximately 1 percentage point.  
2020E  
2020E  
12 August  
outlook  
2020E  
5 November  
outlook  
5 February  
outlook  
2020  
Actual  
DKK  
2020 revenue increased organically by  
8% in local currencies to DKK 3,491 million  
(3,274) and was negatively impacted by  
COVID, predominantly in the USA. Exchange  
rate fluctuations impacted reported revenue  
growth negatively by 1 percentage point.  
The divestment of the US veterinary business  
in late 2019 reduced reported growth by  
approximately 0.5 of a percentage point.  
Revenue  
+8-12% organic  
Lower end of  
+8-12% organic  
~ +8% organic  
+8% organic  
EBITDA  
200-300m  
~(300)m  
300-350m  
~(200)m  
350-400m  
~0m  
395m  
+56m  
Free cash flow  
Capacity costs decreased 1% in local  
currencies to DKK 1,877 million (1,922).  
R&D expenses increased by 11% in local  
currencies to DKK 515 million (466) in  
support of clinical trials, although this was  
significantly lower than expected following  
delays to clinical activities due to the COVID  
pandemic. Particularly affected was the  
recruitment of patients for clinical trials.  
Sales and marketing expenses decreased  
organically by 5% in local currencies to DKK  
1,125 million (1,210), reflecting savings as a  
consequence of COVID restricting sales and  
marketing activities in many markets, and  
operational leverage of ALK’s commercial  
activities. Administrative expenses  
decreased 4% in local currencies to DKK 237  
million (246).  
Cost of sales increased 7% organically  
in local currencies to DKK 1,463 million  
(1,382). The gross profit of DKK 2,028  
million (1,892) yielded a gross margin of  
Continues  
Revenue  
Gross profit  
Research and development  
Sales, marketing and administration  
Revenue  
Total revenue growth  
Gross profit  
Cost of sales  
Gross margin  
Research and development expenses  
Percentage of revenue  
Administrative expenses  
Sales and marketing expenses  
Percentage of revenue  
DKKm  
%
DKKm  
%
DKKm  
500  
%
DKKm  
%
3,500  
30  
3,500  
80  
20  
1,500  
70  
3,000  
2,500  
2,000  
1,500  
1,000  
20  
10  
0
3,000  
2,500  
2,000  
1,500  
1,000  
70  
60  
50  
40  
30  
400  
300  
200  
100  
0
16  
12  
8
1,200  
900  
600  
300  
0
60  
50  
40  
30  
20  
-10  
-20  
4
0
2016 2017 2018 2019 2020  
2016 2017 2018 2019 2020  
2016 2017 2018 2019 2020  
2016 2017 2018 2019 2020  
 
 
Management’s review • Annual report 2020 • ALK 18  
EBITDA (operating profit before  
impacted by changes in working capital as  
a consequence of the company’s growth  
momentum.  
At the end of 2020, cash and marketable  
securities totalled DKK 298 million (316). In  
addition, ALK has an unused credit facility of  
DKK 600 million which runs until 2022.  
depreciation and amortisation) increased  
64% to DKK 395 million (241) and was  
better than expected, reflecting savings  
and delayed R&D expenditure due to COVID.  
Exchange rates did have a small negative  
impact on operating profit.  
Cash flow from investment activities was  
DKK minus 245 million (minus 157) mainly  
relating to upgrades to legacy production  
and the build-up of capacity for SLIT-tablet  
production.  
Equity totalled DKK 3,153 million (3,176) at  
the end of the year, and the equity ratio was  
57% (58%).  
Net financials were a loss of DKK 49 million  
(loss of 17) mainly relating to net interest  
expenses and currency fluctuations on  
intercompany loans. Tax on the profit  
totalled DKK 76 million (19) and net profit  
was DKK 25 million (a loss of 50).  
At the end of 2020, ALK held 212,873 of its  
own shares or 1.9% (2.2%) of the share  
capital.  
Free cash flow was positive at DKK 56  
million (minus 25), which was better than  
expected due to higher earnings.  
Cash flow from financing activities was  
DKK minus 62 million (minus 57), mainly  
relating to minor repayments of borrowings  
and the settlement of incentive programmes.  
Cash flow from operating activities was  
positive at DKK 301 million (132) mainly as  
a consequence of the increased EBITDA.  
Furthermore, cash flow was negatively  
EBITDA  
EBITDA  
EBITDA margin  
DKKm  
%
1,000  
25  
800  
600  
400  
200  
0
20  
15  
10  
5
0
2016 2017 2018 2019 2020  
 
Management’s review • Annual report 2020 • ALK 19  
Q4 review  
(Comparative figures for 2019 are shown  
in brackets. Revenue growth rates are  
organic and stated in local currencies, unless  
otherwise indicated)  
selected European markets, but the overall  
impact of the pandemic was reduced.  
Combined SCIT and SLIT-drops sales were  
down 2% at DKK 477 million (501)  
general inventory stocking at wholesalers  
ahead of 2021 was observed in selected  
markets.  
Q4 highlights  
Sales of other products declined 1% to  
DKK 105 million (113)  
Total revenue was up 16% organically in  
local currencies at DKK 991 million (883).  
Portfolio rationalisations reduced growth  
by 3 percentage points. In addition,  
reported growth was negatively impacted  
by 4 percentage points due to exchange  
rate fluctuations  
In North America, Q4 revenue was down  
2%, which nevertheless reflected a rise in  
demand after the very challenging market  
conditions caused by COVID in Q2 and Q3.  
Tablet sales in the region were up 37%,  
while sales of bulk allergen extracts (SCIT)  
decreased 1%. Sales of other products  
and services declined 13% on the impact  
of COVID. In December, RAGWITEK® was  
approved for the treatment of moderate-to-  
Strong Q4 delivers results in line  
with latest outlook  
In Europe, revenue was up 17%, driven by  
strong uptake of the tablets, for which sales  
grew 54%. Combined sales of SCIT and  
SLIT-drops were down 2%, reflecting product  
discontinuations, patients switching to tablets  
and COVID-related constraints on clinic visits.  
Sales of other products increased 18% on  
high growth in sales of the Jext® adrenaline  
auto-injector, which were up 45%. Some  
ALK finished 2020 with a strong final  
quarter, registering 16% in organic revenue  
growth, fuelled by very strong tablet sales  
growth of 55% during the peak season for  
AIT treatment initiations. COVID continued  
to impact patients’ ability and willingness  
to visit clinics, especially in the USA and in  
Tablet sales grew by 55% to DKK 409  
million (269) with high, double-digit  
growth in all sales regions  
Continues  
Income statement  
Revenue by geography  
Revenue by product line  
Q4 Growth  
Q4  
Q4 Growth  
Q4  
Amounts in DKKm  
Q4 2020  
Q4 2019  
DKKm  
2020  
(l.c.)  
2019  
DKKm  
2020  
(l.c.)  
2019  
Revenue  
991  
412  
579  
58%  
178  
338  
72  
883  
368  
515  
58%  
149  
325  
65  
Europe  
734  
155  
102  
991  
17%  
-2%  
46%  
16%  
638  
173  
72  
SCIT/SLIT-drops  
SLIT-tablets  
Other  
477  
409  
105  
991  
-2%  
55%  
-1%  
16%  
501  
269  
113  
883  
Cost of sales  
North America  
Int'l markets  
Revenue  
Gross profit  
Gross margin  
883  
Revenue  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Other operating items, net  
Operating profit/(loss) (EBIT)  
Net financial items  
Revenue by geography  
Revenue by product line  
0
14  
Europe  
International markets  
North America  
SCIT/SLIT-drops  
Other  
SLIT-tablets  
(9)  
(10)  
(4)  
(5)  
(14)  
17  
10% (8%)  
11% (13%)  
Profit/(loss) before tax (EBT)  
Tax on profit  
(14)  
15  
74% (72%)  
48% (57%)  
16% (20%)  
41% (30%)  
Net profit/(loss)  
(31)  
(29)  
2020  
(2019)  
2020  
(2019)  
Operating profit before depreciation and amortisation (EBITDA)  
64  
48  
 
 
Management’s review • Annual report 2020 • ALK 20  
severe ragweed pollen allergy in children  
age five and older in Canada.  
robustness in product supply, as well as  
the implementation of the product and site  
strategy.  
Revenue from International markets grew  
by 46%, fuelled by the strong uptake of  
tablets in Japan including planned, advance  
stocking by Torii ahead of 2021, which  
provided an extraordinary boost to revenue  
during the quarter.  
Capacity costs increased 11% in local  
currencies. Sales and marketing expenses  
increased 7% in local currencies as ALK  
increasingly focused on its digital platforms  
while COVID restricted other promotional  
activities. R&D expenses increased by 21% in  
local currencies, however, COVID continued to  
hinder the recruitment of patients for clinical  
trials.  
During Q4, ALK saw a clear impact on its  
clinical development activities from COVID.  
The anticipated new timelines for ALK's key  
clinical trials are detailed below.  
EBITDA of DKK 64 million (48) was in line  
with the most recent expectations, reflecting  
higher sales, as well as savings and delayed  
R&D expenditure due to COVID.  
Gross margin was 58% (58%), reflecting  
changes in the product mix, higher tablet  
sales, and increased lower-gross margin  
shipments to Japan, but also significant  
costs for compliance efforts to solidify  
Original  
Expected  
Trial  
completion  
completion  
Comments  
HDM SLIT-tablet  
Registration trial  
China  
2021  
2022  
Expected to restart in mid-2021  
HDM SLIT-tablet  
Paediatric allergic rhinitis  
Europe/North America  
2022  
2023  
Patient recruitment extended with  
additional cohort  
HDM SLIT-tablet  
Paediatric allergic asthma  
Europe/North America  
2022  
2022  
Ongoing  
Tree SLIT-tablet  
Paediatric allergic rhinitis  
Europe/Canada  
2023  
2023  
To be initiated in 2021  
 
Management’s review • Annual report 2020 • ALK 21  
After collecting, drying and sieving  
catkins to release pollen, the lipid layer  
is removed to prepare the pollen for  
protein extraction  
Strategic  
transformation  
22 Strategy update  
26 Succeed in North America  
27 Complete and commercialise the tablet portfolio for all relevant ages  
29 Consumer engagement and new horizons  
30 Optimise for excellence  
31 Lead the way – people and planet  
32 Medium-term financial ambitions  
 
 
Management’s review • Annual report 2020 • ALK 22  
Strategy update  
company’s improved consumer engagement  
capabilities not only offer help and resources  
to millions of people with allergy, they  
also help mobilise consumers towards AIT  
treatment. Finally, through investments  
in quality upgrades, ongoing portfolio  
reduction and its site specialisation strategy,  
ALK has taken significant steps in improving  
manufacturing quality, efficiency and  
robustness.  
In December 2017, ALK  
announced a three-year strategic  
transformation to establish a  
broader presence in the allergy  
market and stimulate a new period  
of sustained growth.  
Over the past three years, the company  
has pursued a series of initiatives under  
four areas of focus: succeed in North  
America, complete and commercialise  
the tablet portfolio for all relevant ages,  
patient engagement and adjacent business  
opportunities, and optimise and reallocate  
resources towards growth initiatives.  
On the next page is a summary of what has  
been achieved in each of these focus areas.  
Continues  
The USA still holds considerable potential  
for ALK’s tablets despite long-standing  
financial disincentives for allergists to  
prescribe these products. ALK’s approach  
will be, with creativity and persistence, to  
continue establishing new and broader sales  
channels with the aim of gradually unlocking  
the potential of this market. Meanwhile,  
progress on the other three priorities has  
been significant. The SLIT-tablets now cover  
five of the most common global respiratory  
allergies and have become ALK’s growth  
engine, delivering an average growth of  
37% over the past three years (CAGR). The  
Over the past three  
years, ALK has pursued  
a series of initiatives under  
four areas of focus.  
Right: Tablets will remain ALK's primary  
growth driver for the foreseeable future and  
will be the focus of efforts to extend coverage  
to new patient groups – including children  
 
 
Management’s review • Annual report 2020 • ALK 23  
Key achievements 2018-20  
Financial results exceed  
expectations  
Accumulated three-year revenue  
Infrastructure established & ACARIZAX®/ODACTRA® launched  
Commercial strategy tested & rolled out, execution challenged by market barriers  
Initial tablet prescriber base established  
Succeed in  
North America  
>DKK 700 million  
better than expected*  
Growth in value of bulk business, pre-COVID  
(Actual: DKK 9.7 billion)  
Tablets now launched for all five major respiratory allergies  
Complete and  
commercialise  
tablet portfolio  
Accumulated three-year EBITDA  
Tablets as primary growth drivers with 37% growth (3-year CAGR)  
Ongoing clinical programme for paediatrics/adolescents, asthma, new market entries: on track pre-COVID  
~DKK 800 million  
better than expected  
(Actual: DKK 772 million)  
Digital platforms rolled out in six markets with hundreds of thousands of users  
US adrenaline strategy in place  
Patient  
engagement and  
adjacencies  
Small-scale consumer division launched  
Accumulated three-year free cash flow  
Drug discovery partnerships established  
>DKK 700 million  
better than expected  
Ongoing quality and robustness upgrades for legacy products  
New site strategy implemented  
(Actual: DKK minus 263 million)  
Optimise and  
reallocate  
Portfolio rationalisation: more than 300 products phased out  
Life-cycle management of core legacy portfolio: ~3,500 regulatory updates  
Cultural transformation in progress  
*
Based on the original 2018 outlook of DKK 2.7 billion and  
10% growth from 2019 onwards  
Continues  
 
Management’s review • Annual report 2020 • ALK 24  
Delivering sustainable growth and  
profitability  
ALK’s overall strategy remains unchanged,  
and is still anchored in the same four areas  
of focus, albeit with minor adjustments to  
some of the names to reflect the necessary  
steps to achieving profitability: succeed in  
North America, complete and commercialise  
the tablet portfolio, consumer engagement  
and new horizons, and finally, optimise for  
excellence.  
With the transformation complete, ALK is  
entering the next phase of its development.  
The challenge now is to use what has  
been achieved as the launchpad for future  
success as ALK seeks to become the allergy  
company by extending its leadership in  
respiratory allergy, expanding its position  
in anaphylaxis, establishing a presence in  
food allergy, and pursuing new innovations  
through research.  
In addition, some longer-term initiatives have  
been introduced which, as they develop, are  
designed to provide the additional impetus  
to accelerate ALK towards its longer-term  
aspiration of becoming a global allergy  
leader.  
The emphasis for the period 2021-23 is on  
achieving sustainable growth and increasing  
profitability following the significant  
investments made to successfully deliver the  
transformation.  
 
Management’s review • Annual report 2020 • ALK 25  
Focus areas during 2021-23  
Sustainable growth and profitability  
Sales growth of 10% or more  
Improving EBIT  
ALK seeks to  
become the  
Establish broader, scalable sales model for tablets  
Leverage digital platforms to mobilise patients  
Succeed in  
North America  
allergy company by  
Drive sales recovery across wider non-tablet product portfolio  
extending its leadership  
in respiratory allergy,  
expanding its position  
in anaphylaxis,  
Complete paediatric development and commercialise across ALK’s markets  
Complete and  
commercialise  
tablet portfolio  
establishing a presence  
in food allergy,  
Sustain commercial momentum of tablets (expand breadth and depth of prescriber base)  
Complete clinical development and prepare for launch in China, leverage clinical data to enter new markets  
and pursuing new  
innovations through  
research.  
From consumers to AIT patients – develop and leverage digital ecosystem for consumers, patients and HCPs  
Drive growth of Jext® in EU and prepare next generation global adrenaline solution  
Consumer  
engagement and  
new horizons  
Develop innovative new treatments for high-impact allergic conditions, including food allergies  
Maintain quality excellence and IT robustness  
Complete portfolio rationalisation and site specialisation  
Maintain and upgrade core legacy products  
Optimise for  
excellence  
Lead the way – people and planet  
Continues  
 
Management’s review • Annual report 2020 • ALK 26  
Succeed in North America  
Succeeding in North America –  
and particularly the USA, which  
is the world’s largest market for  
Short-term objectives  
Increase total sales  
pharmaceuticals – continues to  
in North America  
be an important priority for ALK,  
2021 target  
despite the setbacks caused by the  
COVID pandemic.  
≥+10% p.a.  
(2020 status: DKK 573m)  
ALK will continue to invest in its strategy for  
North America, developing and adapting its  
platform there to mobilise allergy patients  
How COVID impacted  
and deliver accelerated tablet sales,  
Mobilise consumers in the USA via  
and securing paediatric and adolescent  
indications for ACARIZAX®/ODACTRA® and  
RAGWITEK®, as well as introducing other  
prescription allergy solutions.  
digital engagement  
the US AIT market  
2021 target  
20,000  
(2020 status: ~5,800)  
COVID made its first big impact in the USA in March 2020, when a nationwide lockdown  
was ordered after infection rates spiked. The timing coincided with the start of the spring  
allergy season which is the peak season for treatment initiations in the USA, when the  
onset of seasonal allergy symptoms usually prompts a rush to allergy clinics.  
Central to this approach will be the further  
evolution of digital engagement tools, first  
mobilising patients to seek treatment for  
their allergies, and second, providing a  
framework that connects them with ever  
more healthcare professionals who are  
willing and able to prescribe ALK products.  
But by now, many clinics were closed, and where they remained open, patients were  
either unable or too fearful to visit them such that, during Q2, in-person visits to doctors'  
offices fell by around 70% versus the same period in 2019.  
Secure paediatric and adolescent  
indications for ACARIZAX®/ODACTRA®  
and RAGWITEK®  
This severely limited the number of new treatment initiations across ALK’s portfolio since,  
even for the tablets, US labelling requires that first doses should be administered under  
medical supervision. As a result, ODACTRA® new patient initiations fell by more than  
50% between March and May when compared with pre-COVID levels. ALK responded  
with a range of measures – supporting allergists by phone and online, ramping up  
direct-to-consumer communications, offering direct mail-outs of maintenance treatment  
to those already on tablets, and introducing digital tools to support customers, patients  
and its own sales organisation – so that, by Q4, ODACTRA® new patient initiations were  
exceeding those of Q1.  
2021 target  
Finally, ALK will continue to maintain and  
promote its bulk allergens and other  
products that underpin its relationship with,  
and commitment to, existing customers.  
These products represent an important  
commitment to offering a full range of allergy  
products and treatment options and will  
continue to play a role in delivering value  
growth in the region for ALK.  
RAGWITEK® paediatric  
approval in the USA,  
ACARIZAX® adolescents  
approval in Canada  
(2020 status: RAGWITEK® paediatric approval  
in Canada)  
By the end of the year, capacity in clinics had returned to around 80% of normal and  
ALK reverted to a mix of traditional and virtual sales methods. Despite the constrained  
capacity at clinics during 2020, ALK still saw an overall year-on-year increase in tablet  
sales volumes and saw further encouraging signs in December, when ODACTRA®  
prescription volumes substantially outpaced those from the same period in 2019.  
 
 
Management’s review • Annual report 2020 • ALK 27  
Complete and commercialise  
the tablet portfolio for  
all relevant ages  
e tablet portfolio now covers all five of the allergies that were targeted  
under this programme – house dust mite, grass, tree, ragweed and  
Japanese cedar. ese tablets remain ALK’s core assets and further  
development will focus on consolidating and expanding the leadership  
they give ALK in respiratory AIT.  
To achieve this, ALK will extend the reach of  
these products to cover new geographies  
and new patient groups – such as children  
and adolescents, and strengthening the  
evidence for their use in allergic asthma.  
What is critical, is that each of these steps  
goes hand in hand with the ability to  
successfully commercialise each expanded  
opportunity, and to fully realise the market  
potential of these assets.  
e transition towards registered  
products in Germany  
The AIT market in Germany has undergone a major transformation over the past  
decade, as a combination of key opinion leader-recommendations, tighter regulation,  
and revised rules on reimbursement and the doctors' fee structure have taken effect.  
Together, these changes have resulted in a market that is now much more favourable  
for documented, registered allergy treatments, and have resulted in a reduction from  
more than 6,000 prescription AIT products available in the mid-2000s, to fewer than 200  
today.  
Short-term objectives  
Increase global tablet sales  
in strong double digits annually  
Clinical development for paediatric use and  
geographic expansion  
In addition to key allergy opinion leaders, this shift has had vocal support from  
Germany’s medical insurance funds, who are keen to see evidence of tangible medical  
benefits from the treatments they offer reimbursement for.  
2021 target  
2021 target  
>20%  
(2020 status: DKK 1,370m)  
Progress as planned  
(2020 status: COVID-affected)  
From the pharmaceutical industry’s side, ALK has been a leader of the move towards  
registered treatments, from the thorough clinical documentation that accompanied  
its development of the SLIT-tablet portfolio, to the clinical development work it has  
undertaken in support of key legacy products. To the extent that, in July 2020, ALK  
became the first company in Germany to offer a complete product range for major  
allergens comprised solely of registered AIT treatments, which account for more than  
90% of all AIT treatments currently administered.  
 
 
Management’s review • Annual report 2020 • ALK 28  
SLIT-tablet portfolio covers five of the most common respiratory allergies  
ALK’s SLIT-tablet pipeline  
Phase I  
Phase II  
Phase III  
Filing  
Marketed  
Adults and children – Allergic rhinitis (grass)  
Adults and children – Allergic rhinitis (grass)  
Adults and children – Allergic rhinitis (grass)  
GRAZAX® Europe  
2007  
2014  
2017  
GRASTEK® North America  
GRAZAX® International markets*  
Adults – Allergic rhinitis (ragweed)  
RAGWITEK® North America  
2014  
2020  
~23,000  
Adults – Allergic rhinitis (ragweed)  
Children – Allergic rhinitis (ragweed)  
RAGWIZAX® Europe & Int'l markets  
people participated in  
clinical development of  
the tablets which saw  
21 Phase III trials  
RAGWIZAX® / RAGWITEK® Europe & NA  
***  
Adults – Allergic rhinitis and allergic asthma (HDM)  
Adolescents – Allergic rhinitis (HDM)  
ACARIZAX® Europe  
2016/17  
Adults – Allergic rhinitis (HDM)  
ACARIZAX®/ODACTRA® North America  
MITICURE™ Japan**  
2017/18  
2015/18  
Adults and children – Allergic rhinitis (HDM)  
Adults - Allergic rhinitis and allergic asthma (HDM)  
Adults – Allergic rhinitis (HDM)  
ACARIZAX® International markets*  
ACARIZAX® China  
****  
Children – Allergic asthma (HDM)  
ACARIZAX®/ODACTRA® Europe & NA  
Children – Allergic rhinitis (HDM)  
ACARIZAX®/ODACTRA® Europe & NA  
ODACTRA® North America  
Adolescents – Allergic rhinitis (HDM)  
Adults and children – Allergic rhinitis  
(Japanese cedar)  
CEDARCURE™ Japan**  
2018  
*
Licensed to Abbott for south-east  
Asia and Seqirus for Australia/  
New Zealand  
** Licensed to Torii for Japan  
*** Approved in Europe  
Adults – Allergic rhinitis (tree: birch family)  
Adults – Allergic rhinitis (tree: birch family)  
ITULAZAX® Europe  
ITULATEK® Canada  
2019  
2020  
**** Already marketed in selected markets  
 
Management’s review • Annual report 2020 • ALK 29  
Consumer engagement  
and new horizons  
The previous priority of seeking adjacent  
Over recent years, ALK has  
business opportunities has been broadened  
to encompass not just business development  
and partnership opportunities, but also  
the work of ALK – through its own research  
and development – to formulate and refine  
innovations outside the current respiratory  
AIT niche in order to establish a broader and  
more robust presence in the wider allergy  
segment over the long term. One example  
of this is the goal of entering the US market  
with an adrenaline auto-injector that is  
both affordable and competitive, with a  
submission to the US FDA no later than 2024.  
Another is a platform programme to enter the  
food allergy treatment market, which is an  
area of significant unmet medical need.  
developed a suite of digital tools  
and platforms as part of its klarif-  
branded ecosystem for consumers,  
so that that those most suitable  
for AIT can gain smoother access  
to a definitive diagnosis and  
appropriate treatment.  
Over the next few years, ALK will leverage  
these assets to further engage with and  
mobilise people with allergy. Through this  
engagement, ALK aims to not only promote  
a wider understanding of allergy, its causes  
and potential treatments, but also to more  
easily connect those suitable for treatment  
with AIT with a competent healthcare  
professional who can help them.  
How klarif is  
connecting with consumers  
In Q4, in the USA, ALK added a ‘speak to a doctor’ option to its klarify and branded  
digital engagement platforms, and saw more than 40,000 US consumers take its digital  
‘allergy-control’ test. This allows consumers to test whether their allergy is under control  
and offers them the option of an online consultation with a qualified allergist who can  
either issue an appropriate prescription, or refer them for a diagnosis to identify their  
specific allergy and, potentially, treatment with ALK’s SLIT-tablets. By engaging US  
consumers in this way, and identifying those who need more help and connecting them  
with allergists, ALK is connecting the dots for people suffering in silence with their allergy  
by offering them a convenient, and digitally-driven consumer journey.  
Finally, ALK will continue to identify and  
explore the potential addition of new  
products and services to its portfolio  
through an active programme of business  
development and thorough due diligence.  
In essence, ALK aims to become better at  
clarifying the journey and hand-holding  
eligible treatment candidates along the path  
from curious consumer, to AIT patient.  
This type of service is an important way of offering personalised, professional advice  
on allergy, while helping people with allergy to navigate the often confusing path to a  
clear diagnosis and treatment. In addition, it ensures referrals are directed to allergists  
who are willing and able to prescribe the full range of allergy treatment options – from  
symptomatics, to allergy shots (SCIT) and, importantly for ALK, SLIT-tablets.  
Short-term objectives  
Mobilise consumers globally via  
digital engagement  
Progress R&D innovation projects  
2021 targets  
While the regulations covering such offerings differ from country to country, ALK is  
developing a standardised methodology that can be adapted to local requirements. For  
example, in Germany, ALK is offering users of klarify the option of speaking to a facilitator  
who can guide them through the process of obtaining a diagnosis and contacting a  
healthcare professional who is able to prescribe an appropriate treatment for their  
allergy.  
Food:  
Prepare for clinical  
Anaphylaxis:  
Decide on US  
development pathway  
2021 target  
250,000  
(2020 status: ~200,000)  
development  
(2020 status: Research)  
(2020 status: Development)  
 
 
Management’s review • Annual report 2020 • ALK 30  
Optimise for excellence  
e fourth focus area will see ALK  
continue its already established  
programme of portfolio  
Short-term objectives  
Contribute to improved overall gross  
rationalisation, manufacturing  
site specialisation, and other  
initiatives designed to ensure  
regulatory compliance, robustness  
of supply, and to improve overall  
quality and efficiency. is  
includes an initiative to upgrade  
and safeguard ALK's core legacy  
products in Europe, which will  
continue.  
margin by continuing to prune the portfolio  
and optimising manufacturing operations  
2021 target  
+1-2 p.p.  
(2020 status: 58%)  
Upgrade product documentation and  
facilities to sustain long-term portfolio of  
legacy products  
Driving sales excellence  
across ALK  
2021 target  
In addition, ALK will continue its work to drive  
organisational excellence and to further  
embed the cultural progress delivered by the  
transformation effort. Efforts to improve the  
operational leverage of ALK’s commercial  
activities will also continue.  
Meet project  
milestones  
(2020 status: On track)  
The completion of the tablet portfolio and the rationalisation of ALK's legacy portfolio  
over recent years has significantly standardised the range of products sold by the  
company. By 2018, this increased standardisation allowed ALK to begin an initiative –  
known internally as RISE – to significantly strengthen its sales and marketing execution.  
A 'better practice' analysis was carried out of the company’s approach to preparing,  
conducting, and following up on customer calls, as well as the materials used to support  
them. The results of this, together with input from external benchmarking, were used  
to create and launch a global sales and coaching model for best practice customer  
interactions. In addition, marketing tools began to be developed with this framework in  
mind, maximising the ease and impact of local adaption. Behind the scenes, a digital  
ecosystem of support tools is being implemented, along with a single, global customer  
relationship management (CRM) system.  
No quality-related  
major interruptions to supply  
2021 target  
None  
(2020 status: None)  
All of this has resulted in improved ways of working within the Sales & Marketing  
organisation, and has established a more uniform approach to selling across ALK, as  
well as better leveraging of tools and resources. Meanwhile, ALK’s staff have welcomed  
the training they receive as a valuable investment in their future. The RISE model is now in  
place across Europe and will be expanded to North America, Russia and China in 2021.  
 
 
Management’s review • Annual report 2020 • ALK 31  
Lead the way –  
people and planet  
benefit from a strong framework of support  
Becoming the allergy company  
will require ALK to lead the way in  
many areas, not just scientifically  
and commercially, but also in the  
way it develops its people and  
organisation and in its approach to  
sustainability.  
for leadership and talent development.  
Central to this will be ALK’s cultural beliefs  
which encourage open dialogue, honest  
feedback, and strong cross-organisational  
cooperation.  
In addition, a renewed commitment to  
sustainability will see ALK establish a  
business model that will improve access  
to allergy care and deliver on ALK’s  
wider commitments to the environment,  
sustainability and governance.  
ALK’s efforts in each of the four focus areas  
will therefore be underpinned by a ‘platform’  
which addresses organisational agility and  
sustainability.  
Organisational agility initiatives will ensure  
that ALK’s future growth is enabled by highly  
engaged and motivated employees who  
Continues  
Short-term objectives  
Global talent development  
programme: ASPIRE  
New dialogue tool to support  
organisational development  
Sustainability progress*  
2021 target  
2021 target  
2021 target  
Implement  
(2020 status: N/A)  
Implement  
(2020 status: N/A)  
Meet ALK's goals  
(2020 status: See *)  
*
For a detailed breakdown of ALK’s sustainability performance and goals, please refer to the ESG (Environmental, Social, and  
Governance) key figures overview on page 36 of this report and the sustainablilty report available at www.alk.net/sustainability  
 
 
Management’s review • Annual report 2020 • ALK 32  
From EBITDA to EBIT for  
medium-term financial ambitions  
ALK will use EBIT – Earnings Before Interest and Taxes – as the prime indicator of the company’s  
long-term profitability aspirations. Hence, ALK’s long-term financial indications for operating profit  
are stated as EBIT rather than the previously applied EBITDA. The change reflects an increasing  
focus on the underlying earnings generation of the company and the fact that the next phase of the  
strategy is one of stable capital expenditure.  
Medium-term financial ambitions  
ALK's updated range of financial indicators for the next phase of its strategic development are:  
An ALK capable of delivering sustainable revenue growth of 10% or more annually  
An ALK capable of returning its business to profitability, and ramping up its EBIT-margin  
to approximately 25% in 2025  
These indications include costs for the development of food allergy immunotherapy  
solutions and new approaches to the treatment of severe allergic conditions.  
They also assume:  
• A gradually improving gross margin driven by higher sales and greater efficiencies  
• Continued extraordinarily high R&D spend during 2021-22, after which, the spend relative to  
revenue will decrease in parallel with the completion of large-scale development work on the  
respiratory tablet portfolio  
• Further leveraging of ALK’s existing sales and marketing platforms meaning that sales and  
marketing costs relative to revenue will further decrease  
• Annual CAPEX of around DKK 300 million associated with strategic investments, maintenance,  
optimisation efforts and IT  
• No revenue from acquisitions, new partnerships or the in-licensing of adjacent products and  
services has been included, nor have any sizeable payments related to M&As or in-licensing  
activities  
 
 
Management’s review • Annual report 2020 • ALK 33  
Corporate  
matters  
34 Sustainability  
37 Governance and ownership  
40 Risk management  
43 Remuneration  
44 Board of Directors  
46 Board of Management  
 
 
Management’s review • Annual report 2020 • ALK 34  
Sustainability  
In 2020, ALK instigated a step  
change in its commitment to  
sustainability with a continuing  
focus on ensuring good health  
and well-being for all, the details  
of which were formalised in a  
strategy titled Access to Allergy  
Care for All’.  
Materiality assessment chart  
Monitoring  
development  
and impact  
Continuous  
and systematic  
approach  
Increase strategic  
efforts to optimise  
positive impact  
ALK’s sustainability activities aim to mitigate  
risks and adverse impacts related to its  
business activities while also contributing  
to solving societal and environmental  
challenges where possible.  
To support its sustainability strategy further,  
ALK conducted a materiality assessment  
in 2020 to identify those aspects with  
the highest impact on its business and  
stakeholders. The assessment was based  
on a business analysis as well as input from  
relevant internal and external stakeholders,  
and it now forms the basis for target-setting  
and the prioritisation of resources.  
ALK business impact  
Continues  
 
 
Management’s review • Annual report 2020 • ALK 35  
Access to medicines  
These include policies on sustainability,  
environment, health and safety (EHS), tax,  
diversity, investor relations, remuneration, as  
well as anti-corruption and bribery policies.  
Performance highlights 2020  
The materiality assessment identified access  
to medicines, and helping as many people  
with allergy as possible, as key priorities  
for ALK’s sustainability activities. Over the  
years, ALK’s solutions have helped many  
people around the world. However, many  
more still lack access to modern medical care  
for their allergies and related asthma.  
38%  
of all consumed energy came from  
These policies guide ALK’s overall approach  
to integrating sustainability considerations  
into its overall business operations and, as  
such, contribute to ongoing improvements  
in the areas of environment and climate,  
labour rights, human rights and responsible  
business practices.  
renewable energy sources  
ALK aims to improve this by partnering  
with healthcare systems and professionals  
around the world, and through the wider  
democratisation and dissemination of its  
allergy solutions. This ambition covers the  
full range of ALK’s research, its diagnosis,  
treatment, disease modification and  
prevention solutions, as well as its training,  
education and awareness-raising expertise.  
The ultimate goal is an introduction of allergy  
solutions earlier in the patient journey in  
order to achieve better treatment outcomes  
for ever more people, wherever they may be.  
CO2 emissions were reduced by  
In addition, ALK’s Code of Conduct outlines  
the company’s expectations when it comes to  
professionalism, honesty and integrity. Every  
ALK manager is tasked with ensuring that  
each employee is familiar with the code and  
its importance. Furthermore, all employees  
are required to read and sign off on their  
commitment to it every year, and to complete  
an online training programme covering  
various aspects of the code.  
32%  
compared to a 2017-baseline  
Women made up  
46%  
of all managers  
At the same time, ALK remains committed  
to the UN Global Compact Principles and  
contributes to addressing 11 of the UN  
Sustainable Development Goals.  
ALK’s statutory annual report on  
sustainability and the gender diversity  
of management (as required by §99a,  
§99b and §107d of the Danish Financial  
Statements Act) is available at www.alk.net/  
sustainability. This report also highlights  
important actions taken in 2020 to support  
the UN Sustainable Development Goals.  
94%  
of employees were trained in  
Policies and guidelines  
ALK has various policies and guidelines  
in place to ensure its everyday activities  
support the commitments it has made.  
business ethics compliance  
 
Management’s review • Annual report 2020 • ALK 36  
ESG key figures overview  
Unit  
2020  
2019  
2018  
2017  
2016  
Environmental data  
CO2e scope 1  
Tonnes  
Tonnes  
GJ  
3,232  
3,380  
3,134  
6,443  
2,989  
6,239  
4,419  
5,238  
3,729  
2,436  
CO2e scope 2  
Energy consumption  
Renewable energy share  
Water consumption  
163,580  
38  
169,398*  
20  
168,035  
13  
169,275  
13  
144,826  
15  
%
m3  
110,530  
122,461  
117,252  
120,960  
102,418  
Social data  
Workforce  
Headcount  
%
2,486  
63  
2,406  
62  
2,369  
62  
2,284  
62  
2,168  
63  
Gender diversity, percentage of women  
Gender diversity, percentage of women  
at all management levels  
%
Times  
%
46  
1.14  
10  
47  
1.13  
11  
46  
1.12  
11  
47  
1.16  
12  
48  
1.23  
11  
Gender pay ratio of men to women  
Employee turnover ratio, voluntary and involuntary  
Absence due to sickness  
%
3.1  
2.7  
n/a  
n/a  
n/a  
Governance data  
Gender diversity, women as a  
percentage of shareholder-elected Board  
%
%
20  
98  
34  
17  
97  
29  
20  
98  
33  
17  
96  
49  
17  
97  
Board meeting attendance rate  
CEO pay ratio  
Times  
n/a**  
*
A reporting discrepancy was found post-publication of the 2020 annual report. The figure is updated to 169,398 from 164,639 reported last year  
** In 2016, ALK did not have a CEO for the full year  
Environment  
CO2 Scope 1 + 2 emissions include all material types of fuels and refrigerants, including HFCs, gas oil, diesel, heating etc. Renewable energy is subtracted from reported total  
CO2-emissions. Energy consumption in GJ is calculated as MWh*3.6. All environmental data is reported for production sites only (Hørsholm, Madrid, Vandeuil, Varennes, Port  
Washington, Post Falls and Oklahoma)  
Social  
Workforce is calculated as the headcount of permanent + temporary employees on 31 December 2020. All data is downloaded from ALK's internal HR system Workday. The gender  
pay ratio is calculated by comparing the median total compensation of men to women. The CEO is excluded. The turnover ratio is calculated by dividing the number of employees  
who left the company by the average number of employees in the reporting year. Absence is calculated as number of working days with absence due to sickness, divided by total  
working days  
Governance  
The CEO pay ratio is calculated as total compensation divided by median staff total compensation. The board meeting attendance rate is calculated as (number of  
meetings*number of members)-meetings not attended/(number of meetings*number of members)*100  
 
 
Management’s review • Annual report 2020 • ALK 37  
Governance and ownership  
ALK share price up  
53%  
Corporate governance  
statement furthermore describes key  
elements of ALK’s internal controls and risk  
management systems relating to financial  
reporting processes.  
The full Board of Directors’ ‘comply or  
explain’ review is available at https://ir.alk.  
net/corporate-governance.  
ALK’s statutory corporate governance  
statement for the financial year 2020,  
pursuant to section 107b of the Danish  
Financial Statement Act, is available at  
https://ir.alk.net/financial-reporting/risk-  
management.  
since 1 January 2020  
At the annual general meeting in March  
2020, Anders Hedegaard was elected as the  
new Chairman of the Board of Directors and  
Lene Skole was re-elected as Vice Chairman.  
Lars Holmqvist, Jakob Riis and Vincent  
Warnery were all re-elected as members of  
the Board of Directors.  
As a listed company, ALK is subject to the  
recommendations of the Danish Committee  
on Corporate Governance. ALK fulfils this  
obligation either by complying with its  
recommendations or by explaining the  
reason for non-compliance. ALK complies  
with 45 of the 47 recommendations. The  
exceptions in 2020 being that there was an  
overweight of non-independent directors  
on the Board (three out of five) and that the  
majority of members of the Audit Committee  
and Remuneration Committee were non-  
independent.  
Major shareholder  
The statement provides a detailed account of  
ALK’s management structure, including the  
Board of Directors’ composition, activities,  
remuneration and self-assessment. The  
40.3%  
The Lundbeck Foundation owns  
40.3% of ALK’s shares  
As announced on 6 November 2020, the  
Board of Directors will propose the election of  
Gitte Pugholm Aabo, CEO of GN Hearing A/S  
and Bertil Lindmark, Chief Medical Officer of  
Galecto A/S as new, independent members  
of the Board at the Company’s annual  
Core data for the share  
Share capital  
Nominal value  
DKK 111,411,960  
DKK 10 per share  
general meeting on 18 March 2021.  
Number of A shares 920,760 units with  
10 votes per share  
The Board has proposed establishing an  
adequate balance between independent  
and non-independent directors in 2021 by  
nominating two new, independent members  
to the Board of Directors, thus increasing the  
number of shareholder-elected members to  
seven. If the nominations are approved at the  
annual general meeting on 18 March 2021,  
the majority of the shareholder-elected  
members will be independent.  
Number of AA shares 92,076 units with  
10 votes per share  
ALK’s statutory corporate  
governance statement for the  
financial year 2020, pursuant to  
section 107b of the Danish Financial  
Statement Act  
Available at: https://ir.alk.net/financial-  
reporting/risk-management  
Number of B shares 10,128,360 units with  
1 vote per share  
Stock exchange  
Ticker symbol  
Indices C  
Nasdaq Copenhagen  
ALK B  
X4500 (healthcare),  
OMXCLCPI (LargeCap) and  
OMXCPI (all)  
ISIN  
DK0060027142  
ALKB.DC  
Bloomberg code  
Reuters code  
ADR ticker symbol  
LEI code  
The Board of Directors’  
‘comply or explain’ review  
Available at: https://ir.alk.net/  
corporate-governance  
ALKB_CO  
For the Audit and Remuneration Committees,  
ALK took an approach of selecting the best  
possible options in terms of experience and  
capabilities.  
AKABY  
529900SGCREUZCZ7P020  
Continues  
 
 
Management’s review • Annual report 2020 • ALK 38  
Shareholder information  
capital (98%). As at 31 December 2020, two  
shareholders had notified shareholdings of  
5% or more: the Lundbeck Foundation had  
a 40.3% interest (including A shares and AA  
shares) and ATP had a 7.5% interest. Of the  
30 largest registered shareholders, the vast  
majority were institutional investors – from  
North America, the UK and Scandinavia in  
particular. In the shareholder register, the  
international ownership was estimated at  
approximately 23% (23%), representing 36%  
of the free float of the B share capital (36%),  
excluding the Lundbeck Foundation’s holding  
and treasury shares.  
Major shareholders* and treasury shares as at 31 December 2020  
Shareholder  
Registered office  
Number of shares  
Interest  
40.3%  
Votes  
The aim is that the share price should offer  
a fair representation of ALK and reflect the  
company’s actual and expected ability to  
create shareholder value. ALK would further  
like the share to be liquid and to have a sound  
foundation, allowing for fair pricing and  
trading in the share.  
The Lundbeck Foundation  
Copenhagen, Denmark  
920,720 A shares  
92,072 AA shares  
67.2%  
3,474,827 B shares  
830,794 B shares  
212,873 B shares  
ATP**  
Hillerød, Denmark  
7.5%  
1.9%  
4.1%  
-
ALK – own shares  
Hørsholm, Denmark  
* Notified shareholdings of 5% or more of the company’s shares  
** The Danish Labour Market Supplementary Pension  
Ownership  
The total share capital is divided into A  
shares, AA shares and B shares (cf. core  
data table on the previous page). The A  
shares and AA shares are not listed and  
are predominantly held by the Lundbeck  
Foundation, while all B shares are listed and  
freely negotiable. At the end of 2020, ALK  
had 17,697 registered shareholders, versus  
12,979 at the end of 2019. The registered  
shareholders owned 98% of the share  
obligations related to ALK’s long-term  
incentive programmes.  
2020 at DKK 2,500. The daily trading liquidity  
improved further during 2020 and averaged  
DKK 31 million (20).  
ALK’s holding of its own shares was reduced  
following the settlement of share option and  
conditional share programmes. At the end  
of the year, ALK held 212,873 or 1.9% of its  
own shares (2.2% at the end of 2019) which  
is considered sufficient to cover current  
Return and liquidity  
ALK aims to provide long-term shareholder  
return through an increased share price, the  
paying-out of dividends, and the purchase of  
its own shares. At the end of 2019, the share  
price was DKK 1,635 and the share closed  
Dividend and capital structure  
The Board of Directors considers that ALK’s  
financial resources, including credit facilities,  
still constitute a sufficient financial basis  
for implementing the next stage of ALK’s  
strategy. In support of the strategy, the Board  
of Directors is extending its recommendation  
that dividend payments be temporarily  
suspended until business profitability  
improves further. In line with this decision, at  
the annual general meeting in March 2021,  
the Board of Directors will propose that no  
dividend be declared.  
Shareholders as at 31 December 2020  
The ALK share in 2020  
The Lundbeck Foundation  
ALK  
ATP  
Other  
ALK  
OMXC20 CAP (indexed)  
Pharma, biotech and life sciences (NBI-NAS, indexed)  
Index  
160  
140  
120  
100  
80  
40.3%  
50.3%  
The Board of Directors will revisit the dividend  
policy and ALK’s capital structure on an  
ongoing basis during the next phase of the  
strategy.  
2020  
7.5%  
1.9%  
60  
Continues  
Jan  
Feb  
Mar  
Apr  
May  
Jun  
Jul  
Aug  
Sep  
Oct  
Nov  
Dec  
 
Management’s review • Annual report 2020 • ALK 39  
Investor relations  
Financial calendar 2021  
Annual general meeting  
Based on its investor relations (IR) policy  
(https://ir.alk.net/corporate-governance/  
ir-policy), ALK seeks to provide timely,  
accurate and relevant information on  
matters of importance to the assessment of  
the share, including strategy, operations,  
performance, expectations, goals, pipeline,  
market development, and other matters. ALK  
continuously works to strengthen its dialogue  
with all financial stakeholders in accordance  
with good IR practice and the provisions for  
companies listed on Nasdaq Copenhagen.  
18 March  
5 May  
Three-month interim report (Q1)  
Six-month interim report (Q2)  
Nine-month interim report (Q3)  
11 August  
11 November  
Find out more  
Visit Investor Relations at  
https://ir.alk.net/investors  
Besides hosting regular telephone  
conferences, ALK representatives held a  
large number of individual meetings and  
briefing calls with analysts and investors in  
2020 and also presented at various investor  
conferences.  
e Lundbeck Foundation  
Contact Investor Relations:  
Per Plotnikof  
Tel. +45 4574 7527  
As one of the largest commercial foundations in Denmark, the Lundbeck Foundation  
lives its purpose every day through engaged ownership of its three subsidiaries and an  
annual spend of at least DKK 500 million in grants to support biomedical research with  
a special focus on neuroscience. Founded in 1954 by the widow of the founder of the  
Danish pharmaceutical company, H. Lundbeck A/S, the Foundation is the largest and  
controlling shareholder of ALK, owning 67% of the votes (40% of the capital). In addition,  
the Foundation is the majority shareholder of two other large Danish companies,  
Lundbeck and Falck, and manages securities of about DKK 19 billion. The Lundbeck  
Foundation also invests in European and American life-science companies and supports  
a range of early-stage investment projects based on Danish research. Every year, the  
Foundation awards The Brain Prize, a personal research prize of DKK 10 million. The  
prize is awarded to one or more scientists who have distinguished themselves through  
an outstanding contribution to global neuroscience and who are still active in research.  
For further information on the Foundation, please visit www.lundbeckfonden.com.  
During the year, ALK published 13 company  
announcements (22), including reports  
on transactions by managerial staff. All  
announcements are available on ALK’s  
website together with reports, presentations,  
access to telephone conferences, share  
price information, estimates from analysts  
following the share, and related information.  
Registered shareholders are encouraged to  
sign up at the InvestorPortal.  
e Lundbeck Foundation’s business activities encompass  
three large subsidiaries, an international portfolio of 17  
venture companies, a portfolio of seven biotech start-ups  
based on research from Danish universities, and internal  
management of securities of around DKK 19 billion.  
www.lundbeckfonden.com  
 
Management’s review • Annual report 2020 • ALK 40  
Risk management  
Production and sub-supplier issues  
impacting product supply  
Quality issues impacting  
patient safety and product supply  
ALK’s Board of Management  
is responsible for the ongoing  
management of risks throughout  
the value chain, including risk  
mapping, the assessment of  
probabilities and potential  
consequences, and the  
Description  
Description  
ALK has concentrated its key in-house production capacity at  
plants in Denmark, France, Spain and the USA. Although the plants  
are located in areas that have not historically been hit by natural  
disasters, this geographical spread calls for risk planning in order to  
avoid emergencies, such as lack of, or poor access to raw materials:  
for instance, pollen.  
ALK’s products are subject to a large number of statutory and  
regulatory requirements with respect to issues such as safety,  
efficacy and production.  
Meeting high product quality standards is a prerequisite for the  
company’s ability to supply products and hence its competitive  
strength.  
introduction of risk-reducing  
measures.  
As ALK works to rationalise its portfolio, there may be risks  
associated with the discontinuation of its products. Among others,  
these may include potential disruption at manufacturing sites during  
decommissioning work, the loss of sales from products for which no  
suitable ALK substitute product exists, or the inability to meet sudden  
spikes in demand for other products due to patients switching from  
discontinued products.  
ALK’s products may be associated with allergic reactions of varying  
extents, durations and severities. If such events occur in unexpected  
situations, they may have an impact on the company’s earnings and  
sales.  
The Board of Management has established  
a risk committee to assist it in meeting its  
overall responsibility for risk management.  
The Risk Committee comprises  
Dependency on third parties for supplying input for key production  
processes and commercialising the company’s products in several  
markets entails risks that ALK would not be subject to if the company  
possessed the necessary in-house capabilities.  
representatives from each functional area  
relevant to ALK’s risk profile. It meets twice  
a year or more, as required, to perform its  
tasks. Risks are systematically assessed  
according to a two-dimensional matrix,  
rating the impact and probability of each  
risk. A risk management report with key  
risks and recommended mitigation plans is  
presented to Board of Management before it  
is submitted to the Board of Directors on an  
annual basis for their review and approval.  
Risk mitigation  
Risk mitigation  
ALK conducts risk planning including for the prevention of unwanted  
events, and preventative inventory management, such as the build-  
up of contingency stocks in order to ensure an unbroken chain of  
production and supply.  
Production and manufacturing processes are subject to periodic and  
routine inspections by regulatory authorities as a regular part of their  
monitoring processes to ensure that ALK observes the prescribed  
requirements and standards.  
ALK’s production processes and quality standards have been  
developed and optimised over many years. ALK has invested  
significantly to increase the robustness and compliance of the legacy  
business by reducing manufacturing complexity, and all possible  
steps are taken during portfolio rationalisation work to mitigate  
any potential impact on other areas of manufacturing or the wider  
business.  
ALK stringently monitors product quality and safety, both in clinical  
development and in sales and marketing activities. If, despite the  
high levels of quality and safety, a situation should occur in which it is  
necessary to recall a product, ALK has procedures in place to ensure  
that this can be managed swiftly and effectively and in accordance  
with regulatory requirements.  
ALK manages third party dependency risks through contractual  
stipulations, planning, monitoring, and joint steering committees.  
Continues  
 
 
Management’s review • Annual report 2020 • ALK 41  
Failures or delays in  
product development  
Tablets not gaining market  
acceptance  
Authorities introducing  
new pricing pressures  
Competition becoming  
more intense  
Description  
Description  
Description  
Description  
The future success of ALK depends on the  
company’s ability to maintain current products  
and to successfully identify, develop and market  
new, innovative drugs, which involves significant  
risks.  
If ALK and its partners succeed in developing new  
products and obtaining regulatory approvals for  
them, the ability to generate revenue depends  
on the products being accepted by doctors and  
patients.  
In most of the countries in which ALK operates,  
prescription drugs are subject to reimbursement  
from, and price controls by, national authorities  
and healthcare providers. This often results in  
significant price differences between individual  
markets. Regulatory requirements and  
interventions, as well as price control measures,  
may therefore have a significant impact on the  
company’s earnings capacity.  
ALK operates in competitive markets. If, for  
instance, a competitor were to launch a new and  
more effective treatment for allergy, it may have  
a material impact on ALK’s sales. A competitive  
market may also lead to market-driven price  
reductions just as national and regional authorities  
may mandate price reductions. Equally, there  
may be circumstances that prevent planned price  
increases, with a consequent impact on revenue.  
Both competition and pricing risks may have a  
material impact on ALK’s ability to achieve its long-  
term goals.  
A pharmaceutical drug must be subjected to  
extensive and lengthy clinical trials to document  
qualities such as safety and efficacy before  
it can be approved for marketing. During the  
development process, the outcomes of these  
trials are subject to significant risks. Even  
though substantial resources are invested in the  
development process, the trials may produce  
negative results.  
The degree of market acceptance for a new  
product or drug candidate depends on several  
factors, including the demonstration of  
clinical efficacy and safety, cost-effectiveness,  
convenience and ease of administration, potential  
advantages over alternative treatment methods,  
competition, and marketing and distribution  
support.  
Exceptionally, governments and national  
authorities may introduce economic measures  
that also affect the pricing and reimbursement of  
medicines, for example, as a consequence of the  
impact of COVID on healthcare budgets or as a  
result of a major economic downturn.  
If ALK’s new products, primarily tablets, fail to  
achieve market acceptance, this could have a  
significant influence on the company’s ability to  
generate revenue. Even if market acceptance of  
the tablets is successfully achieved, the extent of  
their acceptance could influence the company’s  
ability to fully deliver on its sales -growth targets  
for these products.  
Failures or delays in the development process or in  
obtaining regulatory approvals may have a major  
impact for the patients not being able to benefit  
from the products and on the ability of ALK to  
achieve its long-term goals.  
Risk mitigation  
Risk mitigation  
Risk mitigation  
Risk mitigation  
ALK and its collaborative partners perform  
thorough risk assessments of their research  
and development programmes throughout the  
development and registration processes with  
the objective of risk mitigation to optimise the  
likelihood of the products reaching the market.  
ALK regularly conducts extensive surveys of  
market conditions and similar factors and commits  
significant resources to providing information on  
its products to doctors and patients. Sales growth  
targets are set with a full understanding of the  
potential risks involved in successfully marketing  
any product and these are anticipated and  
managed so far as is possible.  
ALK is strongly committed to evidenced-based  
medicine, based on strong clinical and health  
economic evidence as the basis for pricing and  
reimbursement. ALK actively engages in dialogue  
with authorities with the aim of securing fair  
pricing and reimbursement agreements and  
maintains a strong focus on its market access  
strategy.  
ALK’s Scientific Committee monitors the competitor  
landscape in global AIT research and development  
to ensure a timely response to developments by  
competitors or in the market. As a consequence,  
and to stay ahead of competition, ALK monitors  
economic, market and regulatory developments  
as they relate to product pricing, along with  
the competitive situation and initiatives in all  
important markets with the aim of appropriate risk  
mitigation.  
ALK’s Scientific Committee is responsible for other  
patient-/product-related innovation activities.  
The committee advises on matters relating to R&D  
activities and other patient-/product-related  
innovation activities, including reviewing R&D  
programmes and the overall R&D pipeline.  
Continues  
 
Management’s review • Annual report 2020 • ALK 42  
IT security breaches impacting  
business continuity  
Breaches of legal or  
ethical standards  
Fluctuations in exchange rates and  
interest rates  
Description  
Description  
Description  
Disruption to IT systems, such as breaches of  
data security, may occur across the global value  
chain, where well-functioning IT systems and  
infrastructure are critical for the company’s ability  
to operate effectively.  
Non-compliance with applicable regulations,  
legislation, or ALK’s Code of Conduct could  
negatively affect the company’s good reputation  
which is essential for operating within the  
pharmaceutical industry.  
Due to the nature of its operations, investments  
and financing, ALK is exposed to fluctuations in  
exchange rates and interest rates, which could  
impact the company’s cash flow and earnings.  
Patents and other intellectual property rights are  
important for developing and retaining ALK’s  
competitive strength.  
Risk mitigation  
Risk mitigation  
Risk mitigation  
ALK manages this risk, among other ways, by  
having a security strategy in place to prevent  
intruders from causing damage to systems or  
gaining access to critical data and systems.  
Awareness campaigns, access controls, intrusion  
detection and prevention systems have all  
been implemented, and systems are regularly  
upgraded to increase network security.  
ALK strives to act professionally, honestly, and with  
high integrity throughout the company in relation  
to stakeholders. ALK’s Code of Conduct defines  
ALK’s high standard of ethical behaviour in relation  
to customers, employees, shareholders, society,  
suppliers and partners. Immediate action is taken  
on substantiated non-compliance. Annually, all  
employees are asked to sign and confirm their  
knowledge of the Code of Conduct and to take an  
online test.  
The company’s financial risks are managed  
centrally, based on policies approved by the  
Board of Directors. The objective of ALK’s financial  
risk management is to reduce the sensitivity of  
earnings to fluctuations in exchange rates, interest  
rates, liquidity and changes in credit rating.  
Company policy is to refrain from active financial  
speculation.  
See note 25 of this annual report for a specification  
of the company’s exposure to currency, interest  
rate and credit risks and its use of derivative  
financial instruments.  
Internal controls and policies are in place to  
safeguard ALK’s intellectual property rights. The  
risk that ALK might infringe patents or trademark  
rights held by other companies, as well as the  
risk that other companies may attempt to infringe  
the patents and/or trademark rights of ALK are  
monitored and, if necessary, suitable measures  
are taken.  
 
Management’s review • Annual report 2020 • ALK 43  
Remuneration  
Contribute to promoting value creation  
at ALK and to support ALK’s business  
strategy  
ALK’s remuneration policy was  
prepared in accordance with  
the Danish Companies Act and  
approved by shareholders at  
the annual general meeting  
in 2020. e remuneration  
policy replaced the previous  
remuneration guidelines and  
guidelines for incentive pay, and  
governs the remuneration for the  
Board of Directors and Board of  
Management.  
Ensure that the remuneration of individual  
members of Board of Management reflect  
the company's performance as well as  
individual results  
In 2020, the remuneration for the Board of  
Directors and Board of Management followed  
the structure and principles outlined in the  
remuneration policy.  
Read the full remuneration report  
Available at: https://ir.alk.net/  
corporate-governance  
ALK has prepared a separate report that  
describes remuneration for the Board  
of Directors and Board of Management  
in more detail. The remuneration report  
provides an overview of the components in  
the remuneration for the Board of Directors  
and Board of Management, including an  
overview of the actual remuneration in 2020,  
the development in remuneration for the past  
three years, as well as the shareholdings  
of the Board of Directors and Board of  
Management. The remuneration report is  
available at https://ir.alk.net/corporate-  
governance.  
The overall aim of the remuneration  
policy is to outline the overall framework  
for remuneration at ALK and to provide  
shareholders with a clear, understandable  
and comprehensive overview of the  
remuneration provided by ALK. The  
objectives of the remuneration policy are to:  
Attract, motivate and retain qualified  
members of the Board of Directors and  
Board of Management  
Align the remuneration components to the  
interests of shareholders  
 
 
Management’s review • Annual report 2020 • ALK 44  
Board of Directors and Board of Management  
Board of Directors  
Anders Hedegaard (1960, male)  
Lene Skole* (1959, female)  
Lars Holmqvist* (1959, male)  
Jakob Riis* (1966, male)  
Rodenstock Group, CEO  
The Lundbeck Foundation, CEO,  
and directorships at two subsidiaries  
Professional board member  
Falck A/S, President & CEO  
Board member since 2013**  
Chairman of the Audit Committee  
Chairman  
Board member since 2020**  
Board member since 2015**  
Vice Chairman  
Board member since 2014**  
Member of the Remuneration Committee  
Member of the Audit Committee  
Chairman of the Nomination Committee  
Chairman of the Remuneration Committee  
Chairman of the Scientific Committee  
Member of the Audit Committee  
Member of the Nomination Committee  
Member of the Remuneration Committee  
Member of the Scientific Committee  
Competences  
Competences  
Competences  
Competences  
Specific expertise within management and sales  
& marketing in international life science and  
consumer care companies.  
Experience in management, financial and  
economic expertise, experience in strategy and  
communication in international companies.  
Experience in management, finance, and sales &  
marketing in international life science companies,  
including med-tech and pharmaceutical  
companies.  
Experience in management and sales &  
marketing in the international healthcare  
industry.  
Directorships  
Directorships  
Directorships  
Directorships  
Orphazyme A/S  
Falck A/S, Vice Chairman  
H. Lundbeck A/S, Vice Chairman  
Tryg Forsikring A/S  
Tryg A/S  
Biovica International AB, Chairman  
H. Lundbeck A/S  
The Lundbeck Foundation  
Tecan AG, Switzerland  
Naga UK Topco Limited, UK  
Vitrolife AB, Sweden  
Danish Business Promotion Board, Chairman  
Ørsted A/S, Vice Chairman  
Continues  
*
These board members are not regarded as independent in the sense of the definition contained in the Danish recommendations on corporate governance due to being affiliated with the Lundbeck Foundation, which owns 40.3% of ALK’s shares  
**All members elected at the annual general meeting are subject to re-election each year  
 
 
Management’s review • Annual report 2020 • ALK 45  
Board of Directors and Board of Management  
Board of Directors – continued  
Vincent Warnery (1968, male)  
Katja Barnkob (1969, female)  
Nanna Rassov Carlson (1976, female)  
Johan Smedsrud (1972, male)  
Beiersdorf AG, Executive Board Member  
Board member since 2019**  
Project Director, Global CMC Development,  
ALK-Abelló A/S  
Manager, QA Release, ALK-Abelló A/S  
Board member since 2019  
Employee-elected  
Maintenance Supporter, Process &  
Production Support, ALK-Abelló A/S  
Board member since 2011  
Employee-elected  
Board member since 2019  
Employee-elected  
Competences  
Competences  
Competences  
Competences  
Experience in management and sales &  
marketing in the international consumer  
healthcare industry.  
Experience in project management of global  
drug development projects in the pharmaceutical  
industry.  
Expertise in production and release of ALK’s  
active pharmaceutical ingredients for SLIT  
products.  
Experience in HVAC systems, cleanroom  
testing, utensil washing and sterilisation for the  
pharmaceutical industry.  
** All members elected at the annual general meeting are subject to re-election each year  
Attendence at meetings  
Attended  
Absent  
Board  
meetings  
Audit  
Committee  
Remuneration  
Scientific  
Committee  
Nomination  
Committee1  
Committee  
Anders Hedegaard2  
Steen Riisgaard3  
All meetings  
All meetings  
All meetings  
Lene Skole  
Lars Holmqvist  
Gonzalo De Miquel3  
Jakob Riis  
Vincent Warnery  
Katja Barnkob4  
Nanna Rassov Carlson4  
Johan Smedsrud4  
The Nomination Committee meets when required  
1
2
3
4
elected at the AGM on 11 March 2020  
stepped down at the AGM on 11 March 2020  
employee-elected  
 
Management’s review • Annual report 2020 • ALK 46  
Board of Directors and Board of Management  
Board of Management  
Carsten Hellmann (1964, male)  
Henrik Jacobi (1965, male)  
Søren Jelert (1972, male)  
Søren Niegel (1971, male)  
President & CEO  
Executive Vice President,  
Research & Development  
Executive Vice President & CFO  
Executive Vice President,  
Commercial Operations  
Competences  
Competences  
Competences  
Competences  
Executive management experience in global  
healthcare and biopharmaceutical companies.  
Experience in management, innovation, and  
research & development in the pharmaceutical  
industry.  
Experience in management, and financial and  
economic expertise in the pharmaceutical  
industry and other sectors.  
Experience in management as well as global  
production and sales & marketing within the  
pharmaceutical industry.  
Henrik Jacobi holds a degree in Medicine from  
1993.  
Directorships  
Coloplast A/S  
Dansk Erhverv  
 
 
Consolidated financial statements • Annual report 2020 • ALK  
47  
Financial  
statements  
Statements  
48 Statement by Management on the annual report  
49 Independent auditor’s reports  
Consolidated financial statements  
54 Income statement  
54 Statement of comprehensive income  
55 Cash flow statement  
56 Balance sheet  
57 Statement of changes in equity  
58 Notes  
Parent company financial statements  
88 Income statement  
89 Balance sheet  
90 Statement of changes in equity  
91 Notes  
 
 
Statements • Annual report 2020 • ALK 48  
Statement by Management on the annual report  
The Board of Directors and the Board of Management  
have today considered and adopted the annual report  
of ALK-Abelló A/S for the financial year 1 January to  
31 December 2020.  
Board of Management  
Carsten Hellmann  
The consolidated financial statements have been prepared  
in accordance with International Financial Reporting  
Standards as adopted by the EU and further requirements  
in the Danish Financial Statements Act. The parent company  
financial statements have been prepared in accordance with  
the Danish Financial Statements Act. Management's review  
has been prepared in accordance with the Danish Financial  
Statements Act.  
President & CEO  
Henrik Jacobi  
Executive Vice President,  
Research & Development  
Søren Jelert  
Executive Vice President  
& CFO  
Søren Daniel Niegel  
Executive Vice President,  
Commercial Operations  
In our opinion, the consolidated financial statements and the  
parent company financial statements give a true and fair view  
of the financial position at 31 December 2020 of the group  
and the parent company and of the results of the group and  
parent company operations and consolidated cash flows for  
the financial year 1 January to 31 December 2020.  
Board of Directors  
Anders Hedegaard  
Chairman  
Lene Skole  
Vice Chairman  
Katja Barnkob  
Jakob Riis  
In our opinion, Management's review includes a true and fair  
account of the development in the operations and financial  
circumstances of the group and the parent company, of the  
results for the year and of the financial position of the group  
and the parent company as well as a description of the most  
significant risks and elements of uncertainty facing the group  
and the parent company.  
Nanna Rassov Carlson  
Johan Smedsrud  
Lars Holmqvist  
In our opinion, the annual report of ALK-Abelló A/S for the  
financial year 1 January to 31 December 2020 identified as  
"ALK-2020-12-31.zip” is prepared, in all material respects, in  
compliance with the ESEF Regulation.  
Vincent Warnery  
We recommend that the annual report be adopted at the  
annual general meeting.  
Hørsholm, 10 February 2021  
   
 
Statements • Annual report 2020 • ALK 49  
Independent auditor’s reports  
To the shareholders of ALK-Abelló A/S  
What we have audited  
Independence  
The Consolidated Financial Statements and  
the Parent Company Financial Statements  
of ALK-Abelló A/S for the financial year  
1 January to 31 December 2020 which  
comprise income statement, balance sheet,  
statement of changes in equity and notes,  
including summary of significant accounting  
policies for the Group as well as for the Parent  
Company and statement of comprehensive  
income and cash flow statement for the  
Group.  
We are independent of the Group in  
accordance with the International Ethics  
Standards Board for Accountants’ Code of  
Ethics for Professional Accountants (IESBA  
Code) and the additional requirements  
applicable in Denmark. We have also  
fulfilled our other ethical responsibilities in  
accordance with the IESBA Code.  
Report on the audit of  
the Financial Statements  
Our opinion  
In our opinion, the Consolidated Financial  
Statements give a true and fair view of the  
Group’s financial position at 31 December  
2020 and of the results of the Group’s  
operations and cash flows for the financial  
year 1 January to 31 December 2020 in  
accordance with International Financial  
Reporting Standards as adopted by the  
EU and further requirements in the Danish  
Financial Statements Act.  
To the best of our knowledge and belief,  
prohibited non-audit services referred to in  
Article 5(1) of Regulation (EU) No 537/2014  
were not provided.  
Collectively referred to as the “Financial  
Statements”.  
Appointment  
Basis for opinion  
We were appointed auditors of ALK-Abelló  
A/S for the first time on 11 March 2020 for the  
financial year 2020.  
We conducted our audit in accordance with  
International Standards on Auditing (ISAs)  
and the additional requirements applicable  
in Denmark. Our responsibilities under those  
standards and requirements are further  
described in the Auditor’s responsibilities for  
the audit of the Financial Statements section  
of our report.  
Moreover, in our opinion, the Parent  
Company Financial Statements give a true  
and fair view of the Parent Company’s  
financial position at 31 December 2020  
and of the results of the Parent Company’s  
operations for the financial year 1 January  
to 31 December 2020 in accordance with the  
Danish Financial Statements Act.  
Key audit matters  
Key audit matters are those matters that, in  
our professional judgement, were of most  
significance in our audit of the Financial  
Statements for 2020. These matters were  
addressed in the context of our audit of the  
Financial Statements as a whole, and in  
forming our opinion thereon, and we do not  
provide a separate opinion on these matters.  
We believe that the audit evidence we have  
obtained is sufficient and appropriate to  
provide a basis for our opinion.  
Our opinion is consistent with our Auditor’s  
Long-form Report to the Audit Committee and  
the Board of Directors.  
 
 
Statements • Annual report 2020 • ALK 50  
Statement on Management’s Review  
Management is responsible for  
Management’s Review, pages 1-46, and  
page 97.  
Key audit matter  
How our audit addressed the key audit matter  
Valuation of inventories  
Inventories of the Group comprise raw materials, work in progress  
and manufactured goods and goods for resale.  
We evaluated and discussed inventory accounting policy with  
Management.  
Our opinion on the Financial Statements does  
not cover Management’s Review, and we do  
not express any form of assurance conclusion  
thereon.  
Inventories are measured at cost determined under the FIFO method  
or net realisable value where this is lower.  
We evaluated related application and monitoring controls.  
We selected a sample and tested the costing model for allocation  
of indirect production costs and analysed the allocation of indirect  
production costs between the Group’s products.  
The valuation is based on a costing model, which includes a number  
of significant accounting judgements and estimates related to  
allocation of indirect production costs, including capacity utilisation,  
and the model for eliminating unrealised internal profit in the  
Consolidated Financial Statements.  
In connection with our audit of the Financial  
Statements, our responsibility is to read  
Management’s Review and, in doing so,  
consider whether Management’s Review  
is materially inconsistent with the Financial  
Statements or our knowledge obtained in the  
audit, or otherwise appears to be materially  
misstated.  
We selected a sample and tested product cost prices, including tests  
of raw material prices and allocated indirect production costs.  
We focused on this area as the amounts involved are material and  
as the valuation is associated with significant accounting estimates  
and judgements. This includes the complex models for indirect  
production costs and eliminating unrealised internal profits and  
the assumptions used for measuring indirect production costs and  
unrealised internal profits.  
We assessed and challenged Management’s assumptions and  
judgements related to the allocation of indirect production costs,  
including capacity utilisation, and the assumptions used in  
eliminating unrealised internal profit.  
Furthermore, we tested the Group’s model for eliminating unrealised  
internal profit in the Consolidated Financial Statements.  
Moreover, we considered whether  
Management’s Review includes the  
disclosures required by the Danish Financial  
Statements Act.  
We refer to notes 2 and 15 in the Consolidated Financial Statements.  
We assessed the appropriateness of the related disclosure provided  
in the Consolidated Financial Statements.  
Valuation of deferred tax assets  
A significant part of the recognised deferred tax assets relates to tax  
losses carried forward in Denmark.  
We assessed the method applied by Management for calculating the  
deferred tax assets and assessing its valuation.  
Based on the work we have performed,  
in our view, Management’s Review is in  
accordance with the Consolidated Financial  
Statements and the Parent Company  
Financial Statements and has been prepared  
in accordance with the requirements of the  
Danish Financial Statements Act. We did  
not identify any material misstatement in  
Management’s Review.  
Utilisation of the recognised deferred tax assets is depending on  
the expected future taxable income within the Danish joint taxation  
group with the Lundbeck Foundation and its other subsidiaries.  
We tested the calculation of the deferred tax assets prepared by  
Management and involved our internal tax specialist in assessing  
the tax calculation to ensure compliance with relevant tax legislation.  
We focused on this area as the amounts involved are material and  
as the valuation of deferred tax assets is associated with significant  
accounting estimates and judgements. This includes the estimation  
uncertainty regarding assessing the future taxable profits in ALK-  
Abelló A/S and within the Danish joint taxation group.  
We evaluated and challenged the documentation prepared  
by Management regarding the deferred tax asset, including  
Management’s best estimate of the probability of realising the  
future taxable profits in Denmark and within the joint Danish taxation  
group, including sensitivity and risk analysis.  
We refer to notes 2, 9 and 14 in the Consolidated Financial  
Statements.  
We assessed the appropriateness of the related disclosure provided  
in the Consolidated Financial Statements.  
 
Statements • Annual report 2020 • ALK  
51  
Management’s responsibilities for  
the Financial Statements  
Management is responsible for the  
that an audit conducted in accordance  
with ISAs and the additional requirements  
applicable in Denmark will always detect  
a material misstatement when it exists.  
Misstatements can arise from fraud or error  
and are considered material if, individually or  
in the aggregate, they could reasonably be  
expected to influence the economic decisions  
of users taken on the basis of these Financial  
Statements.  
Evaluate the appropriateness of  
accounting policies used and the  
reasonableness of accounting estimates  
and related disclosures made by  
Management.  
activities within the Group to express an  
opinion on the Consolidated Financial  
Statements. We are responsible for the  
direction, supervision and performance  
of the group audit. We remain solely  
responsible for our audit opinion.  
preparation of consolidated financial  
statements that give a true and fair view  
in accordance with International Financial  
Reporting Standards as adopted by the  
EU and further requirements in the Danish  
Financial Statements Act and for the  
preparation of parent company financial  
statements that give a true and fair view  
in accordance with the Danish Financial  
Statements Act, and for such internal control  
as Management determines is necessary  
to enable the preparation of financial  
statements that are free from material  
misstatement, whether due to fraud or error.  
Conclude on the appropriateness of  
Management’s use of the going concern  
basis of accounting and based on the  
audit evidence obtained, whether a  
material uncertainty exists related  
to events or conditions that may cast  
significant doubt on the Group’s and the  
Parent Company’s ability to continue  
as a going concern. If we conclude  
that a material uncertainty exists, we  
are required to draw attention in our  
auditor’s report to the related disclosures  
in the Financial Statements or, if such  
disclosures are inadequate, to modify  
our opinion. Our conclusions are based  
on the audit evidence obtained up to the  
date of our auditor’s report. However,  
future events or conditions may cause the  
Group or the Parent Company to cease to  
continue as a going concern.  
We communicate with those charged  
with governance regarding, among other  
matters, the planned scope and timing of the  
audit and significant audit findings, including  
any significant deficiencies in internal control  
that we identify during our audit.  
As part of an audit in accordance with ISAs  
and the additional requirements applicable  
in Denmark, we exercise professional  
judgement and maintain professional  
scepticism throughout the audit. We also:  
We also provide those charged with  
governance with a statement that we  
have complied with relevant ethical  
requirements regarding independence, and  
to communicate with them all relationships  
and other matters that may reasonably be  
thought to bear on our independence, and  
where applicable, related safeguards.  
Identify and assess the risks of material  
misstatement of the Financial Statements,  
whether due to fraud or error, design and  
perform audit procedures responsive to  
those risks, and obtain audit evidence  
that is sufficient and appropriate to  
provide a basis for our opinion. The risk  
of not detecting a material misstatement  
resulting from fraud is higher than for one  
resulting from error, as fraud may involve  
collusion, forgery, intentional omissions,  
misrepresentations, or the override of  
internal control.  
In preparing the Financial Statements,  
Management is responsible for assessing  
the Group’s and the Parent Company’s ability  
to continue as a going concern, disclosing,  
as applicable, matters related to going  
concern and using the going concern basis  
of accounting unless Management either  
intends to liquidate the Group or the Parent  
Company or to cease operations, or has no  
realistic alternative but to do so.  
From the matters communicated with those  
charged with governance, we determine  
those matters that were of most significance  
in the audit of the Financial Statements  
of the current period and are therefore  
the key audit matters. We describe these  
matters in our auditor’s report unless law  
or regulation precludes public disclosure  
about the matter or when, in extremely rare  
circumstances, we determine that a matter  
should not be communicated in our report  
because the adverse consequences of  
doing so would reasonably be expected to  
outweigh the public interest benefits of such  
communication.  
Evaluate the overall presentation,  
structure and content of the Financial  
Statements, including the disclosures,  
and whether the Financial Statements  
represent the underlying transactions  
and events in a manner that achieves fair  
presentation.  
Auditor’s responsibilities for the audit of  
the Financial Statements  
Our objectives are to obtain reasonable  
assurance about whether the Financial  
Statements as a whole are free from material  
misstatement, whether due to fraud or error,  
and to issue an auditor’s report that includes  
our opinion. Reasonable assurance is a high  
level of assurance, but is not a guarantee  
Obtain an understanding of internal  
control relevant to the audit in order  
to design audit procedures that are  
appropriate in the circumstances, but not  
for the purpose of expressing an opinion  
on the effectiveness of the Group’s and the  
Parent Company’s internal control.  
Obtain sufficient appropriate audit  
evidence regarding the financial  
information of the entities or business  
 
Statements • Annual report 2020 • ALK  
52  
Report on compliance with  
the ESEF Regulation  
taxonomy, for all financial information  
required to be tagged using judgement  
where necessary;  
Obtaining an understanding of the  
company’s iXBRL tagging process and of  
internal control over the tagging process;  
Hellerup, 10 February 2021  
PricewaterhouseCoopers  
Statsautoriseret Revisionspartnerselskab  
CVR No 3377 1231  
As part of our audit of the Financial  
Statements we performed procedures to  
express an opinion on whether the annual  
report of ALK-Abelló A/S for the financial  
year 1 January to 31 December 2020 with the  
filename ALK-2020-12-31.zip is prepared,  
in all material respects, in compliance with  
the Commission Delegated Regulation (EU)  
2019/815 on the European Single Electronic  
Format (ESEF Regulation) which includes  
requirements related to the preparation  
of the annual report in XHTML format and  
iXBRL tagging of the Consolidated Financial  
Statements.  
Ensuring consistency between iXBRL  
tagged data and the Consolidated  
Financial Statements presented in human-  
readable format; and  
Evaluating the completeness of the iXBRL  
tagging of the Consolidated Financial  
Statements;  
Evaluating the appropriateness of the  
company’s use of iXBRL elements selected  
from the ESEF taxonomy and the creation  
of extension elements where no suitable  
element in the ESEF taxonomy has been  
identified;  
Lars Baungaard  
State Authorised  
Public Accountant  
mne23331  
Kim Tromholt  
State Authorised  
Public Accountant  
mne33251  
For such internal control as Management  
determines necessary to enable the  
preparation of an annual report that is  
compliant with the ESEF Regulation.  
Our responsibility is to obtain reasonable  
assurance on whether the annual report  
is prepared, in all material respects, in  
compliance with the ESEF Regulation based  
on the evidence we have obtained, and to  
issue a report that includes our opinion.  
The nature, timing and extent of procedures  
selected depend on the auditor’s judgement,  
including the assessment of the risks of  
material departures from the requirements  
set out in the ESEF Regulation, whether due to  
fraud or error. The procedures include:  
Evaluating the use of anchoring of  
extension elements to elements in the  
ESEF taxonomy; and  
Management is responsible for preparing  
an annual report that complies with the ESEF  
Regulation. This responsibility includes:  
Reconciling the iXBRL tagged data with  
the audited Consolidated Financial  
Statements.  
The preparing of the annual report in  
XHTML format;  
In our opinion, the annual report of ALK-  
Abelló A/S for the financial year 1 January to  
31 December 2020 with the file name ALK-  
2020-12-31.zip is prepared, in all material  
respects, in compliance with the ESEF  
Regulation.  
The selection and application of  
appropriate iXBRL tags, including  
extensions to the ESEF taxonomy and  
the anchoring thereof to elements in the  
Testing whether the annual report is  
prepared in XHTML format;  
 
Consolidated financial statements • Annual report 2020 • ALK 53  
Contents of the consolidated financial statements  
Consolidated financial statements  
Notes  
Income statement  
54  
54  
55  
56  
57  
1
2
3
4
5
6
7
8
9
Accounting policies  
58  
64  
65  
66  
66  
69  
69  
69  
70  
70  
70  
71  
72  
74  
75  
75  
17 Share capital and earnings per share  
18 Pensions and similar liabilities  
19 Mortgage debt and bank loans  
20 Other provisions  
76  
76  
78  
78  
79  
79  
79  
79  
80  
83  
84  
84  
84  
85  
Statement of comprehensive income  
Cash flow statement  
Significant accounting estimates and judgements  
Revenue and segment information  
Staff costs  
Balance sheet  
Statement of changes in equity  
Share-based payments  
21 Other payables  
Depreciation, amortisation and impairment  
Other operating items, net  
22 Changes in working capital  
23 Contingent liabilities and commitments  
24 Leases  
Notes  
58  
86  
Definitions  
Financial income and expenses  
Tax on profit/(loss) for the year  
25 Financial risks and financial instruments  
26 Fees to the ALK Group’s auditors  
27 Related parties  
10 Adjustments for non-cash items  
11 Sale of companies and operations  
12 Intangible assets  
28 Events after the reporting period  
29 Approval of financial statements  
30 List of companies in the ALK Group  
13 Property, plant and equipment  
14 Deferred tax  
15 Inventories  
16 Trade receivables  
 
 
Consolidated financial statements • Annual report 2020 • ALK 54  
Income statement  
Statement of comprehensive income  
Amounts in DKKm  
Note  
2020  
2019  
Amounts in DKKm  
Note  
2020  
25
2019  
Revenue  
3
3,491
1,463
2,028
3,274
1,382
1,892
Net profit/(loss)  
(50)
Cost of sales  
Gross profit  
4-6,15  
Items that will subsequently not be reclassified to the income  
statement:  
Actuarial gains/(losses) on pension plans  
Tax related to actuarial gains/(losses) on pension plans  
18  
(3)
(37)
11
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
4-6  
4-6  
4-6  
7
515
1,125
237
466
1,210
246
1
(2)
(26)
Other operating items, net  
(1)
16
Items that will subsequently be reclassified to the income statement,  
when specific conditions are met:  
Operating profit/(loss) (EBIT)  
150
(14)
Foreign currency translation adjustment of foreign affiliates  
(106)
23
Financial income  
8
8
5
54
22
39
Tax related to other comprehensive income, that will subsequently  
be reclassified to the income statement  
Financial expenses  
1
(3)
Profit/(loss) before tax (EBT)  
101
(31)
(105)
20
Tax on profit/(loss)  
9
76
19
Total  
(107)
(82)
(6)
Net profit/(loss)  
25
(50)
Total comprehensive income/(loss)  
(56)
Earnings/(loss) per share (EPS)  
Earnings/(loss) per share (EPS)  
17  
2.29
2.27
(4.59)
(4.59)
Earnings/(loss) per share (DEPS), diluted  
 
 
Consolidated financial statements • Annual report 2020 • ALK 55  
Cash flow statement  
Amounts in DKKm  
Note  
2020  
25
2019  
Net profit/(loss)  
(50)
Adjustments  
Adjustments for non-cash items  
Changes in working capital  
Financial income, received  
Financial expenses, paid  
Income taxes, paid (net)  
Cash flow from operating activities  
10  
22  
462
(154)
4
389
(95)
5
(22)
(14)
301
(33)
(84)
132
Acquisitions of companies and operations*  
Sale of companies and operations  
Investments in intangible assets  
-
-
(20)
29
11  
12  
13  
(26)
(196)
(23)
(245)
(20)
(147)
1
Investments in tangible assets  
Investments in other financial assets**  
Cash flow from investing activities  
(157)
Free cash flow  
56
(25)
Sale of treasury shares  
11
11
Exercised share options, paid  
Repayment of lease liabilities  
Repayment of borrowings  
5
(24)
(30)
(19)
(62)
(24)
(28)
(16)
(57)
Cash flow from financing activities  
Net cash flow  
(6)
(82)
Cash beginning of year  
316
-
296
100
396
Marketable securities beginning of year  
Cash and marketable securities beginning of year  
316
Unrealised gain/(loss) on cash held in foreign currency and  
financial assets carried as cash and marketable securities  
(12)
(6)  
2
Net cash flow  
(82)  
Cash year end  
298
-
316
-
Marketable securities year end  
Cash and marketable securities year end  
298
316
The consolidated statement of cash flow is compiled using the indirect method. As a result, the individual figures in the cash flow  
statement cannot be reconciled directly to the income statement and the balance sheet.  
*
Relates to final instalment payment for the acquisition of the operating assets of Allergy Laboratory of Oklahoma Inc. and Crystal  
Labs LLC in 2017.  
** Relates to long-term prepayments to a strategic supplier.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 56  
Balance sheet  
31 Dec.  
2020  
31 Dec.  
2019  
31 Dec.  
2020  
31 Dec.  
2019  
Amounts in DKKm  
Note  
Amounts in DKKm  
Note  
Assets  
Equity and liabilities  
Non-current assets  
Equity  
Intangible assets  
Goodwill  
Share capital  
17  
111
(125)
3,167
3,153
111
(19)
12  
12  
452
172
624
461
221
682
Currency translation adjustment  
Retained earnings  
Total equity  
Other intangible assets  
3,084
3,176
Tangible assets  
Land and buildings  
13  
13  
13  
13  
921
442
1,023
325
Liabilities  
Plant and machinery  
Other fixtures and equipment  
Property, plant and equipment in progress  
72
61
Non-current liabilities  
Mortgage debt  
269
330
19  
19  
18  
24  
14  
240
446
345
207
-
259
448
297
234
4
1,704
1,739
Bank loans  
Pensions and similar liabilities  
Lease liabilities  
Other non-current assets  
Receivables  
30
697
168
895
46
620
160
826
Deferred tax liabilities  
Income taxes  
Deferred tax assets  
Income tax receivables  
14  
143
1,381
143
1,385
Current liabilities  
Mortgage debt  
Trade payables  
Lease liabilities  
Other provisions  
Income taxes  
Total non-current assets  
Current assets  
3,223
3,247
19  
18
74
18
81
24  
20  
32
31
3
23
Inventories  
15  
16  
27  
1,093
544
20
1,056
407
116
9
21
20
Trade receivables  
Receivables from group companies  
Income tax receivables  
Other receivables  
Prepayments  
Other payables  
Deferred income  
21  
880
1
760
1
24
1,029
934
96
133
211
316
2,248
Total liabilities  
2,410
5,563
2,319
5,495
265
298
2,340
Cash  
Total equity and liabilities  
Total current assets  
Total assets  
5,563
5,495
 
 
Consolidated financial statements • Annual report 2020 • ALK 57  
Statement of changes in equity  
Currency  
Currency  
Share  
capital adjustment  
translation  
Retained  
earnings  
Total  
equity  
Share  
capital adjustment  
translation  
Retained  
earnings  
Total  
equity  
Amounts in DKKm  
Amounts in DKKm  
2020  
2019  
Equity at 1 January  
111
(19)
3,084
3,176
Equity at 1 January  
111
(42)
3,110
3,179
Net profit/(loss)  
-
-
-
-
25
25
(107)
(82)
Net profit/(loss)  
-
-
-
-
23
23
(50)
(29)
(79)
(50)
(6)
Other comprehensive income/(loss)  
Total comprehensive income/(loss)  
(106)
(106)
(1)
Other comprehensive income/(loss)  
Total comprehensive income/(loss)  
24
(56)
Share-based payments  
-
-
-
-
-
-
-
-
-
-
29
(24)
11
29
(24)
11
Share-based payments  
-
-
-
-
-
-
-
-
-
-
39
(24)
11
39
(24)
11
Share options settled  
Share options settled  
Sale of treasury shares  
Sale of treasury shares  
Tax related to items recognised directly in equity  
Other transactions  
43
43
Tax related to items recognised directly in equity  
Other transactions  
27
27
59
59
53
53
Equity at 31 December  
111
(125)
3,167
3,153
Equity at 31 December  
111
(19)
3,084
3,176
 
 
Consolidated financial statements • Annual report 2020 • ALK 58  
Notes to the consolidated financial statements  
1 Accounting policies  
no material impact on the consolidated financial  
statements for 2020 and in the coming years.  
Acquisitions are accounted for using the purchase  
method, according to which the identifiable assets,  
accumulated foreign exchange adjustments  
recognised in other comprehensive income, and  
anticipated disposal costs. The disposal amount  
is measured as the fair value of the consideration  
received.  
General  
liabilities and contingent liabilities of companies  
acquired are measured at fair value at the date of  
acquisition. However, non-current assets held for  
sale are measured at fair value less expected costs  
to sell.  
The consolidated financial statements for the  
period 1 January to 31 December 2020 have been  
prepared in accordance with the International  
Financial Reporting Standards (IFRS) as adopted  
by the EU and in accordance with Danish disclosure  
requirements for listed companies. Additional  
Danish disclosure requirements for annual reports  
are imposed by the Statutory Order on Adoption of  
IFRS issued under the Danish Financial Statements  
Act.  
The consolidated financial statements  
The consolidated financial statements comprise  
the financial statements of ALK-Abelló A/S (the  
parent company) and companies (subsidiaries)  
controlled by the parent company. The parent  
company is considered to control a subsidiary  
when it holds, directly or indirectly, more than 50%  
of the voting rights, or is otherwise able to exercise  
or actually exercises a controlling influence, and  
has the right to variable returns from the entity.  
Foreign currency translation  
On initial recognition, transactions denominated  
in currencies other than DKK are translated  
at average exchange rates, which are an  
approximation of the exchange rates at the  
transaction date. Receivables and debt and other  
monetary items not settled at the balance sheet  
date are translated at the closing rate.  
Restructuring costs are only recognised in the  
takeover balance sheet if they represent a  
liability to the acquired company. The tax effect of  
revaluations is taken into account.  
The cost of a company is the fair value of the  
consideration paid. If the final determination of the  
consideration is conditional on one or more future  
events, these are recognised at their fair value as  
of the acquisition date.  
The consolidated financial statements are  
presented in Danish kroner (DKK), which is  
considered the primary currency of the ALK Group’s  
activities and the functional currency of the parent  
company.  
Basis of consolidation  
The consolidated financial statements are  
prepared based on the financial statements  
of ALK-Abelló A/S and its subsidiaries. The  
consolidated financial statements are prepared  
as a consolidation of items of a uniform nature.  
The financial statements used for consolidation  
are prepared in accordance with the ALK Group’s  
accounting policies.  
Exchange rate differences between the exchange  
rate at the date of the transaction and the exchange  
rate at the date of payment or the balance sheet  
date, respectively, are recognised in the income  
statement under financial items. Tangible assets  
and intangible assets, inventories and other  
nonmonetary assets acquired in foreign currency  
and measured based on historical cost are  
translated at the exchange rates at the transaction  
date.  
Costs that can be attributed directly to the transfer  
of ownership are recognised in the income  
statement when they are incurred. As a general  
rule, adjustments to estimates of conditional  
consideration are recognised directly to the income  
statement.  
The consolidated financial statements are  
presented on a historical cost basis, apart from  
certain financial instruments, which are measured  
at fair value. Otherwise, the accounting policies are  
as described below.  
On consolidation, intra-group income and  
expenses, intra-group balances and dividends,  
and gains and losses arising on intra-group  
transactions are eliminated.  
The accounting policies are unchanged from last  
year except for the below mentioned.  
If the fair value of the acquired assets or liabilities  
subsequently proves different from the values  
calculated at the acquisition date, cost is adjusted  
for up to 12 months after the date of acquisition.  
On recognition in the consolidated financial  
statements of subsidiaries whose financial  
statements are presented in a functional currency  
other than DKK, the income statements are  
translated at average exchange rates for the  
respective months, unless these deviate materially  
from the actual exchange rates at the transaction  
dates. In that case, the actual exchange rates are  
used. Balance sheet items are translated at the  
exchange rates at the balance sheet date. Goodwill  
is considered to belong to the acquired company in  
question and is translated at the exchange rate at  
the balance sheet date.  
New standards effective from 1 January 2020  
The ALK Group has implemented all new and  
amended standards and interpretations (IFRIC)  
which are effective for the financial year 2020. This  
has not resulted in any changes to the accounting  
policies of the ALK Group.  
Business combinations  
Newly acquired or newly established companies  
or operations are recognised in the consolidated  
financial statements from the date of acquisition or  
establishment. The date of acquisition is the date  
when control of the company actually passes to the  
ALK Group. Companies sold or discontinued are  
recognised in the consolidated income statement  
up to the date of disposal. The date of disposal  
is the date when control of the company actually  
passes to a third party.  
Any excess of the cost of an acquired company over  
the fair value of the acquired assets, liabilities and  
contingent liabilities (goodwill) is recognised as  
an asset under intangible assets and tested for  
impairment at least once a year.  
New standards effective after 1 January 2021  
A number of IFRS standards, amended standards  
and IFRIC interpretations, which are effective on or  
after 1 January 2021, have not been implemented.  
Based on a preliminary assessment it is estimated  
that these standards and interpretations will have  
Gains or losses on disposal of subsidiaries  
Gains or losses on disposal of subsidiaries are  
stated as the difference between the disposal  
amount and the carrying amount of net assets  
including goodwill at the date of disposal,  
Exchange rate differences arising on the translation  
of foreign subsidiaries’ opening balance sheet  
 
 
Consolidated financial statements • Annual report 2020 • ALK 59  
Notes to the consolidated financial statements  
1 Accounting policies – continued  
items to the exchange rates at the balance  
sheet date and on the translation of the income  
statements from average exchange rates to  
exchange rates at the balance sheet date are  
recognised in other comprehensive income.  
is recognised in the income statement, and the  
tax expense relating to items recognised in other  
comprehensive income and directly in equity,  
respectively, is recognised in other comprehensive  
income or directly in equity. Exchange rate  
countries when the deferred tax is expected to  
Revenue from the sale of goods is recognised in the  
income statement upon the control of the goods  
being transferred to the customer, i.e. when goods  
are delivered. Revenue is recognised by the ALK  
Group at a point in time.  
crystallise as current tax. Changes in deferred  
tax as a result of changed tax rates or rules are  
recognised in the income statement, in other  
comprehensive income or in equity, depending on  
where the deferred tax was originally recognised.  
Deferred tax related to equity transactions is  
recognised in equity.  
adjustments of deferred tax are recognised as part  
of the adjustment of deferred tax for the year.  
Foreign exchange rate adjustment of receivables  
or debt to subsidiaries which are considered part  
of the parent company’s overall investment in  
the subsidiary in question are also recognised in  
other comprehensive income in the consolidated  
financial statements.  
The ALK Group's customers have payment terms  
that reflect the customer type and the market in  
which sales take place, which typically varies from  
0 to 180 days.  
Current tax payable and receivable is recognised  
in the balance sheet as the expected tax on the  
taxable income for the year, adjusted for tax paid  
on account.  
Deferred tax assets, including the tax value of tax  
loss carry-forwards, are recognised in the balance  
sheet at the value at which the asset is expected  
to be realised, either through a set-off against  
deferred tax liabilities or as net assets to be offset  
against future positive taxable income. Deferred  
tax assets including the tax value of tax losses are  
recognised if it is probable that it can be utilised  
against future taxable income within a foreseeable  
future (5 years). This includes an assessment of the  
possibilities to utilise tax losses in the joint Danish  
taxation scheme with the Lundbeck Foundation  
(Lundbeckfond Invest A/S).  
Revenue is measured as the fair value of the  
consideration received or receivable.  
Share-based incentive plans  
The current tax charge for the year is calculated  
based on the tax rates and rules enacted at the  
balance sheet date.  
Share-based incentive plans (equity-settled share-  
based payments), which comprise share options  
and performance share units, are measured at  
the grant date at fair value and recognised in the  
income statement under the respective functions  
over the vesting period and offset in equity.  
Revenue is measured exclusive of VAT, taxes etc.  
charged on behalf of third parties and less any  
commissions and discounts in connection with  
sales.  
Uncertain tax position is recognised for those  
matters for which the tax determination is uncertain  
but it is considered probable that there will be a  
future outflow of funds to a tax authority (and a  
future inflow of funds from a tax authority). The  
uncertain tax positions are measured at the best  
estimate of the amount expected to become  
payable (and receivable).  
Furthermore, revenue includes licence income  
and royalties from outlicensed products as well  
as up-front payments, milestone payments and  
services in connection with partnerships. These  
revenues are recognised in the income statement  
in accordance with the agreements and when the  
ALK Group obtains the right to the payments, which  
is at the point in time the subsequent sales occur or  
services have been delivered to the customer.  
The fair value of share options is determined  
using the Black & Scholes model. The fair value of  
performance share units is determined using the  
average share price (closing) 5 days after annual  
general meeting.  
At each balance sheet date, it is reassessed  
whether it is likely that there will be sufficient future  
taxable income for the deferred tax asset to be  
utilised.  
Deferred tax is measured using the balance sheet  
liability method on all temporary differences  
between the carrying amount and the tax base  
of assets and liabilities. However, deferred tax is  
not recognised on temporary differences relating  
to the initial recognition of goodwill or the initial  
recognition of a transaction, apart from business  
combinations, and where the temporary difference  
existing at the date of initial recognition affects  
neither profit/loss for the year nor taxable income.  
The ALK Group settles the equity-settled share-  
based incentive plans in shares. However, the  
share option agreement entitles the ALK Group  
to demand cash settlement of the options. The  
ALK Group recognises share options, in case of  
cash settlement, as other liabilities and adjusts  
to fair value as from the time when the ALK Group  
has an obligation to settle in cash. The ALK Group  
recognises subsequent adjustment to fair value in  
the income statement under financial income or  
financial expenses.  
The parent company is included in a joint Danish  
taxation scheme with the Lundbeck Foundation  
(Lundbeckfond Invest A/S) and its Danish  
subsidiaries. The tax charge for the year is  
allocated among the jointly taxed companies in  
proportion to the taxable incomes of individual  
companies, taking into account taxes paid.  
Nonrefundable payments that are not attributable  
to subsequent research and development activities  
are recognised when the related right is obtained,  
whereas payments attributable to subsequent  
research and development activities are  
recognised over the term of the activities.  
When combined contracts are entered into, the  
elements of the contracts are identified and  
assessed separately for accounting purposes.  
Deferred tax is calculated based on the planned  
use of each asset and settlement of each liability,  
respectively. Deferred tax is measured using the  
tax rates and tax rules that, based on legislation  
enacted or in reality enacted at the balance sheet  
date, are expected to apply in the respective  
Income statement  
Tax  
Revenue  
Tax on the profit for the year comprises the year’s  
current tax and changes in deferred tax. The tax  
expense relating to the profit/loss for the year  
The primary performance obligation of the ALK  
Group is the sale and delivery of own-manufactured  
goods and goods for resale for allergy treatment.  
Cost of sales  
The item comprises cost of sales and production  
costs incurred in generating the revenue for the  
 
Consolidated financial statements • Annual report 2020 • ALK 60  
Notes to the consolidated financial statements  
1 Accounting policies – continued  
year. Costs for raw materials, consumables, goods  
for resale, production staff and a proportion of  
production overheads, including maintenance  
and depreciation, amortisation and impairment  
of tangible assets and intangible assets used in  
production as well as operation, administration  
and management of factories are recognised in  
cost of sales and production costs. In addition, the  
costs and write-down to net realisable value of  
obsolete and slow-moving goods are recognised.  
Administrative expenses  
shorter useful life. Acquired intellectual property  
rights are written down to their recoverable amount  
where this is lower than the carrying amount, as  
Balance sheet  
The item comprises expenses incurred for  
management and administration, including  
expenses for administrative staff and  
management, office expenses and depreciation,  
amortisation and impairment losses on  
tangible assets and intangible assets used in  
administration.  
Goodwill  
described below.  
On initial recognition, goodwill is measured and  
recognised as the excess of the cost of the acquired  
company over the fair value of the acquired assets,  
liabilities and contingent liabilities, as described  
under ‘Business combinations’.  
Individual minor development projects running for  
short-term periods which fulfil the requirement in  
IFRS are capitalised under other intangible assets  
as described under ‘Research and development  
expenses’ and are measured at cost less  
Other operating items  
On recognition of goodwill, the goodwill amount is  
allocated to those of the ALK Group’s activities that  
generate separate cash flows (cash-generating  
units). The determination of cash-generating units  
is based on the ALK Group’s management structure  
and internal financial management and reporting.  
Other operating items comprise income and  
expenses of a secondary nature relative to the  
principal activities of the ALK Group.  
accumulated amortisation and impairment.  
Research and development expenses  
The item comprises research and development  
expenses, including expenses incurred for  
wages and salaries, amortisation, impairment  
of capitalised development projects in progress,  
and other overheads as well as costs relating  
to research partnerships. Research expenses  
are recognised in the income statement when  
incurred. Due to the long development periods  
and significant uncertainties in relation to  
the development of new products, including  
risks regarding clinical trials and regulatory  
approvals, it is the assessment that most of the  
ALK Group’s development expenses do not meet  
the capitalisation criteria in IAS 38, Intangible  
Assets. Consequently, development expenses  
are generally recognised in the income statement  
when incurred. Development expenses relating to  
individual minor development projects running for  
short-term periods and subject to limited risk are  
capitalised under other intangible assets.  
Intangible assets with indeterminable useful lives  
are not amortised, but are tested for impairment  
at least once a year. To the extent that the carrying  
amount of the assets exceeds the recoverable  
amount, the assets are written down to this lower  
amount, as described below.  
Financial items  
Financial items comprise interest receivable  
and interest payable, the interest element of  
lease payments, realised and unrealised gains  
and losses on securities, cash and marketable  
securities, liabilities and foreign currency  
transactions, mortgage amortisation premium/  
allowance etc. and supplements/provisions under  
the on-account tax scheme.  
Goodwill is not amortised, but is tested for  
impairment at least once a year, as described  
below.  
Tangible assets  
Land and buildings, plant and machinery and other  
fixtures and equipment are measured at cost less  
accumulated depreciation and impairment. Land is  
not depreciated.  
Intangible assets  
Acquired intellectual property rights in the form  
of patents, brands, licenses, software, customer  
base and similar rights are measured at cost less  
accumulated amortisation and impairment.  
Interest expenses and income related to uncertain  
tax positions are recognised on the balance sheet  
as tax liabilities and tax assets respectively upon  
the receipt of ruling from the tax authorities and  
correspondingly reflected in the income statement  
as financial items net.  
Cost comprises the purchase price and any costs  
directly attributable to the acquisition and any  
preparation costs incurred until the date when the  
asset is available for use.  
Interest expenses on loans to finance the  
development of intangible assets are included  
in cost if they relate to the production period.  
Other borrowing costs are charged to the income  
statement.  
Lease assets are recognised at the commencement  
date of the contract if it is or contains a lease. Lease  
assets are recognised at cost less accumulated  
depreciation and impairment. Cost is defined as  
the lease liability adjusted for any lease payments  
made at or before the commencement date. Lease  
assets are depreciated on a straight-line basis over  
the lease term.  
Interest income and expenses are accrued based  
on the principal and the effective rate of interest.  
The effective rate of interest is the discount rate to  
be used on discounting expected future payments  
in relation to the financial asset or the financial  
liability so that their present value corresponds  
to the carrying amount of the asset or liability,  
respectively.  
The cost of software includes costs of instalment  
and direct salaries.  
Sales and marketing expenses  
The item comprises selling and marketing  
expenses, including salaries and expenses  
relating to sales staff, advertising and exhibitions,  
depreciation, amortisation and impairment losses  
on tangible assets and intangible assets used in  
the sales and marketing process as well as other  
indirect costs.  
Such acquired intellectual property rights are  
amortised on a straight-line basis over the  
expected useful lives of the assets, typically  
not exceeding 10 years. If the actual useful life  
is shorter than either the remaining life or the  
contract period, the asset is amortised over this  
Interest expenses on loans to finance the  
manufacture of tangible assets are included in  
 
Consolidated financial statements • Annual report 2020 • ALK 61  
Notes to the consolidated financial statements  
1 Accounting policies – continued  
there is no reasonable expectation of recovery.  
Financial assets written off may still be subject to  
enforcement activities. Any recoveries made are  
recognised in the income statement.  
cost if they relate to the production period. Other  
borrowing costs are recognised in the income  
statement.  
If the asset does not generate any cash flows  
independently of other assets, the recoverable  
amount is calculated for the smallest cash-  
generating unit that includes the asset.  
measured at fair value either through the income  
statement or through comprehensive income.  
Inventories  
The depreciation base is cost less the estimated  
residual value at the end of the useful life. The  
residual value, estimated at the acquisition date  
and reassessed annually, is determined as the  
amount the company expects to obtain for the asset  
less costs of disposal.  
Inventories are measured at cost determined under  
the FIFO method or net realisable value where this  
is lower.  
The recoverable amount is calculated as the higher  
of the fair value less costs to sell and the value  
in use of the asset or the cash-generating unit,  
respectively. In determining the value in use, the  
estimated future cash flows are discounted to their  
present value, using a discount rate reflecting  
current market assessments of the time value of  
money as well as risks that are specific to the asset  
or the cash-generating unit and which have not  
been taken into account in the estimated future  
cash flows.  
Prepayments  
Prepayments are recognised as an asset and  
comprise incurred costs relating to subsequent  
financial years. Prepayments are measured at cost.  
Cost comprises raw materials, goods for  
resale, and direct payroll costs as well as fixed  
and variable production overheads. Variable  
production overheads comprise indirect materials  
and payroll costs and are allocated based on  
predetermined costs of the goods actually  
produced. Fixed production overheads comprise  
maintenance of and depreciation on the machines,  
factory buildings and equipment used in the  
manufacturing process as well as the cost of factory  
management and administration. Fixed production  
overheads are allocated based on the normal  
capacity of the production plant.  
Dividend  
Dividend is recognised as a liability when adopted  
by the shareholders at the annual general meeting.  
The cost of an asset is divided into smaller  
components that are depreciated separately if  
such components have different useful lives.  
Treasury shares  
Acquisition and sales sums arising on the purchase  
and sale of treasury shares and dividends on  
treasury shares are recognised directly in retained  
earnings under equity.  
Assets are depreciated on a straight-line basis over  
their estimated useful lives as follows:  
If the recoverable amount of the asset or the  
cash-generating unit is lower than the carrying  
amount, the carrying amount is written down to the  
recoverable amount. For cash-generating units, the  
write-down is allocated in such a way that goodwill  
amounts are written down first, and any remaining  
need for write-down is allocated to other assets in  
the unit, although no individual assets are written  
down to a value lower than their fair value less  
costs to sell.  
Buildings  
Plant and machinery  
Other fixtures and equipment  
25-50 years  
5-10 years  
5-10 years  
Pensions and similar liabilities  
The ALK Group has entered into pension  
agreements and similar agreements with some of  
the ALK Group’s employees.  
Depreciation methods, useful lives and residual  
values are reassessed once a year. Tangible assets  
are written down to the recoverable amount, if  
lower, as described below.  
The net realisable value of inventories is calculated  
as the expected selling price less completion costs  
and costs incurred in making the sale.  
In respect of defined contribution plans, the ALK  
Group pays in fixed contributions to independent  
pension funds etc. The contributions are  
recognised in the income statement during the  
period in which the employee renders the related  
service. Payments due are recognised as a liability  
in the balance sheet.  
Receivables  
On initial recognition, receivables are measured at  
fair value, subsequently at amortised cost.  
Impairment of tangible assets and intangible  
assets  
Impairment write-downs are recognised in the  
income statement. If write-downs are subsequently  
reversed as a result of changes in the assumptions  
on which the calculation of the recoverable amount  
is based, the carrying amount of the asset or the  
cash-generating unit is increased to the adjusted  
recoverable amount, not, however, exceeding the  
carrying amount that the asset or cash-generating  
unit would have had, had the write-down not been  
made. Impairment of goodwill is not reversed.  
The carrying amounts of tangible assets and  
intangible assets with determinable useful lives are  
reviewed at the balance sheet date to determine  
whether there are any indications of impairment.  
If such indications are found, the recoverable  
amount of the asset is calculated to determine  
any need for an impairment write-down and, if  
so, the amount of the write-down. For intangible  
assets with indeterminable useful lives and  
goodwill, the recoverable amount is calculated  
annually, regardless of whether any indications of  
impairment have been found.  
Expected credit losses are measured based  
on historical data adjusted by forward-looking  
information. Forward-looking information includes  
assessment of the probability of default as well as  
consideration of various external sources of actual  
and economic information that is reasonable and  
supportable without undue cost or effort.  
In respect of defined benefit plans, the ALK Group  
is required to pay an agreed benefit in connection  
with the retirement of the employees covered by  
the plan, e.g. in the form of a fixed amount or a  
percentage of the salary at retirement.  
An impairment gain or loss is recognised in the  
income statement.  
Other financial assets  
For defined benefit plans, an annual actuarial  
assessment is made of the net present value of  
future benefits to which the employees have earned  
the right through their past service for the ALK  
On initial recognition, investments and  
other financial assets are measured at cost,  
corresponding to fair value. They are subsequently  
Receivables are written down when information  
indicates severe financial difficulties and that  
 
Consolidated financial statements • Annual report 2020 • ALK 62  
Notes to the consolidated financial statements  
1 Accounting policies – continued  
Group and which will have to be paid under the  
plan. The Projected Unit Credit Method is applied to  
determine net present value.  
Mortgage debt  
Deferred income  
Cash flows from financing activities comprise  
Mortgage debt is recognised on the raising of a  
loan at cost, equalling fair value of the proceeds  
received, and net of transaction costs incurred.  
Subsequently, mortgage debt is measured at  
amortised cost.  
Deferred income comprises income received  
relating to subsequent financial years. Deferred  
income is measured at cost.  
changes to the parent company’s share capital and  
related costs as well as the raising and repayment  
of loans, instalments on interest-bearing debt,  
lease liabilities, purchase of treasury shares,  
and settlement of share options and payment of  
dividends.  
The net present value is calculated based on  
assumptions of the future development of salary,  
interest, inflation, mortality and disability rates.  
Debt  
Trade payables, other payables, including sales  
discounts and rebates as well as debt to public  
authorities etc., are measured at amortised cost.  
Lease liabilities  
The net present value of pension liabilities is  
recognised in the balance sheet, after deduction of  
the fair value of any assets attached to the plan, as  
either plan assets or pension liabilities, depending  
on whether the net amount is an asset or a liability,  
as described below.  
On initial recognition, lease liabilities are measured  
as the present value of future payments. The lease  
payments contain fixed payments less any lease  
incentives receivable and variable lease payments  
that depend on an index or a rate.  
Cash flows in currencies other than the functional  
currency are recognised in the cash flow statement  
using average exchange rates for the individual  
months if these are a reasonable approximation of  
the actual exchange rates at the transaction dates.  
If this is not the case, the actual exchange rates for  
the specific days in questions are used.  
Other accounting information  
Cash flow statement  
On subsequent recognition, lease liabilities are  
measured at amortised cost. The difference  
between the present value and the nominal value  
of lease payments is recognised in the income  
statement over the term of the lease as a finance  
charge.  
The cash flow statement of the ALK Group is  
presented using the indirect method and shows  
cash flows from operating, investing and financing  
activities as well as cash and marketable securities  
at the beginning and at the end of the financial  
year.  
If the assumptions made with respect to discount  
factor, inflation, mortality and disability are  
changed, or if there is a discrepancy between  
the expected and realised return on plan assets,  
actuarial gains or losses occur. These gains and  
losses concerning previous financial years are  
recognised in other comprehensive income.  
Cash and marketable securities comprise cash and  
short-term securities subject to an insignificant  
risk of changes in value less any overdraft facilities  
that are an integral part of the ALK Group’s cash  
management.  
If the interest rate cannot be determined in the  
agreement, the lease payments are discounted  
using the ALK Group’s incremental borrowing rate  
adjusted for the functional currency and length of  
the lease term. The lease liability is remeasured if  
or when the future payment or lease term changes.  
The cash effect of acquisitions and divestments is  
shown separately under cash flows from investing  
activities. In the cash flow statement, cash flows  
concerning acquired companies are recognised  
from the date of acquisition, while cash flows  
concerning divested companies are recognised  
until the date of divestment.  
Segment reporting  
Provisions  
Based on the internal reporting used by the Board  
of Management to assess the results of operations  
and allocation of resources, the ALK Group  
has identified one operating segment ‘Allergy  
treatment’, which is in accordance with the way the  
activities are organised and managed. In addition,  
the disclosures in the financial statements include  
a breakdown of revenue by product line and a  
geographical breakdown of revenue and non-  
current assets.  
Provisions are recognised when, as a consequence  
of a past event during the financial year or previous  
years, the ALK Group has a legal or constructive  
obligation, and it is likely that settlement of the  
obligation will require an outflow of the ALK Group’s  
financial resources.  
Short term lease expenses and low value assets  
are not recognised as part of lease liabilities. They  
are recognised in the income statement when  
incurred as an operating expense.  
Cash flows from operating activities are stated as  
net profit, adjusted for non-cash operating items  
and changes in working capital, less the income tax  
paid and plus net financial items.  
Provisions are measured as the best estimate of  
the costs required to settle the obligations at the  
balance sheet date. Provisions with an expected  
term of more than a year after the balance sheet  
date are measured at present value.  
Other financial liabilities  
Other financial liabilities, including bank loans  
and trade and other payables, are on initial  
recognition measured at fair value. The liabilities  
are subsequently measured at amortised cost.  
Cash flows from investing activities comprise  
payments in connection with acquisition and  
divestment of companies and financial assets as  
well as purchase, development, improvement and  
sale of intangible and tangible assets.  
Definitions and ratios  
The key ratios have been calculated in accordance  
with generally accepted financial ratios applied by  
financial analysts. Definitions are shown on page  
86.  
 
Consolidated financial statements • Annual report 2020 • ALK 63  
Notes to the consolidated financial statements  
1 Accounting policies – continued  
Reporting under the ESEF regulation  
The Commission Delegated Regulation (EU)  
2019/815 on the European Single Electronic  
Format (ESEF) (ESEF Regulation) has introduced  
a single electronic reporting format for the annual  
financial reports of issuers with securities listed on  
the EU regulated markets.  
As part of the tagging process financial statement  
line items are marked up to elements in the ESEF  
taxonomy. If a financial statement line item is not  
defined in the ESEF taxonomy, an extension to  
the taxonomy is created. Extensions have to be  
anchored to elements in the ESEF taxonomy, except  
for elements corresponding to subtotals.  
The tagging process is a process where iXBRL tags  
are applied to financial statement line items, etc.  
Taxonomy is an electronic dictionary of business  
reporting elements used to report business data.  
A taxonomy element is an element defined in a  
taxonomy that is used for the machine-readable  
labeling of information in an XBRL data record.  
The ESEF Regulation sets out the following main  
requirements: (1) Issuers shall draw up and  
disclose their annual financial reports using the  
XHTML format; and (2) issuers that draw-up their  
primary consolidated financial statements in  
accordance with IFRS as endorsed by the EU shall  
tag those consolidated financial statements using  
inline eXtensible Business Reporting Language  
(iXBRL) and with effect from the 2022 annual report  
block-tag the notes to the consolidated financial  
statements.  
The annual report 2020 for the ALK Group  
submitted to the Danish Financial Supervisory  
Authority (The Officially Appointed Mechanisms)  
consists of the XHTML document together with  
some technical files all included in a ZIP file named  
"ALK-2020-12-31.zip".  
Key definitions  
XHTML (eXtensible HyperText Markup Language)  
is a text-based markup language used to structure  
and mark up content such as text, images, and  
hyperlinks in documents that are displayed as Web  
pages in an updated standard Web browser like  
Chrome, Internet Explorer or Safari.  
The combination of the XHTML format with the  
iXBRL tags makes the annual financial reports both  
human-readable and machine-readable, thus  
enhancing accessibility, analysis and comparability  
of the information included in the annual financial  
reports.  
iXBRL tags (or Inline XBRL tags) are hidden  
meta-information embedded in the source code  
of an XHTML document in accordance with the  
Inline XBRL 1.1 specification, which enables the  
conversion of XHTML-formatted information  
into a machine-readable XBRL data record by  
appropriate software.  
iXBRL tags shall comply with the ESEF taxonomy,  
which is included in the ESEF Regulation and  
developed based on the IFRS taxonomy published  
by the IFRS Foundation.  
 
Consolidated financial statements • Annual report 2020 • ALK 64  
Notes to the consolidated financial statements  
2 Significant accounting estimates and judgements  
12 in the consolidated financial statements for  
information on goodwill impairment test.  
The indirect production costs capitalised under  
inventories amounted to DKK 377 million at the end  
of 2020 (2019: DKK 348 million). At 31 December  
2020, the carrying amount of inventories is DKK  
1,093 million (2019: DKK 1,056 million).  
Management’s judgements are applied to  
assess the possible effect of exposures and the  
possible outcome of disputes or interpretational  
uncertainties when transfer pricing disputes with  
local tax authorities may occur. Dialogue with local  
tax authorities, tax advisors, business plans and  
knowledge of the business are key parameters  
for Management to estimate the tax assets and  
liabilities.  
In the preparation of the consolidated financial  
statements according to IFRS, Management is  
required to make certain estimates as many  
financial statement items cannot be reliably  
measured, but must be estimated. Such estimates  
comprise judgements made on the basis of the  
most recent information available at the reporting  
date.  
At 31 December 2020, the carrying amount of  
goodwill is DKK 452 million (2019: DKK 461 million).  
Inventories  
The valuation of inventories includes  
Tax  
Management is required to make an estimate in the  
recognition of deferred tax assets and liabilities.  
The ALK Group recognises deferred tax assets  
including the tax value of tax losses if it is probable  
that it can be utilised against future taxable income  
within a foreseeable future (5 years). This includes  
an assessment of the possibilities to utilise tax  
losses in the joint Danish taxation scheme with the  
Lundbeck Foundation (Lundbeckfond Invest A/S)  
and based on forecasts with positive results for  
the coming years in relation to the joint taxation.  
This assessment includes estimates of future  
taxable income in ALK and other members of the  
joint Danish taxation scheme with the Lundbeck  
Foundation. The forecasts for ALK-Abelló A/S with  
increased positive results (EBT) is based on growth  
in revenue and earnings driven by SLIT-tablets.  
Management’s assessment of the saleability of the  
finished goods, and the quality of raw materials to  
be used in the production process. If the expected  
sales price less any completion costs and costs to  
execute sales (net realisable value) of inventories  
is lower than the carrying amount, the inventories  
are written down to net realisable value. When  
assessing salability and net realisable value,  
Management uses estimates for future sales and  
related costs.  
It may be necessary to change previous estimates  
as a result of changes to the assumptions on which  
the estimates were based or due to supplementary  
information, additional experience or subsequent  
events. Similarly, the value of assets and liabilities  
often depends on future events that are somewhat  
uncertain. In that connection, it is necessary  
to set out e.g. a course of events that reflects  
Management’s assessment of the most probable  
course of events.  
At 31 December 2020, the ALK Group recognises  
uncertain tax positions as part of non-current  
tax and deferred tax. The actual outcome may  
deviate and depends on the result of litigation and  
settlements with the relevant local tax authorities.  
Outsourced clinical trials  
Clinical trials, which are outsourced to Clinical  
Research Organisations (“CROs”), take several  
years to complete. As such, Management is  
required to make estimates based on the progress  
and costs incurred to-date for the ongoing trials.  
Estimates are made in determining the amount  
of costs to be expensed during the period or  
recognised as prepayments or accruals on the  
balance sheet.  
Further, work in progress and manufactured  
goods and goods for resale are measured at cost  
including indirect production costs. The indirect  
production costs are measured using a standard  
cost method. This is reviewed regularly to ensure  
reliable measurement of employee costs, capacity  
utilisation, cost drivers and other relevant factors.  
When including the indirect productions costs for  
capitalisation, Management makes estimates  
about cost of production, standard cost variances,  
cost drivers and capacity utilisation. Changes in  
these parameters may have a significant impact on  
the gross margin and the overall valuation of work  
in progress and manufactured goods and goods  
for resale.  
In the consolidated financial statements for  
2020, Management considers the following key  
accounting estimates and related judgements  
material to the assets and liabilities recognised in  
the consolidated financial statements.  
At 31 December 2020, the value of the total net  
deferred tax asset is DKK 697 million (2019: DKK  
616 million). It includes a net deferred tax asset in  
Denmark related to tax losses carried forward of  
DKK 322 million (2019: DKK 372 million).  
Recoverable amount of goodwill  
At 31 December 2020, DKK 135 million is  
recognised as accrued expenses (2019: DKK 105  
million) and DKK 218 million as prepayments on  
the balance sheet (2019: DKK 166 million). In 2020,  
clinical trials expenses of DKK 154 million have  
been recognised in the income statement (2019:  
DKK 144 million).  
The assessment of whether goodwill is impaired  
requires a determination of the value in use of  
the cash-generating unit to which the goodwill  
amounts have been allocated. The determination  
of the value in use requires estimates of the  
expected future cash flow of the cash-generating  
unit and a reasonable discount rate. See note  
Complying with tax rules, when conducting  
business globally, can be complex as the  
interpretation of legislation and case law may  
change over time or may not always be clear.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 65  
Notes to the consolidated financial statements  
3 Revenue and segment information  
Based on the internal reporting used by Management to assess profit and allocation of resources, the ALK Group has identified one operating segment “Allergy treatment”  
which complies with the organisation and management of the activities. Even though revenue within the operating segment “Allergy treatment” can be divided by product  
lines and markets, the main part of the activities within production, research and development, sales and marketing and administration are shared by the ALK Group as a  
whole.  
Europe  
2020  
North America  
International markets  
Total  
2020  
Amounts in DKKm  
2019  
2020  
2019  
2020  
2019  
2019  
SCIT/SLIT-drops  
SLIT-tablets  
1,320  
1,019  
211  
1,454  
735  
275  
85  
306  
85  
78  
266  
24  
58  
153  
26  
1,673  
1,370  
448  
1,818  
973  
Other products and services  
Total revenue  
179  
213  
573  
278  
669  
483  
2,550  
2,368  
368  
237  
3,491  
3,274  
Sale of goods  
Royalties  
3,429  
58  
3,240  
34  
Services  
4
-
Total revenue  
3,491  
3,274  
Of total revenue, DKK 83 million (2019: DKK 75 million) is derived from Denmark. The geographical information on markets is based on customer location.  
The ALK Group’s non-current tangible and intangible assets are distributed among the following geographical markets:  
Europe  
2020  
North America  
International markets  
Total  
2020  
Amounts in DKKm  
2019  
2020  
2019  
2020  
2019  
2019  
Non-current tangible and intangible assets  
1,629  
1,616  
695  
800  
4
5
2,328  
2,421  
Of total non-current tangible and intangible assets, DKK 1,257 million relates to assets in Denmark (2019: DKK 1,227 million). The geographical information on assets is  
based on asset location.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 66  
Notes to the consolidated financial statements  
4 Staff costs  
5 Share-based payments  
The ALK Group has established long-term equity-based incentive plans linked to the creation of  
shareholder value and the fulfilment of strategic goals. The plans are established for the members  
of Board of Management and other key employees, reward long-term value creation and align to  
interests of the shareholders.  
Amounts in DKKm  
2020  
2019  
Wages and salaries  
1,342  
110  
1,303  
111  
Pensions, cf. note 18  
Other social security costs, etc.  
Share-based payments, cf. note 5  
Total  
The incentive plans consist of share options and performance share units.  
197  
185  
28  
34  
Ordinary incentive plans  
The share options entitle the holder to acquire one existing B share of DKK 10 nominal value in the  
company per share option and the performance share units entitle the holder to receive one existing B  
share per performance share unit free of charge.  
1,677  
1,633  
Staff costs are allocated as follows:  
Cost of sales  
643  
227  
621  
209  
The vesting period for both share options and performance share units is three years after grant.  
Vesting is conditional upon certain targets being met and upon the participant not having resigned.  
Target achievement is met upon fulfilment of strategic key performance indicators. In case  
performance is below the threshold there will be no units vesting, and if above target, a multiplier is  
applied that can increase the vesting by up to 100%.  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Included in the cost of assets  
Total  
544  
555  
208  
205  
55  
43  
The exercise of share options is possible in the trading windows following the release of annual and  
interim reports conditional upon the share option holder not having resigned at the time of exercise.  
For performance share units, the final transfer of ownership takes place at vesting three years after  
the grant.  
1,677  
1,633  
Remuneration to Management:  
Remuneration to Board of Management:*  
Special incentive plan 2018  
Salaries  
18  
10  
1
16  
9
ALK’s special incentive plan is a one-time scheme designed to implement ALK’s growth strategy  
and consists of both share options and performance share units with a vesting period of three years.  
The value of the plan did not exceed 50% of the Executive’s 2018 annual base salary on the grant/  
allocation date. The special incentive plan is conditional upon strategic key performance indicators  
being attained, with a threshold value below which the plan will not pay out. If the result exceeds the  
threshold, a defined multiplier may increase the grant/allocation in ALK’s special incentive plan by up  
to 300%. However, the overall payout of the plan on the vesting date for the performance share units  
and on the exercise date for the share options can never exceed a total value of 300% of the recipient’s  
2018 annual base salary. The special incentive plan was adopted at the annual general meeting in  
March 2018.  
Cash bonuses  
Pensions  
1
Expensed costs regarding share-based payments, cf. note 5  
Total remuneration to Board of Management  
11  
40  
13  
39  
Remuneration to Board of Directors:**  
Remuneration to Board of Directors  
4
4
Total remuneration to Board of Management and Board of Directors  
44  
43  
For both the ordinary incentive plan 2018 and the special incentive plan 2018, for a limited number of  
share options (45,441) and performance share units (11,458), the vesting can be increased by up to  
300%.  
Employees  
Average number (FTE)  
Number year end (FTE)  
2,419  
2,447  
2,385  
2,391  
Sign on plan, CEO  
In connection with the employment of Carsten Hellmann in 2017, a CEO sign-on plan was launched. No  
KPIs were linked to the plan, which vested in January 2018 with an expiration date on 1 January 2024.  
*
The expensed costs include DKK 3 million (2019: DKK 6 million) related to adjustment in the share options and performance  
share units expected to vest.  
**The total remuneration to the Board of Directors includes remuneration for participation in the Audit Committee DKK 385,000  
(2019: DKK 350,000), the Remuneration Committee DKK 350,000 (2019: DKK 350,000) and the Scientific Committee  
DKK 150,000 (2019: DKK 150,000). The remaining remuneration relates to regular Board of Directors activities.  
Share options and performance share units are considered sufficiently covered by treasury shares.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 67  
Notes to the consolidated financial statements  
5 Share-based payments – continued  
5 Share-based payments – continued  
Specification of outstanding share options and performance share units:  
Specification of outstanding share options and performance share units:  
Share options  
Other  
Performance share units  
Share options  
Weighted  
Performance share units  
Weighted  
Board of  
Manage-  
ment  
average Board of  
exercise Manage-  
Other  
key em-  
ployees  
units  
Board of  
Manage-  
ment  
Other  
key em-  
ployees  
units  
average Board of  
exercise Manage-  
Other  
key em-  
ployees  
units  
key em-  
ployees  
units  
Total  
units  
price  
DKK  
ment  
units  
Total  
units  
Total  
units  
price  
DKK  
ment  
units  
Total  
units  
units  
units  
2020  
2019  
Outstanding  
at 1 January  
Outstanding  
at 1 January  
98,263  
13,253  
62,293 160,556  
12,130 25,383  
904  
1,332  
954  
-
13,569  
3,024  
36,257  
12,528  
49,826  
15,552  
104,020  
14,898  
94,869 198,889  
10,509 25,407  
841  
1,120  
818  
11,301  
30,546  
10,797  
(3,377)  
-
41,847  
13,997  
(4,309)  
-
Additions  
Additions  
3,200  
Exercised/settled  
Cancellations  
(21,758) (15,085) (36,843)  
(3,149) (12,774) (15,923)  
Exercised/settled  
Expired  
(20,655) (38,570) (59,225)  
(932)  
-
-
-
-
(585)  
(585)  
-
-
(1,350)  
(3,165)  
(1,350)  
(3,165)  
474  
-
-
Outstanding  
Cancellations  
852  
(1,709)  
(1,709)  
at 31 December  
89,758  
59,338 149,096  
32,467  
972  
13,444  
35,426  
48,870  
Outstanding  
at 31 December  
Total number of  
vested share options  
98,263  
62,293 160,556  
42,513  
904  
13,569  
36,257  
49,826  
Total number of  
Average remaining  
vested share options  
life at year end (years)  
2.6  
Average remaining  
Exercise prices at  
year end (DKK)  
life at year end (years)  
3.1  
783-1,372  
Exercise prices at  
year end (DKK)  
487-1,183  
The Board of Directors decided for two trading windows in 2020 to settle share options by cash and  
a total of 24,945 share options were exercised and total cash payments amounted to DKK 24 million.  
For two trading windows the Board of Directors decided to settle share options by shares and a total of  
11,898 share options were exercised.  
The Board of Directors decided for one trading window in 2019 to settle share options by cash and a  
total of 41,125 share options were exercised and total cash payments amounted to DKK 24 million. For  
three trading windows the Board of Directors decided to settle share options by shares and a total of  
18,100 share options were exercised.  
 
Consolidated financial statements • Annual report 2020 • ALK 68  
Notes to the consolidated financial statements  
5 Share-based payments – continued  
5 Share-based payments – continued  
Outstanding share options and performance share units have the following characteristics:  
Share options Performance share units  
Average  
Expensed in the income statement:  
Amounts in DKKm  
2020  
2019  
Cost for the year regarding share-based payments is  
recognised as follows:  
Cost of sales  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Financial expenses  
exercise  
price  
Exercise  
period  
(years)  
3
6
9
10  
1
4
7
11  
12  
5
Vested  
as per  
Vested  
as per  
Plan  
Units  
DKK  
Units  
2014 Plan  
2015 Plan  
2016 Plan  
2017 Sign on plan, CEO  
2017 Plan  
2018 Plan  
2018 Plan – special plan  
2019 Plan  
100  
4,025  
5,050  
17,068  
6,224  
30,873  
43,341  
23,738  
18,677  
795 1 Mar 2017  
856 1 Mar 2018  
1,100 1 Mar 2019  
4
4
4
6
2
2
2
2
2
Total  
29  
39  
924  
1 Jan 2018  
1,025 1 Mar 2020  
793 1 Mar 2021  
793 1 Mar 2021  
1,127 1 Mar 2022  
1,442 1 Mar 2023  
In 2020, the total cost of share-based payments included a financial expense of DKK 1 million due  
to the exercise and cash settlement of share options plans (2019: DKK 5 million) and DKK 5 million  
related to adjustment in the share options and performance share units expected to vest (2019: DKK  
13 million).  
15,607 1 Mar 2021  
8,708 1 Mar 2021  
13,241 1 Mar 2022  
11,314 1 Mar 2023  
2020 Plan  
Fair value of share options and performance share units granted:  
Share options  
Outstanding at  
31 December  
149,096  
48,870  
Fair value at grant date is measured in accordance with the Black & Scholes model for valuation of  
share options, using the following assumptions:  
2020  
Plan  
2019  
Plan  
Average share price (DKK)  
Expected exercise price (DKK)*  
Expected volatility rate**  
Expected option life  
Expected dividend per share  
Risk-free interest rate  
1,372  
1,477  
34% p.a.  
4 years  
-
1,072  
1,154  
32% p.a.  
4 years  
-
-0.01% p.a. -0.44% p.a.  
328 233  
Calculated fair value of granted share options (DKK)  
*
The exercise price is equivalent to the average market price of the share for the five trading days immediately preceding the date of  
grant and is increased by 2.5% p.a. and reduced by dividends paid.  
**The expected volatility rate is based on the historical volatility.  
Performance share units  
Performance share units have been granted at the average market price of the share for the five  
trading days immediately preceding the date of grant at DKK 1,372 per share (2019: DKK 1,072 per  
share).  
 
Consolidated financial statements • Annual report 2020 • ALK 69  
Notes to the consolidated financial statements  
6 Depreciation, amortisation and impairment  
7 Other operating items, net  
Amounts in DKKm  
2020  
2019  
In 2020, other operating items include other operating expenses of DKK 1 million related to sale of  
production equipment.  
Depreciation, amortisation and impairment allocation:  
Cost of sales  
In 2019, other operating items included other operating income of DKK 16 million of which income  
of DKK 15 million related to sale of the North American Veterinary Business Unit effective from 30  
November 2019. See note 11 for further information.  
152  
26  
170  
7
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
29  
35  
38  
43  
Total  
245  
255  
8 Financial income and expenses  
Amounts in DKKm  
2020  
2019  
Impairment amounts to DKK 38 million (2019: DKK 30 million), of which DKK 16 million relate to  
tangible assets (2019: DKK 30 million) and DKK 22 million relate to intangible assets (2019: DKK 0).  
Interest income  
5
5
5
5
The impairment of tangible assets is related to impairment of production equipment with no  
recoverable amount after impairment. The impairment is recognised as cost of sales.  
Financial income from financial assets measured at amortised cost  
The impairment of intangible assets is related to impairment of acquired intellectual property rights  
of DKK 13 million and software of DKK 9 million with no recoverable amount after impairment. The  
impairment is recognised with DKK 19 million as research and development expenses and DKK 3  
million as cost of sales.  
Interest income on uncertain tax positions, net  
Interest income on marketable securities  
Currency gains, net  
-
-
11  
1
-
5
Total financial income  
5
22  
Interest expenses*  
30  
30  
39  
39  
Financial expenses from financial liabilities measured at amortised cost  
Interest expenses on uncertain tax positions, net  
Currency losses, net  
4
20  
54  
-
-
Total financial expenses  
39  
*
Includes interest expenses related to leasing of DKK 8 million (2019: DKK 8 million).  
 
 
Consolidated financial statements • Annual report 2020 • ALK 70  
Notes to the consolidated financial statements  
9 Tax on profit/(loss) for the year  
11 Sale of companies and operations  
Amounts in DKKm  
2020  
2019  
No companies or operations were sold in 2020.  
Effective 30 November 2019, ALK sold its North American Veterinary Business Unit to Spectrum  
Veterinary LLC. The operation was previously an integrated part of ALK’s subsidiaries in North  
America.  
Current income tax  
117  
(38)  
(3)  
-
51  
(32)  
8
Adjustment of deferred tax  
Prior year adjustments, income tax  
Prior year adjustments, deferred tax  
Total  
The North American Veterinary Business Unit specialises in products for veterinary use.  
Amounts in DKKm  
(8)  
19  
76  
2019  
Profit/(loss) before tax  
101  
22  
(31)  
(7)  
Sales price  
30  
Income tax, tax rate of 22% (2019: 22%)  
Effect of deviation of foreign subsidiaries’ tax rate  
relative to Danish tax rate  
Carrying value of sold net assets  
Patents, trademarks and rights  
Goodwill  
15  
(2)  
-
41  
3
4
7
Permanent differences  
Adjustment of deferred tax due to coming year change of tax rate  
Other taxes and adjustments  
3
Plant and machinery  
Sold net assets  
3
46  
(2)  
(3)  
-
1
14  
Change in valuation of net tax assets  
Prior year adjustments, income tax  
Prior year adjustments, deferred tax  
Tax on profit/(loss) for the year  
(22)  
8
Transaction cost  
1
(8)  
19  
76  
Net gain on sales of companies and operations included in  
other operating income in the income statement  
15  
Tax related to equity comprises an income of DKK 43 million (2019: income of DKK 27 million) and other  
comprehensive income comprises an income of DKK 2 million (2019: income of DKK 8 million).  
Out of the ALK Group’s total revenue of DKK 3,274 million in 2019, DKK 20 million was attributable to  
the North American Veterinary Business Unit.  
10 Adjustments for non-cash items  
Amounts in DKKm  
2020  
2019  
Tax on profit/(loss)  
76  
49  
19  
17  
Financial income and expenses  
Share-based payments  
29  
39  
Reversal of accounting gain on sale of companies and operations  
Depreciation, amortisation and impairment  
Other adjustments*  
-
(14)  
255  
73  
245  
63  
Total  
462  
389  
*
Other adjustments include mainly provision for transition period for the Danish Holiday Act of DKK 39 million (2019: DKK19  
million) and non-cash transactions related to the divestment of ALK’s part-share of a formulation production line for tablets to  
production partner Catalent of DKK 37 million (2019: DKK 24 million).  
 
 
Consolidated financial statements • Annual report 2020 • ALK 71  
Notes to the consolidated financial statements  
12 Intangible assets  
12 Intangible assets – continued  
Patents,  
trademarks  
and rights  
Goodwill  
Goodwill is related to acquisition of companies in previous years and is recognised as the excess of  
the cost of an acquired company over the fair value of the acquired assets, liabilities and contingent  
liabilities.  
Amounts in DKKm  
Goodwill  
483  
Software  
400  
Other  
251  
Total  
2020  
Goodwill has been subject to an impairment test, which has been submitted to the Audit Committee for  
subsequent approval by the Board of Directors. The impairment test performed in 2020 revealed no  
need for impairment of goodwill.  
Cost beginning of year  
Currency adjustments  
Additions  
Disposals  
Transfer to/from other groups  
Cost year end  
240  
(9)  
1,374  
(20)  
26  
(33)  
-
(8)  
-
-
(1)  
(2)  
3
(7)  
1
-
-
-
23  
(26)  
(1)  
Goodwill has been tested at an aggregated level. The ALK Group is considered as one cash-  
generating unit as the individual companies and business units in the ALK Group cannot be evaluated  
separately due to the value-adding processes are generated across corporations and entities.  
-
475  
396  
231  
245  
1,347  
Amortisation and impairment  
beginning of year  
Currency adjustments  
Amortisation for the year  
Amortisation on disposals  
Impairment for the year, cf. note 6  
22  
1
-
-
-
299  
(2)  
23  
(7)  
-
208  
(7)  
13  
-
-
163  
(1)  
11  
(22)  
22  
692  
(9)  
47  
(29)  
22  
In the calculation of the value in use of the cash-generating unit, future free net cash flow is estimated  
based on Board of Directors-approved financial forecast in line with the ALK Group’s strategy.  
The budget and the strategy plans are based on specific future business initiatives for which the  
risks relating to key parameters have been assessed and recognised in estimated future free cash  
flows. The key parameters in the calculation of the value in use are revenue, earnings, working  
capital, capital expenditure, discount rate and the preconditions for the terminal value. Estimates  
are based on historical data and expectations on future changes in the markets and products. These  
expectations are based on a number of assumptions including expected product launches, volume  
forecasts, price information and profitability of both the ALK Group’s business as well as geographical  
expansions.  
Amortisation and impairment  
year end  
Carrying amount year end  
23  
452  
313  
83  
214  
17  
173  
72  
723  
624  
2019  
Cost beginning of year  
Currency adjustments  
Additions  
Disposals  
Sale of companies and operations,  
cf. note 11  
488  
2
-
353  
2
7
277  
4
281  
4
13  
(1)  
1,399  
12  
20  
(29)  
For financial years after the five year forecast period (2021-2025), the cash flows in the most recent  
period have been extrapolated adjusted for a growth factor of 1.5% (2019: 1.5%) during the terminal  
period.  
-
-
(8)  
(20)  
(7)  
-
483  
-
46  
400  
(21)  
-
240  
-
(46)  
251  
(28)  
-
1,374  
The calculated value in use shows that future earnings and cash flows fully support the carrying  
amount of total net assets, including goodwill.  
Transfer to/from other groups  
Cost year end  
Amortisation and impairment  
beginning of year  
Currency adjustments  
The discount rate used is 10% pre-tax and 7.5% after tax (2019: 10% pre-tax and 7.5% after tax).  
23  
(1)  
283  
2
216  
3
152  
-
674  
4
Other intangible assets  
Amortisation for the year  
Amortisation on disposals  
Amortisation on sale of companies  
and operations, cf note 11  
-
-
22  
(8)  
26  
(20)  
11  
-
59  
(28)  
Other intangible assets cover minor finished development projects and development projects in  
progress including software development projects.  
-
-
(17)  
-
(17)  
Amortisation and impairment  
year end  
Carrying amount year end  
22  
461  
299  
101  
208  
32  
163  
88  
692  
682  
 
 
Consolidated financial statements • Annual report 2020 • ALK 72  
Notes to the consolidated financial statements  
13 Property, plant and equipment  
13 Property, plant and equipment – continued  
Property,  
Property,  
plant and  
Plant and fixtures and equipment  
Other  
Plant and fixtures and equipment  
buildings* machinery equipment in progress  
plant and  
Other  
Land and  
Land and  
Amounts in DKKm  
Total  
Amounts in DKKm  
2019  
buildings* machinery equipment in progress  
Total  
2020  
Cost beginning of year  
Currency adjustments  
Additions  
1,533  
(58)  
15  
807  
(23)  
15  
244  
(4)  
421  
(9)  
3,005  
(94)  
206  
1
Cost beginning of year  
Initial application of IFRS 16  
beginning of year  
1,339  
903  
241  
364  
2,847  
9
-
167  
-
266  
12  
-
-
1
-
2
266  
19  
Lease contract modifications  
Disposals  
1
-
Currency adjustments  
Additions  
4
(1)  
(34)  
177  
942  
(14)  
21  
(18)  
(201)  
360  
(67)  
-
32  
7
-
12  
-
125  
-
176  
Transfer to/from other groups  
Cost year end  
3
Lease contract modifications  
Disposals  
(1)  
(1)  
1,493  
256  
3,051  
(120)  
(153)  
(24)  
(1)  
(298)  
Sale of companies and operations,  
cf. note 11  
-
5
(4)  
50  
-
14  
-
(69)  
421  
(4)  
-
Depreciation and impairment  
beginning of year  
510  
(13)  
76  
482  
(15)  
66  
183  
(3)  
18  
91  
-
1,266  
(31)  
160  
(64)  
16  
Transfer to/from other groups  
Currency adjustments  
Cost year end  
1,533  
807  
244  
3,005  
Depreciation for the year  
Depreciation of disposals  
Impairment for the year, cf. note 6  
-
(1)  
-
(33)  
-
(14)  
-
(16)  
16  
Depreciation and impairment  
beginning of year  
461  
3
521  
3
189  
-
92  
(1)  
-
1,263  
5
Currency adjustments  
Depreciation for the year  
Depreciation of disposals  
Depreciation and impairment  
year end  
572  
921  
500  
442  
184  
72  
91  
1,347  
1,704  
83  
67  
16  
166  
(197)  
(56)  
(119)  
(22)  
-
Carrying amount year end  
269  
Depreciation on sale of companies  
and operations, cf. note 11  
-
(1)  
11  
-
-
-
-
(1)  
30  
Impairment for the year, cf. note 6  
19  
of which financing costs  
-
Depreciation and impairment  
year end  
Value of land and buildings  
subject to mortgages  
510  
482  
325  
183  
61  
91  
1,266  
1,739  
197  
*
Land and buildings include buildings on land leased from Scion DTU A/S, Hørsholm in Denmark. The leases are open-ended and  
the estimated lease terms are 15 years.  
Carrying amount year end  
1,023  
330  
of which financing costs  
-
Value of land and buildings  
subject to mortgages  
209  
*
Land and buildings include buildings on land leased from Scion DTU A/S, Hørsholm in Denmark. The leases are open-ended and  
the estimated lease terms are 15 years.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 73  
Notes to the consolidated financial statements  
13 Property, plant and equipment – continued  
13 Property, plant and equipment – continued  
Specification of right-of-use assets:  
Specification of right-of-use assets:  
Property,  
plant and  
Property,  
plant and  
Other  
Other  
Land and  
Plant and fixtures and equipment  
Land and  
Plant and fixtures and equipment  
Amounts in DKKm  
buildings machinery equipment in progress  
Total  
295  
Amounts in DKKm  
buildings machinery equipment in progress  
Total  
115  
2020  
2019  
Cost beginning of year  
Currency adjustments  
Additions  
293  
(9)  
-
-
-
-
-
2
-
-
-
-
-
-
Cost beginning of year  
Initial application of IFRS 16,  
beginning of year  
Additions  
114  
-
1
-
(9)  
10  
1
-
10  
1
266  
28  
-
-
-
-
-
-
1
-
-
-
-
-
-
266  
29  
Lease contract modifications  
Cost year end  
-
295  
2
297  
Lease contract modifications  
Disposals  
(1)  
(1)  
(114)  
-
(114)  
Depreciation beginning of year  
Currency adjustments  
35  
-
-
-
-
1
-
-
-
-
-
36  
Cost year end  
293  
2
295  
(2)  
(2)  
Depreciation for the year, cf. note 24  
Depreciation year end  
36  
-
36  
Depreciation beginning of year  
Depreciation for the year, cf. note 24  
Depreciation of disposals  
32  
35  
-
-
-
-
-
1
-
-
-
-
-
32  
36  
69  
1
70  
(32)  
35  
(32)  
36  
Carrying amount year end  
226  
-
1
-
227  
Depreciation year end  
1
Carrying amount year end  
258  
-
1
-
259  
 
Consolidated financial statements • Annual report 2020 • ALK 74  
Notes to the consolidated financial statements  
14 Deferred tax  
Current  
and other  
assets  
Tax losses  
carried  
forward  
Intangible  
assets  
Tangible  
assets  
Amounts in DKKm  
Liabilities  
Total  
2020  
Carrying amount beginning of year  
11  
(100)  
206  
(17)  
-
117  
19  
-
382  
616  
-
Adjustment to prior years’ deferred tax  
Adjustment of receivables from group companies  
Currency adjustments  
-
(1)  
(1)  
-
-
(2)  
(1)  
(55)  
-
(2)  
-
1
(19)  
-
3
(1)  
117  
-
(2)  
Recognised in the income statement, net  
Change in valuation of net tax assets  
Recognised in other comprehensive income, net  
Recognised in equity, net (share-based payments)  
Carrying amount year end  
(5)  
(2)  
2
36  
2
-
-
-
-
-
1
1
2
-
35  
340  
-
8
43  
697  
(7)  
(103)  
135  
332  
2019  
Carrying amount beginning of year  
31  
(46)  
166  
41  
17  
(17)  
-
350  
(33)  
7
542  
(10)  
7
Impact from initial application of IFRIC 23  
Adjustment to prior years’ deferred tax  
6
-
-
17  
-
(1)  
1
Adjustment of receivables from group companies  
Adjustment of deferred tax due to coming year change of tax rate  
Recognised in the income statement, net  
Change in valuation of net tax assets  
-
-
10  
-
10  
(3)  
9
-
(25)  
-
1
-
(4)  
43  
26  
11  
-
(56)  
1
46  
-
-
-
26  
8
Recognised in other comprehensive income, net  
Recognised in equity, net (share-based payments)  
Carrying amount year end  
-
-
-
-
(3)  
5
-
22  
206  
27  
616  
11  
(100)  
117  
382  
Deferred tax consists of deferred tax assets of DKK 697 million (2019: DKK 620 million) and deferred tax liabilities of DKK 0 (2019: DKK 4 million).  
The ALK Group recognises deferred tax assets including the tax value of tax losses if it is probable that it can be utilised against future taxable income within  
a foreseeable future (5 years). This includes an assessment of the possibilities to utilise tax losses in the joint Danish taxation scheme with the Lundbeck  
Foundation (Lundbeckfond Invest A/S). See note 2 for further information.  
Unrecognised deferred tax assets comprising tax losses carried forward amount to DKK 16 million and primarily relate to US entities (2019: DKK 19 million).  
 
 
Consolidated financial statements • Annual report 2020 • ALK 75  
Notes to the consolidated financial statements  
15 Inventories  
16 Trade receivables  
Amounts in DKKm  
2020  
2019  
Amounts in DKKm  
Days past due  
Raw materials*  
209  
438  
214  
447  
Not due <180 days  
180-360 >360 days  
Total  
Work in progress  
Manufactured goods and goods for resale  
446  
395  
Total  
1,093  
1,056  
2020  
Average expected credit loss rate  
Trade receivables (gross)  
Loss allowance  
1%  
475  
5
8%  
71  
6
14%  
50%  
Amount of write-down of inventories during the year  
45  
10  
53  
21  
7
1
6
6
3
3
559  
15  
Amount of reversal of write-down of inventories during the year**  
The total cost of materials included in cost of sales amounted to DKK 357 million (2019: DKK 326  
million).  
Trade receivables (net)  
470  
65  
544  
Loss allowance:  
The net carrying amount of inventory not expected to be sold in 2021 is estimated at DKK 225 million  
(2020: DKK 263 million).  
Balance beginning of year  
Change in allowances during the year  
Realised losses during the year  
Loss allowance, year end  
12  
6
(3)  
*
A minor part of ALK’s raw material inventory contains biological assets from agricultural activities. Due to missing market on  
which a fair value can be established these products are not valuated.  
15  
**Reversal of provision for slow moving items, sold in 2020.  
2019  
Average expected credit loss rate  
Trade receivables (gross)  
Loss allowance  
0%  
358  
1
8%  
51  
4
50%  
83%  
4
2
2
6
5
1
419  
12  
Trade receivables (net)  
357  
47  
407  
Loss allowance:  
Balance beginning of year  
Change in allowances during the year  
Realised losses during the year  
Loss allowance, year end  
11  
7
(6)  
12  
Loss allowance for doubtful trade receivables is based on an individual assessment of the receivables.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 76  
Notes to the consolidated financial statements  
17 Share capital and earnings per share  
18 Pensions and similar liabilities  
Amounts in DKKm  
2020  
2019  
The ALK Group has entered into defined contribution plans as well as defined benefit plans.  
In defined contribution plans, the ALK Group is obliged to pay a certain contribution to a pension fund  
or the like but bears no risks regarding the future development in interest, inflation, mortality, disability  
rates etc. regarding the amount to be paid to the employee.  
Share capital  
The share capital consists of:  
A shares  
9
1
9
1
AA shares  
The ALK Group sponsors defined benefit plans for qualifying employees of its subsidiaries in Germany,  
France and Switzerland. The defined benefit plans guarantee employees a certain level of pension  
benefits for life. The pension is based on seniority and salary at the time of retirement. The ALK Group  
bears the risks regarding the future development in interest, inflation, mortality, disability rates etc.  
regarding the amount to be paid to the employee.  
B shares  
101  
111  
101  
111  
Total nominal value  
Each A and AA share carries 10 votes, whereas each B share carries 1 vote. AA shares no longer held by  
individuals or legal entities other than the Lundbeck Foundation (Lundbeckfond Invest A/S) or companies  
which are group affiliated with the Lundbeck Foundation, cf. the definition of groups in section 6 of the Danish  
Companies Act, or in the event that a company which holds AA shares is no longer group affiliated with the  
Lundbeck Foundation, such AA shares shall be transferred to the B share capital.  
Amounts in DKKm  
2020  
2019  
Treasury shares  
Treasury shares beginning of year (B-shares), units  
Sale of treasury shares, units  
Costs related to defined contribution plans  
Costs related to defined benefit plans  
Total  
86  
24  
84  
27  
240,694  
(27,821)  
212,873  
263,203  
(22,509)  
240,694  
110  
111  
Treasury shares year end (B-shares), units  
Proportion of share capital year end  
Nominal value year end  
1.9%  
2.1  
2.2%  
2.4  
Present value of funded pension obligations  
Fair value of plan assets  
20  
(13)  
7
20  
(13)  
7
Market value year end  
532  
394  
Funded pension obligations, net  
Earnings per share  
The calculation of earnings per share is based on the following:  
Net profit/(loss)  
Present value of unfunded pension obligations  
268  
257  
25  
(50)  
Pension obligations  
275  
264  
Number in units:  
Average number of issued shares  
Average number of treasury shares  
11,141,196 11,141,196  
(225,139) (252,533)  
Anniversary liabilities  
12  
-
11  
1
Indemnity fund  
Average number of shares used for calculation of earnings/(loss) per share 10,916,057 10,888,663  
Other liabilities*  
58  
345  
21  
Average dilutive effect of outstanding share options  
78,328  
61,114  
Pension obligations and similar liabilities, year end  
297  
Average number of shares used for calculation  
of diluted earnings/(loss) per share  
10,994,385 10,949,777  
Plan assets consist of assets placed in pension companies. Assets are placed in investments classified  
as other assets than shares, bonds and property by the pension companies, and are not measured at  
quoted prices.  
Earnings/(loss) per share (EPS)  
Earnings/(loss) per share, diluted (DEPS)  
2.29  
2.27  
(4.59)  
(4.59)  
According to a resolution passed by the parent company at the annual general meeting, the parent company  
is allowed to purchase treasury shares, equal to 10% of the share capital. The parent company has purchased  
treasury shares in connection with the issuance of share-based incentive plans.  
The weighted average duration of the pension obligations is 19.64 years (2019: 20.12 years).  
*
Other liabilities include liability related to the transition period for the Danish Holiday Act of DKK 58 million (2019: DKK 19 million).  
At year end 2020 the amount of A shares was 920,760 (2019: 920,760), AA shares 92,076 (2019: 92,076)  
and B shares 10,128,360 (2019: 10,128,360). All shares have a nominal value of DKK 10.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 77  
Notes to the consolidated financial statements  
18 Pensions and similar liabilities – continued  
18 Pensions and similar liabilities – continued  
Amounts in DKKm  
2020  
2019  
Amounts in DKKm  
2020  
2019  
Movements in the fair value of the plan assets in the current year  
Opening fair value of plan assets  
The principal assumptions used for the actuarial valuations  
13  
1
11  
1
Discount rate range of 0.2% - 0.8% (weighted average rate)  
0.7%  
2.4%  
0.8%  
2.0%  
Contribution from plan participants  
Benefits paid  
Expected future rate of salary increase range of 1% - 2.5%  
(weighted average rate)  
(1)  
1
Closing fair value of plan assets  
13  
13  
Assumed life expectations on retirement age for current pensioners  
Movements in present value of unfunded pension obligations  
in the current year  
(years based on weighted average)*:  
Males  
21.1  
24.8  
21.6  
25.4  
Opening present value of unfunded pension obligations  
Current service costs  
257  
8
211  
11  
3
Females  
Assumed life expectations on retirement age for current employees  
(future pensioners) (years based on weighted average)*:  
Interest costs  
2
Actuarial (gains)/losses from changes in financial assumptions  
Actuarial (gains)/losses arising from experience adjustments  
Actuarial (gains)/losses arising from demographic adjustments  
Benefits paid  
7
37  
Males  
22.3  
26.2  
23.2  
27.3  
(1)  
(3)  
Females  
(2)  
(3)  
-
Sensitivity analysis:  
(2)  
Significant actuarial assumptions for determining the  
defined benefit obligation  
Closing present value of unfunded pension obligations  
268  
257  
Discount rate, effect in case of increase in range of 0.25% - 1%**  
Discount rate, effect in case of decrease in range of 0.25% - 1%**  
Salary, effect in case of 0.25% - 0.5% increase**  
(43)  
56  
(41)  
54  
Amount recognised as staff expenses in the income statement  
Current service costs  
Net interest expense  
Total  
10  
2
12  
3
5
4
Salary, effect in case of 0.25% - 0.5% decrease**  
(5)  
12  
(4)  
11  
12  
15  
Life expectancy, effect in case of increase by 1 year*  
Life expectancy, effect in case of decrease by 1 year*  
Amount recognised in comprehensive income in respect  
of defined benefit plans  
(12)  
(11)  
Movements in the present value of the defined benefit obligation  
in the current year  
Actuarial (gains)/losses  
3
37  
Total  
3
37  
Opening defined benefit obligation  
Current service costs  
20  
2
15  
1
The expected contribution for 2021 for the defined benefit plans is DKK 12 million (2020: DKK 8  
million).  
Actuarial (gains)/losses from changes in financial assumptions  
Actuarial (gains)/losses arising from experience adjustments  
Benefits paid  
-
2
(1)  
(1)  
-
-
The most recent actuarial valuations of the defined benefit liability were carried out by external  
independent actuary agents at 31 December 2020. In 2020, a pension plan has been reclassified and  
comparative figures have been adjusted accordingly.  
1
Currency translation adjustment  
1
Closing defined benefit obligation  
20  
20  
*
Based on national statistics for mortality.  
**Based on actuarial reports with different rates.  
 
Consolidated financial statements • Annual report 2020 • ALK 78  
Notes to the consolidated financial statements  
19 Mortgage debt and bank loans  
20 Other provisions  
Carrying amount  
Fair value  
Acquisition  
Restructuring  
programs*  
of operating  
assets**  
Other  
provisions***  
Amounts in DKKm  
2020  
2019  
2020  
2019  
Amounts in DKKm  
Total  
Debt to mortgage credit institutions  
secured by real property  
2020  
Mortgage debt is due as follows*:  
Within 1 year  
Other provisions beginning of year  
Used during the year*  
19  
(19)  
-
-
-
-
4
(1)  
3
23  
(20)  
3
18  
72  
18  
71  
18  
73  
18  
72  
From 1-5 years  
After 5 years  
Other provisions, year end***  
168  
258  
188  
277  
172  
263  
191  
281  
Total  
Other provisions are recognised as follows:  
Current liabilities  
-
-
3
3
Bank loans  
Other provisions, year end  
-
-
3
3
Bank loans are due as follows:  
Within 1 year  
-
446  
-
-
448  
-
-
446  
-
-
448  
-
2019  
From 1-5 years  
After 5 years  
Other provisions beginning of year  
Provisions made during the year  
Used during the year**  
3
16  
-
20  
5
3
28  
19  
Total  
446  
448  
446  
448  
-
(20)  
(2)  
(2)  
4
(22)  
(2)  
23  
Mortgage debt and bank loans  
are recognised accordingly:  
Reversals during the year  
-
-
Other provisions, year end  
19  
-
Non-current liabilities  
Current liabilities  
686  
18  
707  
18  
Other provisions are recognised as follows:  
Current liabilities  
Fair value for mortgage debt is measured by level 1 input (quoted prices in active markets) from the  
fair value hierarchy and fair value for bank loans is measured by level 2 input (inputs other than quoted  
markets that are observable) from the fair value hierarchy.  
19  
-
4
23  
Other provisions, year end  
19  
-
4
23  
*
There is no provision for restructuring programs (2019: DKK 19 million). Provision for restructuring of ALK's Italian entity ALK-  
Abelló S.p.A. (2019: DKK 16 million) and restructuring of production in Denmark (2019: DKK 3 million) was used during 2020.  
Beginning of 2018 the ALK Group extended its financial resources with a DKK 600 million credit facility  
which runs until the end of 2022. By the end of 2020 none of this resource was drawn upon.  
** ALK's acquisition of the operating assets in Allergy Laboratory of Oklahoma Inc. and Crystal Labs LLC in 2017 was fully paid in  
2019.  
*** Other provisions include a provision for sales in Italy of DKK 3 million (2019: DKK 4 million).  
*
Change in mortgage debt during the year of DKK 19 million is cash flows from financing activities (2019: DKK 16 million).  
 
 
Consolidated financial statements • Annual report 2020 • ALK 79  
Notes to the consolidated financial statements  
21 Other payables  
23 Contingent liabilities and commitments – continued  
Amounts in DKKm  
2020  
2019  
Commitments  
Land and buildings provided as security vis-à-vis for mortgage debt amount to DKK 197 million  
(2019: DKK 209 million) out of mortgage debt of DKK 258 million (2019: DKK 277 million).  
Rebates and commissions  
Salaries, holiday payments etc.  
VAT and other taxes  
Other  
243  
242  
109  
286  
880  
177  
253  
65  
Change of control  
The ALK Group's credit facilities are subject to standard change of control clauses according to which  
the lender has the right to cancel the commitment and demand repayment of outstandings.  
265  
760  
Total  
24 Leases  
Leases in the income statement  
22 Changes in working capital  
Amounts in DKKm  
2020  
2019  
Amounts in DKKm  
2020  
2019  
Change in inventories  
(69)  
(159)  
74  
(54)  
(200)  
159  
Expenses from short-term leases  
Expenses from low-value assets (including cars)  
Depreciation of right-of-use assets, cf. note 13  
Interest expenses on lease liabilities  
Total  
1
19  
36  
8
4
18  
36  
8
Change in receivables and prepayments  
Change in short-term payables  
Total  
(154)  
(95)  
64  
66  
Cash outflow related to lease agreements was DKK 38 million (2019: DKK 37 million).  
23 Contingent liabilities and commitments  
Lease liabilities  
Contingent liabilities  
In the ordinary course of business, the ALK Group is involved in certain claims, disputes etc. In the  
opinion of Management, settlement or continuation of pending claims and other disputes will have no  
material impact on the ALK Group’s financial position.  
Amounts in DKKm  
2020  
2019  
Lease liabilities expire as follows:  
Within 1 year  
The ALK Group operates in a wide variety of jurisdictions, in some of which the tax law is subject to  
varying interpretations and potentially inconsistent enforcement. As a result, there can be practical  
uncertainties in applying tax legislation to the ALK Group’s activities. Whilst the ALK Group considers  
that it operates in accordance with applicable tax law, there are potential tax exposures in respect of  
its operations, the impact of which cannot be reliably estimated, but could be material.  
32  
109  
98  
31  
113  
121  
265  
From 1-5 years  
After 5 years  
Total  
239  
Joint taxation scheme  
ALK-Abelló A/S is included in a joint Danish taxation scheme with the Lundbeck Foundation  
(Lundbeckfond Invest A/S) and its Danish subsidiaries. The Danish companies are joint and several  
liable for the joint taxation liability. The joint taxation liability covers income taxes and withholding  
taxes on dividends, royalties and interest. The joint taxation liability is capped at an amount equal to  
the share of the capital of the company directly or indirectly owned by the ultimate parent company.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 80  
Notes to the consolidated financial statements  
25 Financial risks and financial instruments  
25 Financial risks and financial instruments – continued  
Financial risk management policy  
The general objective of the ALK Group’s foreign exchange risk management is to limit and delay  
any adverse impact of exchange rate fluctuations on earnings and cash flows and thus increase  
the predictability of the financial results. The most significant financial risk relates to exchange rate  
fluctuations. The greatest exposure is to USD and in 2020, 15% (2019: 19%) of the revenue was  
denominated in USD. The sales are not deemed to be exposed to EUR due to Denmark’s participation  
in the European Exchange Rate Mechanism.  
As a result of operations, investments and financing, the ALK Group is exposed to exchange and  
interest rate changes. ALK-Abelló A/S manages the ALK Group’s financial risks centrally and  
coordinates the ALK Group’s cash management, including the raising of capital and investment of  
excess cash. The ALK Group complies with a policy, approved by the Board of Directors, to maintain  
a low risk profile, ensuring that the ALK Group is only exposed to foreign exchange rate risk, liquidity  
risk, interest rate risk, and credit risk in connection with its commercial activities.  
The ALK Group is exposed to exchange rate risks when intercompany balances and net assets  
of foreign subsidiaries are translated into DKK. In accordance with the ALK Group’s accounting  
policies, such currency translation adjustments are recognised in the income statement and in other  
comprehensive income, respectively.  
Capital structure  
The ALK Group manages its capital to ensure that all entities will be able to continue as going concern  
while maximising the return to stakeholders through the optimisation of the debt and equity balances.  
The capital structure of the ALK Group consists of net debt and equity. The dividend policy of the ALK  
Group is to distribute maximum possible dividend to ALK-Abelló A/S.  
The ALK Group has no open exchange rate hedge contracts at 31 December 2020 or 31 December  
2019.  
The ALK Group’s Risk Committee reviews the capital structure annually. As a part of this review, the  
committee considers the cost of capital and the risks associated with each class of capital.  
Sensitivity to a 10% increase in USD exchange rate  
The table below shows the estimated effect of a 10% increase in the USD exchange rate on revenue,  
EBITDA and equity levels, respectively. In the sensitivity analysis, data for revenue and EBITDA are  
based on current short-term expectations and data for equity are based on actual equity at 31  
December 2020.  
Foreign exchange rate risk  
Foreign exchange rate risk arises due to imbalances between revenue and expenses in each individual  
currency. Foreign exchange rate exposure relating to future transactions and assets and liabilities is  
evaluated and hedged through matching of payments received and paid in the same currency. This  
serves to limit the impact on the financial results of any exchange rate fluctuations. The exchange  
rate exposure relating to net investments in foreign subsidiaries is not hedged by forward exchange  
contracts. The ALK Group hedges significant exchange rate exposures regarding future sales and  
purchase of goods in the coming six months in accordance with the ALK Group’s policy.  
Amounts in DKKm  
Revenue  
EBITDA  
Equity  
31 December 2020  
USD  
approx.+60  
approx.+75  
approx.  
0
0
approx. +90  
approx. +95  
31 December 2019  
USD  
approx.  
A decrease in the exchange rates will have a corresponding adverse effect.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 81  
Notes to the consolidated financial statements  
25 Financial risks and financial instruments – continued  
25 Financial risks and financial instruments – continued  
Net positions  
Liquidity risk  
In connection with the ALK Group’s ongoing financing of operations, including refinancing, efforts are  
made to ensure adequate and flexible liquidity. This is guaranteed by placing free funds in credit-  
worthy, liquid, interest bearing instruments of relatively short durations in accordance with the ALK  
Group’s policy.  
Amount  
hedged  
Net  
position  
Amounts in DKKm  
Cash Receivables  
Liabilities  
The liquidity risk is considered to be minimal due to the ALK Group’s current capital structure.  
31 December 2020  
Liquidity exposure  
DKK  
USD  
EUR  
18  
65  
150  
5
124  
88  
(936)  
(144)  
(1,243)  
(16)  
-
-
-
-
-
-
-
(794)  
9
Revaluation/payment date  
Carrying  
amount  
Total  
cash flow*  
Within  
1 year  
From  
1-5 years  
After  
5 years  
345  
20  
(748)  
9
Amounts in DKKm  
GBP  
SEK  
7
28  
(14)  
21  
31 December 2020  
Other  
Total  
53  
298  
109  
714  
(57)  
105  
(2,410)  
(1,398)  
Mortgage debt and bank loans  
Trade payables  
704  
74  
746  
74  
29  
74  
535  
-
182  
-
Other financial liabilities**  
Financial liabilities  
1,140  
1,918  
1,171  
1,991  
939  
126  
661  
106  
288  
31 December 2019  
1,042  
DKK  
USD  
EUR  
(75)  
62  
237  
97  
(865)  
(163)  
(1,183)  
(33)  
-
-
-
-
-
-
-
(703)  
(4)  
31 December 2019  
232  
32  
276  
12  
(675)  
11  
GBP  
SEK  
Mortgage debt and bank loans  
Trade payables  
725  
81  
777  
81  
29  
81  
546  
-
202  
-
8
16  
(13)  
11  
Other  
Total  
57  
74  
(62)  
69  
Other financial liabilities**  
Financial liabilities  
1,045  
1,851  
1,085  
1,943  
820  
930  
131  
677  
134  
336  
316  
712  
(2,319)  
(1,291)  
*
Total cash flow includes interests.  
**Other financial liabilities include lease liabilities of DKK 239 million (2019: DKK 265 million).  
 
Consolidated financial statements • Annual report 2020 • ALK 82  
Notes to the consolidated financial statements  
25 Financial risks and financial instruments – continued  
25 Financial risks and financial instruments – continued  
Interest rate risk  
Credit risk  
The ALK Group does not hedge its interest rate exposure, as this is not considered to be financially  
viable.  
The ALK Group’s primary credit exposure is related to trade receivables and cash. The ALK Group has  
no major exposure relating to one single customer or business partner. According to the ALK Group’s  
policy for assuming credit exposure, all customers and business partners are credit rated regularly.  
Trade receivables are monitored at the local level and are distributed across a number of markets and  
customers. Therefore, the credit risk is considered to be low. For more information, see note 16.  
Concerning the ALK Group’s financial assets and financial liabilities, the earlier of the contractual  
revaluation and redemption date is applied. Effective interest rates are stated on the basis of the  
current level of interest rates on the balance sheet date.  
Embedded derivative financial instruments  
The ALK Group has made a systematic review of contracts that might contain terms that would make  
the contract or parts thereof a derivative financial instrument. The review did not lead to recognition of  
derivative financial instruments relating to the contracts.  
Interest rate exposure  
Carrying  
amount  
Fixed/  
floating interest rate  
Effective  
Amounts in DKKm  
Currency Expiry date  
31 December 2020  
Cash  
298  
Various  
Floating (1.40)-(0.05)  
Interestbearing assets  
298  
Mortgage debt  
258  
239  
446  
943  
DKK  
2035  
Floating  
Fixed  
0.2  
2.0  
1.8  
Lease liabilities  
Various 2021-2033  
Bank loans  
EUR  
2022  
Fixed  
Interestbearing liabilities  
31 December 2019  
Cash  
316  
Various  
DKK  
Floating (0.91)-1.32  
Interestbearing assets  
316  
Mortgage debt  
277  
265  
448  
990  
2035  
Floating  
Fixed  
1.2  
2.0  
1.8  
Lease liabilities  
Various 2020-2033  
EUR 2022  
Bank loans  
Fixed  
Interestbearing liabilities  
An increase in the interest rate of 1 percentage point on mortgage debt and bank loans would  
decrease net profit and equity by approximately DKK 5 million (2019: decrease of DKK 6 million).  
An increase in the interest of 1 percentage point on cash would increase net profit and equity by  
approximately DKK 3 million (2019: increase of DKK 3 million).  
 
Consolidated financial statements • Annual report 2020 • ALK 83  
Notes to the consolidated financial statements  
25 Financial risks and financial instruments – continued  
26 Fees to the ALK Group’s auditors  
Categories of financial instruments  
Amounts in DKKm  
2020  
2019  
Amounts in DKKm  
2020  
2019  
Fees to the auditors appointed at the annual general meeting*:  
Audit services  
Other opinions  
Tax advisory services  
Other services  
Total  
3
-
3
1
Financial assets  
-
2
Financial assets measured  
at amortised cost  
-
5
Impairment method  
12m ECL  
3
11  
Receivables from group companies  
20  
30  
116  
46  
*
In 2020, PricewaterhouseCoopers was appointed as the Group auditor at the annual general meeting (2019: Deloitte).  
Receivables  
Trade receivables  
Other receivables  
Cash  
12m ECL  
Lifetime ECL (simplified approach)  
12m ECL  
544  
96  
407  
The fee for non-audit services provided by PricewaterhouseCoopers Statsautoriseret  
Revisionspartnerselskab (Denmark) of DKK 0.4 million relates to tax advisory and other general  
financial accounting matters.  
133  
298  
988  
316  
Total  
1,018  
In 2019, the fee for non-audit services provided by Deloitte Statsautoriseret Revisionspartnerselskab  
(Denmark) amounted to DKK 6.7 million. This included fees for consultancy services related to  
optimisation projects for the amount of DKK 5 million, which was preapproved by the Audit Committee.  
The remaining amount related to review of tax returns, review of other tax related matters, and other  
general financial accounting matters.  
Financial liabilities  
Financial liabilities measured at amortised cost  
Mortgage debt  
Bank loans  
258  
446  
277  
448  
For information on ALK entities intended to be exempt from local audits of the 2020 accounts, see  
note 30.  
Lease liabilities  
Trade payables  
Other payables  
Total  
239  
265  
74  
81  
880  
760  
1,897  
1,831  
Measurement and fair value hierarchy  
All financial assets and liabilities are measured at cost or amortised cost. The carrying amounts for  
these approximate fair value.  
There are no financial derivatives used in 2020 or 2019.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 84  
Notes to the consolidated financial statements  
27 Related parties  
28 Events after the reporting period  
Related party exercising control  
No events have occured after the reporting period, that influence the evaluation of the consolidated  
financial statements.  
ALK-Abelló A/S is controlled by the Lundbeck Foundation (Lundbeckfond Invest A/S) domiciled  
in Copenhagen, Denmark, which holds 67.2% of the total number of votes in ALK Abelló A/S. The  
remaining shares are widely held. ALK-Abelló A/S is parent company, and ultimate parent for the ALK  
Group is the Lundbeck Foundation (Lundbeckfond Invest A/S, incorporated in Denmark).  
29 Approval of financial statements  
Other related parties comprise ALK’s Board of Management and Board of Directors, companies in  
which the majority shareholder exercises control, and such companies’ subsidiaries, in this case  
H. Lundbeck A/S and Falck A/S and their subsidiaries.  
The financial statements were approved by the Board of Directors and authorised for issue on  
10 February 2021.  
Transactions and balances  
Transactions and balances with the parent company’s majority shareholder:  
ALK-Abelló A/S received DKK 121 million (2019: DKK 18 million) concerning outstanding company  
tax from the Lundbeck Foundation (Lundbeckfond Invest A/S). The company tax relates to ALK-  
Abelló A/S, ALK-Abelló Nordic A/S, and ALK e-com A/S.  
Receivables from group companies to ALK-Abelló A/S relate to outstanding company tax of DKK 20  
million (2019: DKK 116 million) covering ALK-Abelló A/S, ALK-Abelló Nordic A/S, and ALK e-com  
A/S.  
Transactions with key management personnel consist of remuneration and exercise of share options,  
see notes 4 and 5 of the consolidated financial statements.  
No other transactions have taken place during the year with Board of Directors, Board of Management,  
major shareholders or other related parties.  
 
 
Consolidated financial statements • Annual report 2020 • ALK 85  
Notes to the consolidated financial statements  
30 List of companies in the ALK Group  
31 December 2020 (wholly owned unless otherwise stated). Nominal capital in 1,000.  
Denmark  
France  
Spain  
China  
ALK-Abelló A/S (parent)  
CVR no. 63 71 79 16  
Horsholm  
DKK 111,412  
DKK 1,000  
DKK 500  
ALK-Abelló S.A.  
Varennes-en-Argonne  
EUR 160  
EUR 1,790  
EUR 73  
ALK-Abelló S.A.  
Madrid  
EUR 4,671  
EUR 2,000  
ALK-Abelló A/S (branch)  
Hong Kong  
ALK (Shanghai) Medical Technology  
Company Limited  
Shanghai  
CNY 500  
ALK-Abelló Nordic A/S  
CVR no. 31 50 12 96  
Horsholm  
Germany  
Italy  
ALK-Abelló Arzneimittel GmbH  
Hamburg  
ALK-Abelló S.p.A.  
Milan  
ALK e-com A/S  
CVR no. 39 26 68 81  
Horsholm  
Wholly owned by ALK-Abelló S.A.  
Slovakia  
Austria  
ALK Slovakia s.r.o.  
Bratislava  
EUR 5  
Poland  
ALK-Abelló Allergie-Service GmbH  
Linz  
ALK-Abelló Sp. z o.o.  
Krakow  
PLN 325  
Sweden  
Czech Republic  
ALK-Abelló Nordic A/S (branch)  
Kungsbacka  
Switzerland  
ALK Slovakia s.r.o. – od šteˇpny´ zavod (branch)  
Prague  
USA  
ALK-Abelló AG  
Volketswil  
CHF 100  
ALK-Abelló, Inc.  
Austin, Texas  
USD 50  
USD 329  
USD 1  
Norway  
ALK-Abelló Nordic A/S (branch)  
Oslo  
ALK AG  
Volketswil  
In Liquidation  
CHF 1,000  
ALK-Abelló, Source Materials, Inc.  
Spring Mills, Pennsylvania  
Finland  
OKC Allergy Supplies Inc.  
Oklahoma City, Oklahoma  
Wholly owned by ALK-Abelló Inc.  
Turkey  
ALK-Abelló Nordic A/S (branch)  
Helsinki  
ALK ilaç ve Alerji Ürünleri Ticaret  
Anonim S¸irketi  
Istanbul  
TRY 5,150  
EUR 23  
OKC Crystal Laboratory Inc.  
Luther, Oklahoma  
USD 1  
United Kingdom  
Wholly owned by ALK-Abelló,Source Materials, Inc.  
ALK-Abelló Ltd.  
VAT Reg no. GB724461445  
Reading  
Exemption for local audit of the 2020 accounts according  
to the requirements of the UK Companies Act is intended.  
GBP 1  
Netherlands  
Canada  
ALK-Abelló B.V.  
Btw-nr. NL005302766B01  
Nieuwegein  
Exemption for local audit of the 2020 accounts under the  
ruling of the Article 2:403 of the Dutch Civil Code is intended.  
ALK-Abelló Pharmaceuticals, Inc.  
Mississauga, Ontario  
CAD 3,000  
 
 
Consolidated financial statements • Annual report 2020 • ALK 86  
Definitions  
Term  
Definitions  
Alternative Performance Measures  
Gross margin – %  
Gross profit x 100 / Revenue  
Amounts in DKKm  
2020  
2019  
EBITDA margin – %  
Net asset value per share  
Invested capital  
EBITDA x 100 / Revenue  
EBITDA reconciliation to net profit / (loss)  
Net profit / (loss) for the year  
Tax  
25  
76  
(50)  
19  
Net asset value / Number of shares end of period  
Financial income  
(5)  
(22)  
39  
Intangible assets, tangible assets, inventories and current  
receivables reduced by liabilities except for mortgage debt and  
bank loans  
Financial expenses  
54  
245  
395  
Depreciation, amortisation and impairment  
EBITDA  
255  
241  
Return on equity (ROE) – %  
Pay-out ratio – %  
Net profit/(loss) for the period x 100 / Average equity  
Proposed dividend x 100 / Net profit/(loss) for the year  
Net asset value  
Equity  
3,153  
3,176  
Net asset value  
3,153  
3,176  
Earnings/(loss) per share  
(EPS)  
Net profit/(loss) for the period / Average number of  
outstanding shares  
Invested capital reconciliation  
Intangible assets  
624  
1,704  
1,093  
544  
682  
1,739  
1,056  
407  
Tangible assets  
Earnings/(loss) per share  
diluted (DEPS)  
Net profit/(loss) for the period / Average number of  
outstanding shares diluted  
Inventories  
Trade receivables  
Receivables from group companies  
Income tax receivables  
Other receivables  
20  
116  
Cash flow per share (CFPS)  
Cash flow from operating activities / Average number of  
outstanding shares  
24  
9
96  
133  
Prepayments  
265  
211  
ROIC incl. goodwill – %  
Price earnings ratio (PE)  
Markets  
Operating profit x 100 / Average invested capital incl. goodwill  
Share price / Earnings per share  
Pensions and similar liabilities  
Lease liabilities (non-current)  
Deferred tax liabilities  
Income taxes (non-current)  
Lease liabilities (current)  
Trade payables  
(345)  
(207)  
-
(297)  
(234)  
(4)  
(143)  
(32)  
(74)  
(21)  
(3)  
(143)  
(31)  
(81)  
(20)  
(23)  
(760)  
(1)  
Geographical markets (based on customer location):  
Europe comprises the EU, UK, Norway and Switzerland  
North America comprises the USA and Canada  
International markets comprise Japan, China and all other  
countries  
Income taxes (current)  
Other provisions (current)  
Other payables  
(880)  
(1)  
Deferred income  
The definitions are aligned with generally accepted financial ratios applied by financial analysts.  
The definitions are part of the Management’s review.  
Invested capital  
2,664  
2,759  
 
 
Parent company financial statements • Annual report 2020 • ALK 87  
Contents of the parent company financial statements  
Parent company financial statements  
Notes  
Income statement  
Balance sheet  
88  
89  
90  
91  
1
2
3
4
5
6
7
8
9
Accounting policies  
91  
92  
92  
92  
93  
93  
93  
94  
94  
95  
95  
95  
95  
95  
96  
96  
96  
96  
96  
96  
Revenue and segment information  
Staff costs  
Statement of changes in equity  
Notes  
Special items  
Financial income and expenses  
Tax on profit/(loss) for the year  
Intangible assets  
Property, plant and equipment  
Deferred tax  
10 Investments in subsidiaries  
11 Inventories  
12 Mortgage debt and bank loans  
13 Pensions and similar liabilities  
14 Lease liabilities  
15 Tax payables to group companies  
16 Contingent liabilities and commitments  
17 Related parties  
18 Fees to ALK-Abelló A/S’ auditors  
19 Proposed appropriation of net profit/(loss)  
20 Events after the reporting period  
 
 
Parent company financial statements • Annual report 2020 • ALK 88  
Income statement  
Amounts in DKKm  
Note  
2020  
2019  
Revenue  
2
2,015  
1,011  
1,004  
856  
747  
109  
Cost of sales  
Gross profit  
3,4  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
3,4  
3
508  
195  
101  
458  
176  
117  
-
3,18  
Other operating items, net  
(2)  
Operating profit/(loss) (EBIT)  
198  
(642)  
Income from investments in subsidiaries  
Financial income  
10  
5
831  
14  
773  
80  
Financial expenses  
5
49  
33  
Profit/(loss) before tax (EBT)  
994  
178  
Tax on profit/(loss)  
6
105  
(129)  
Net profit/(loss)  
19  
889  
307  
 
 
Parent company financial statements • Annual report 2020 • ALK 89  
Balance sheet  
31 Dec.  
2020  
31 Dec.  
2019  
31 Dec.  
2020  
31 Dec.  
2019  
Amounts in DKKm  
Note  
Amounts in DKKm  
Note  
Assets  
Equity and liabilities  
Non-current assets  
Equity  
Intangible assets  
Share capital  
111  
2,771  
4
111  
1,822  
5
Intangible assets  
7
119  
137  
Retained earnings  
Capitalised development costs  
Total equity  
119  
137  
2,886  
1,938  
Tangible assets  
Land and buildings  
8
8
8
8
324  
263  
35  
346  
158  
22  
Liabilities  
Plant and machinery  
Other fixtures and equipment  
Property, plant and equipment in progress  
Mortgage debt  
12  
12  
13  
14  
15  
240  
446  
57  
259  
448  
19  
151  
773  
186  
712  
Bank loans  
Pensions and similar liabilities  
Lease liabilities  
Other non-current assets  
Investments in subsidiaries  
Receivables from group companies  
Receivables  
121  
111  
975  
129  
109  
964  
10  
9
1,062  
998  
1,058  
731  
Tax payables to group companies  
Non-current liabilities  
27  
43  
Deferred tax assets  
326  
356  
Mortgage debt  
12  
14  
18  
31  
18  
21  
Income tax receivables  
109  
133  
Trade payables  
2,522  
2,321  
Payables to group companies  
Lease liabilities  
841  
8
1,225  
9
Total non-current assets  
Current assets  
3,414  
3,170  
Other payables  
332  
1,230  
318  
1,591  
Current liabilities  
Inventories  
11  
361  
80  
418  
5
Total liabilities  
2,205  
5,091  
2,555  
4,493  
Trade receivables  
Receivables from group companies  
Other receivables  
Prepayments  
770  
71  
419  
113  
180  
1,135  
Total equity and liabilities  
233  
1,515  
Cash  
162  
188  
Total cash  
162  
188  
Total current assets  
Total assets  
1,677  
5,091  
1,323  
4,493  
 
 
Parent company financial statements • Annual report 2020 • ALK 90  
Statement of changes in equity  
Reserve for  
capitalised  
Share  
capital  
Retained development  
Proposed  
dividend  
Total  
equity  
Amounts in DKKm  
earnings  
costs  
2020  
Equity at 1 January  
111  
1,822  
889  
29  
5
-
-
-
-
-
-
-
1,938  
889  
29  
Appropriated from net profit  
Share-based payments  
Share options settled  
-
-
-
-
-
-
(24)  
11  
-
(24)  
11  
Sale of treasury shares  
Transfer to/(from) legal reserves  
-
1
(1)  
-
Tax related to items recognised  
directly in equity  
-
43  
-
-
43  
Other transactions  
-
949  
(1)  
-
948  
Equity at 31 December  
111  
2,771  
4
-
2,886  
See note 17 in the consolidated financial statements for information on treasury shares.  
 
 
Parent company financial statements • Annual report 2020 • ALK 91  
Notes to the parent company financial statements  
1 Accounting policies  
General  
Balance sheet  
Other accounting information  
The financial statements of the parent company  
ALK-Abelló A/S for the period 1 January –  
31 December 2020 have been prepared in  
accordance with the Danish Financial Statements  
Act for large reporting class D enterprises.  
Acquisition of activities from subsidiaries  
Acquisition of activities from subsidiaries is  
accounted for using the purchase method. On initial  
recognition, goodwill is measured and recognised  
as the excess of the consideration transferred  
exceeding the fair value of the net assets acquired  
at the acquisition date.  
Cash flow statement  
As allowed under section 86 (4) of the Danish  
Financial Statements Act, no cash flow statement  
is presented, as this is included in the consolidated  
cash flow statement.  
The financial statements are presented in Danish  
kroner (DKK), which is also the functional currency  
of the company.  
Goodwill  
Goodwill is measured at cost less accumulated  
amortisation and impairment. Amortisation is  
calculated using the straight-line method over  
the expected useful life, estimated at 10 years.  
This estimate was made on the basis of estimated  
useful lives of the assets acquired.  
Changes in accounting policies  
The accounting policies are unchanged from last  
year.  
Accounting policies  
Investments in subsidiaries  
The accounting policies are as described below.  
Investments in subsidiaries are measured at cost.  
Differences relative to the ALK Group’s  
accounting policies  
The parent company’s accounting policies for  
recognition and measurement are in accordance  
with the ALK Group’s accounting policies with the  
following exceptions:  
Where the recoverable amount of the investments  
is lower than cost, the investments are written down  
to this lower value.  
In addition, cost is written down to the extent that  
dividends distributed exceed the accumulated  
earnings in the company since the acquisition  
date. In the event of indications of impairment, an  
impairment test is performed of investments in  
subsidiaries.  
Income statement  
Results of investments in subsidiaries  
Dividends from investments in subsidiaries are  
recognised in the parent company’s financial  
statements when the right to the dividend finally  
vests, typically at the date of the company’s  
approval in general meeting of the dividend of the  
company in question less any write-downs at the  
investments.  
Capitalisation of development costs  
A reserve for capitalisation of development costs  
less deferred tax is recognised in the statement of  
equity. The reserve contains development costs,  
less amortisation/impairment losses, and less  
deferred tax, capitalised since 1 January 2016.  
 
 
Parent company financial statements • Annual report 2020 • ALK 92  
Notes to the parent company financial statements  
2 Revenue and segment information  
4 Special items  
Amounts in DKKm  
2020  
2019  
Special items include impairment of DKK 24 million (2019: DKK 262 million) of which DKK 22 million is  
related to intangible assets (2019: DKK 0) and DKK 2 million is related to tangible assets (2019: DKK  
30 million). In 2020, investments in subsidiaries were not impaired (2019: DKK 232 million).  
Sale of goods  
Royalties  
1,953  
58  
822  
34  
-
The impairment of intangible assets includes DKK 13 million related to impairment of acquired  
intellectual property rights and DKK 9 million related to impairment of software projects in progress.  
In the income statement, the impairment of intangible assets is recognised with DKK 19 million in  
research and development expenses and DKK 3 million as cost of sales.  
Services  
4
Total revenue  
2,015  
856  
Europe  
1,735  
280  
694  
162  
856  
The impairment of tangible assets of DKK 2 million is related to impairment of production equipment in  
progress. In the income statement, the impairment of tangible assets is recognised as cost of sales.  
International markets  
Total revenue  
2,015  
In 2019, impairment of investments in subsidiaries of DKK 232 million decreased the income from  
investments in subsidiaries. The impairment was calculated as the result of assessment of recoverable  
amount of the subsidiaries. Based on the assessment, the investments in the following subsidiaries  
were impaired: ALK-Abelló Source Materials Inc., ALK e-com A/S, and ALK ilac ve Alerji Ürünleri Ticaret  
Anonim Sirketi. The impairment of tangible assets of DKK 30 million was related to ALK’s divestment  
of its part-share of a formulation production line for tablets to production partner Catalent effective 30  
June 2019. The impairment of tangible assets was recognised as cost of sales.  
3 Staff costs  
Amounts in DKKm  
2020  
2019  
Wages and salaries  
Pensions  
609  
57  
578  
53  
For the assets where ALK estimates that there is a recoverable amount, such amount was determined  
based on the fair value less cost to sell or the value in use of the respective asset.  
Other social security costs, etc.  
Share-based payments  
Total  
22  
19  
20  
26  
708  
676  
Staff costs are allocated as follows:  
Cost of sales  
291  
193  
76  
283  
179  
77  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Included in the cost of assets  
Total  
104  
44  
104  
33  
708  
676  
Remuneration to Board of Management and Board of Directors:  
See note 4 and 5 in the consolidated financial statements  
Employees  
Average number (FTE)  
Number year end (FTE)  
855  
873  
820  
836  
 
 
Parent company financial statements • Annual report 2020 • ALK 93  
Notes to the parent company financial statements  
5 Financial income and expenses  
7 Intangible assets  
Amounts in DKKm  
2020  
2019  
Patents, Develop-  
trademarks  
Amounts in DKKm Goodwill and rights  
ment  
cost* Software  
Assets in  
progress  
2020  
2019  
Interest on receivables from group companies  
Other interest income  
10  
4
40  
14  
26  
80  
Cost beginning  
of year  
Currency gain, net  
-
867  
82  
-
14  
-
278  
26  
24  
1,267  
25  
1,275  
20  
Total financial income  
14  
Additions  
Disposals  
-
-
1
-
(13)  
-
(9)  
(22)  
(28)  
Other interest expenses*  
Currency loss, net  
29  
20  
49  
33  
-
Transfer to/  
from other  
Total financial expenses  
33  
groups  
-
-
-
1
(1)  
-
-
*
In 2020, other interest expenses include net interest related to uncertain tax positions of DKK 7 million (2019: DKK 11 million was  
included in other interest income) and DKK 3 million related to lease interest expenses (2019: DKK 3 million).  
Cost year end  
867  
69  
14  
280  
40  
1,270  
1,267  
Amortisation and  
impairment  
beginning of year  
867  
67  
-
6
1
-
190  
20  
-
-
-
1,130  
21  
1,137  
20  
6 Tax on profit/(loss) for the year  
Amortisation  
for the year  
-
-
-
Amounts in DKKm  
2020  
2019  
Amortisation  
on disposals  
(13)  
13  
(9)  
9
(22)  
22  
(27)  
-
Current income tax  
28  
79  
(114)  
(18)  
4
Impairment for  
the year  
Adjustment of deferred tax  
Prior year adjustments, income tax  
Prior year adjustments, deferred tax  
Total  
-
-
(2)  
Amortisation  
and impairment  
year end  
-
(1)  
105  
(129)  
867  
67  
7
210  
-
1,151  
1,130  
Profit/(loss) before tax  
994  
178  
Carrying amount  
year end  
-
2
7
70  
40  
119  
137  
*
The capitalised development cost relates to development of medical device products where the individual minor development  
projects are running for short-term periods and are subject to limited risk. The development projects are generating ecomomic  
benefits in the form of sale of goods. At 31 December 2020, the capitalised development cost relates to the historical  
development of the adrenaline auto-injector Jext® for the European market.  
Income tax, tax rate of 22%  
219  
(199)  
9
39  
(179)  
6
Non-taxable income  
Non-deductible expenses  
Prior year adjustments, income tax  
Prior year adjustments, deferred tax  
Other taxes and adjustments  
Change in valuation of net tax asset  
Tax on profit/(loss) for the year  
(2)  
-
4
(1)  
3
78  
-
(1)  
(129)  
105  
 
 
Parent company financial statements • Annual report 2020 • ALK 94  
Notes to the parent company financial statements  
8 Property, plant and equipment  
9 Deferred tax  
Property,  
plant and  
Plant and fixtures and equipment  
Other  
Current  
and other  
assets  
Tax losses  
carried  
forward  
Land and  
Intangible  
assets  
Tangible  
assets  
Amounts in DKKm  
buildings machinery equipment in progress  
2020  
2019  
Amounts in DKKm  
Liabilities  
Total  
356  
Cost beginning of year  
Additions  
610  
417  
8
28  
8
271  
105  
1,326  
122  
1,361  
223  
2020  
1
-
Carrying amount  
beginning of year  
Disposals  
(24)  
(5)  
(4)  
(33)  
(258)  
16  
(59)  
17  
31  
-
351  
Transfer to/from  
other groups  
Adjustment of receivables  
from group companies  
-
125  
11  
(136)  
-
-
-
-
-
6
6
Cost year end  
611  
526  
42  
236  
1,415  
1,326  
Recognised in the income  
statement, net  
(19)  
(6)  
8
(1)  
(61)  
(79)  
Depreciation and  
impairment beginning  
of year  
Recognised in equity, net  
(share-based payments)  
-
-
35  
-
8
43  
264  
23  
-
259  
28  
6
6
85  
-
614  
57  
680  
63  
Carrying amount  
year end  
Depreciation for the year  
Depreciation of disposals  
Impairment for the year  
(3)  
(65)  
60  
30  
304  
326  
(24)  
-
(5)  
-
(2)  
2
(31)  
2
(159)  
30  
-
2019  
Depreciation and  
Carrying amount  
beginning of year  
impairment year end  
287  
324  
263  
263  
7
85  
642  
773  
614  
712  
66  
(29)  
(12)  
1
331  
357  
Impact from initial  
Carrying amount  
year end  
application of IFRIC 23  
Adjustment to prior years  
Adjustment of receivables  
from group companies  
(24)  
-
-
-
-
-
(33)  
4
(57)  
-
35  
151  
(1)  
(3)  
of which assets held  
under leases*  
-
-
-
-
10  
34  
10  
19  
127  
-
-
-
127  
197  
137  
209  
Recognised in the income  
statement, net  
(26)  
(29)  
10  
30  
Value of land and buildings subject to mortgages  
Recognised in equity, net  
(share-based payments)  
*
Land and buildings in Denmark include buildings on land leased from Scion DTU A/S, Hørsholm. The leases are open-ended  
and the estimated lease terms are 15 years.  
-
-
22  
-
5
27  
Carrying amount  
year end  
16  
(59)  
17  
31  
351  
356  
ALK-Abelló A/S is included in a joint Danish taxation scheme with the Lundbeck Foundation  
(Lundbeckfond Invest A/S) and its Danish subsidiaries.  
ALK-Abelló A/S recognises deferred tax assets including the tax value of tax losses if it is probable  
that it can be utilised against future taxable income within a foreseeable future (5 years). This includes  
an assessment of the possibilities to utilise tax losses in the joint Danish taxation scheme with the  
Lundbeck Foundation (Lundbeckfond Invest A/S).  
 
 
Parent company financial statements • Annual report 2020 • ALK 95  
Notes to the parent company financial statements  
10 Investments in subsidiaries  
12 Mortgage debt and bank loans  
Amounts in DKKm  
2020  
2019  
Amounts in DKKm  
2020  
2019  
Cost beginning of year  
1,466  
4
905  
561  
Debt to mortgage credit institutions secured by real property  
Capital contribution in subsidiaries during the year  
Cost year end  
Mortgage debt is due as follows:  
Within 1 year  
1,470  
1,466  
18  
72  
18  
71  
From 1-5 years  
After 5 years  
Write-down beginning of year  
Write-down during the year, cf. note 4  
Write-down year end  
408  
-
176  
232  
408  
168  
258  
188  
277  
Total  
408  
Bank loans  
Bank loans are due as follows:  
Within 1 year  
Carrying amount year end  
1,062  
1,058  
-
446  
-
-
448  
-
From 1-5 years  
After 5 years  
In the income statement, income from investments in subsidiaries is dividends, which amounts to DKK  
831 million (2019: DKK 1,005 million) less write-down of investments in subsidiaries which amounts to  
DKK 0 (2019: DKK 232 million).  
Total  
446  
448  
For an overview of all subsidiaries see note 30 in the consolidated financial statements.  
13 Pensions and similar liabilities  
11 Inventories  
Amounts in DKKm  
2020  
2019  
Amounts in DKKm  
2020  
2019  
Pensions and similar liabilities expire as follows:*  
Within 1 year  
1
2
_
1
Raw materials  
75  
255  
31  
87  
307  
24  
From 1-5 years  
Work in progress  
After 5 years  
55  
58  
18  
19  
Manufactured goods and goods for resale  
Total  
Total  
361  
418  
*
Pensions and similiar liabilities relate to the provision for transition period for the Danish Holiday Act.  
Amount of write-down of inventories during the year  
4
2
3
8
Amount of reversal of write-down of inventories during the year  
14 Lease liabilities  
Amounts in DKKm  
2020  
2019  
Lease liabilities expire as follows:  
Within 1 year  
8
35  
9
34  
From 1-5 years  
After 5 years  
86  
95  
Total  
129  
138  
 
 
Parent company financial statements • Annual report 2020 • ALK 96  
Notes to the parent company financial statements  
15 Tax payables to group companies  
18 Fees to ALK-Abelló A/S’ auditors  
Non-current tax payables to group companies of DKK 111 million (2019: DKK 109 million) is expected  
to expire after 1 to 5 years.  
Amounts in DKKm  
2020  
2019  
Fees to the auditors appointed at the annual general meeting*:  
Audit services  
Tax advisory services  
Other services  
Total  
2
-
2
1
5
8
16 Contingent liabilities and commitments  
-
In December 2020, ALK-Abelló A/S issued a hold-harmless letter to ALK-Abelló Arzneimittel GmbH  
regarding costs under ongoing tax audits in Germany (unlimited guarantee). The letter replaces the  
letter issued in April 2019.  
2
* In 2020, PricewaterhouseCoopers was appointed as the Group auditor at the annual general meeting (2019: Deloitte).  
In 2019, other services included fees for consultancy services related to optimisation projects for the  
amount of DKK 5 million, which was preapproved by the Audit Committee. The remaining amount was  
related to various deliveries including compliance and advisory services.  
In January 2021, ALK-Abelló A/S issued a letter of financial support to ALK e-com A/S. The policy  
continues for a period of at least 12 months from the date of approval of the 31 December 2020  
financial statements.  
Provisions recognised as debt to affiliates have been made to cover such exposures and  
the mentioned possible uncertainties are in addition to what is already provided for.  
19 Proposed appropriation of net profit/(loss)  
For more information on contingent liabilities and commitments, see note 23 in the consolidated  
financial statements.  
Amounts in DKKm  
2020  
2019  
Proposed dividend  
Retained earnings  
Total  
-
889  
889  
-
307  
307  
17 Related parties  
ALK-Abelló A/S is included in the consolidated financial statements of the Lundbeck Foundation  
(Lundbeckfond Invest A/S, incorporated in Denmark).  
20 Events after the reporting period  
ALK-Abelló A/S has had transactions with susidiaries during 2020. All subsidiaries are owned 100%.  
The transactions are eliminated in the consolidated financial statements.  
No events have occured after the reporting period, that influence the evaluation of the parent company  
financial statements.  
Transactions with the majority shareholder are disclosed in note 27 in the consolidated financial  
statements. Apart from remuneration, no other transactions have taken place during the year with  
Board of Directors, Board of Management, major shareholders or other related parties.  
Remuneration etc. to Board of Directors and Board of Management  
For information on remuneration and exercise of share options for the ALK Group’s Board of Directors  
and Board of Management, see note 4 and 5 in the consolidated financial statements.  
 
 
Management’s review • Annual report 2020 • ALK 97  
Financial highlights and key ratios by quarter for the ALK Group* (unaudited)  
Q4  
Q3  
Q2  
Q1  
Q4  
Q3  
Q2  
Q1  
Amounts in DKKm  
2020  
unaudited  
unaudited  
unaudited  
unaudited  
Amounts in DKKm  
2020  
unaudited  
unaudited  
unaudited  
unaudited  
Income statement  
Revenue  
Balance sheet  
Total assets  
3,491  
1,463  
515  
991  
412  
178  
338  
72  
772  
344  
121  
252  
48  
772  
336  
103  
254  
63  
956  
371  
113  
281  
54  
5,563  
2,664  
3,153  
5,563  
2,664  
3,153  
5,573  
2,827  
3,203  
5,683  
2,748  
3,243  
5,639  
2,814  
3,279  
Cost of sales  
Invested capital  
Equity  
Research and development expenses  
Sales and marketing expenses  
Administrative expenses  
Other operating items, net  
Operating profit/(loss) (EBIT)  
Net financial items  
1,125  
237  
Cash flow and investments  
Depreciation, amortisation and impairment  
Cash flow from operating activities  
Cash flow from investing activities  
(1)  
-
(1)  
-
-
245  
301  
73  
195  
(72)  
52  
59  
84  
61  
70  
150  
(49)  
101  
25  
(9)  
6
16  
137  
(15)  
122  
86  
(48)  
(46)  
(5)  
(14)  
(31)  
64  
(19)  
(13)  
(20)  
58  
(10)  
6
(245)  
(78)  
(49)  
Profit/(loss) before tax (EBT)  
Net profit/(loss)  
– of which investment in intangible assets  
– of which investment in tangible assets  
(26)  
(196)  
(15)  
(59)  
(7)  
(39)  
-
(4)  
(45)  
(10)  
75  
(53)  
EBITDA  
395  
198  
Free cash flow  
56  
123  
(94)  
6
21  
Average number of employees (FTE)  
2,419  
2,433  
2,419  
2,418  
2,404  
Information on shares  
Dividend  
-
111  
-
111  
-
111  
-
111  
-
111  
Revenue  
Share capital  
(Organic growth in revenue in local currency %)  
Shares in thousands of DKK 10 each  
Share price, end period – DKK  
Net asset value per share – DKK  
11,141  
2,500  
283  
11,141  
2,500  
283  
11,141  
2,098  
287  
11,141  
1,771  
291  
11,141  
1,542  
294  
Europe  
2,550 (8)  
1,320 (-9)  
1,019 (40)  
211 (18)  
734 (17)  
391 (-2)  
301 (54)  
42 (18)  
556 (6)  
280 (-18)  
211 (56)  
65 (35)  
540 (-2)  
258 (-15)  
236 (22)  
46 (-11)  
720 (11)  
391 (-3)  
271 (33)  
58 (36)  
– SCIT/SLIT-drops  
– SLIT-tablets  
– Other products and services  
Key figures  
Gross margin – %  
58  
11  
58  
6
55  
8
56  
10  
61  
21  
North America  
573 (-10)  
275 (-5)  
85 (4)  
155 (-2)  
75 (-1)  
22 (37)  
58 (-13)  
138 (-14)  
68 (-3)  
17 (-19)  
53 (-24)  
130 (-19)  
58 (-22)  
20 (-16)  
52 (-16)  
150 (-4)  
74 (7)  
26 (22)  
50 (-24)  
EBITDA margin – %  
– SCIT/SLIT-drops  
– SLIT-tablets  
Earnings/(loss) per share (EPS) – DKK  
Earnings/(loss) per share diluted (DEPS) – DKK  
Cash flow per share (CFPS)– DKK  
Share price/Net asset value  
2.3  
2.3  
27.6  
8.8  
(2.9)  
(2.9)  
17.9  
8.8  
(1.8)  
(1.8)  
(4.4)  
7.3  
(0.9)  
(0.9)  
7.7  
7.9  
7.8  
6.4  
5.2  
– Other products and services  
213 (-19)  
6.1  
International markets  
– SCIT/SLIT-drops  
368 (58)  
78 (41)  
266 (74)  
24 (-2)  
102 (46)  
11 (-17)  
86 (65)  
78 (110)  
19 (525)  
53 (90)  
102 (56)  
26 (53)  
68 (64)  
86 (43)  
22 (1)  
59 (87)  
5 (-29)  
*
Management’s review comprises this page as well as pages 1-46 and Financial highlights and key ratios for the ALK Group on  
page 13.  
– SLIT-tablets  
– Other products and services  
5
(23)  
6
(-1)  
8 (12)  
Definitions: see page 86.  
Total revenue  
3,491 (8)  
1,673 (-7)  
1,370 (42)  
448 (-4)  
991 (16)  
477 (-2)  
409 (55)  
105 (-1)  
772 (7)  
367 (-11)  
281 (52)  
124 (0)  
772 (0)  
342 (-14)  
324 (25)  
106 (-12)  
956 (10)  
487 (-2)  
356 (38)  
113 (-2)  
– SCIT/SLIT-drops  
– SLIT-tablets  
– Other products and services  
 
 
ALK-Abelló A/S
Bøge Allé 6-8
DK-2970 Hørsholm, Denmark
CVR no. 63 71 79 16  
Tel. +45 45 74 75 76  
www.alk.net